FACULTY

Prof Zaigham Abbas

Professor and Head
Department of HepatoGastroenterology
Dr. Ziauddin University Hospital Clifton Karachi
Pakistan

Bio:
Dr. Zaigham Abbas is heading of the Department of Hepatogastroenterology at the Ziauddin University Hospital, Karachi. He is the President of Pakistan Society for the Study of Liver Diseases (PSSLD), member and ex-Dean of the Faculty of Gastroenterology in the College of Physicians and Surgeons Pakistan, and Governor of the American College of Gastroenterology for Pakistan. He is a member of the Guidelines Committees and Hepatology Interest Group of the World Gastroenterology Organization. He is Associate Editor of Hepatology International. He is currently doing collaborative work with the Hepatitis Delta International Network and APASL ACLF Research Consortium. He has 240 publications to his credit.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Assoc Prof Leon Adams

Consultant Hepatologist
Medical School
University of Western Australia
Australia

Bio:
Leon Adams (MBBS, FRACP, PhD) is an Associate Professor (Medical School, University of Western Australia) and Consultant Hepatologist in the Liver Transplant Unit at Sir Charles Gairdner Hospital. His research interests focus on translational, clinical and epidemiological aspects of nonalcoholic fatty liver disease and non-invasive assessment of liver fibrosis, in which he has published over 150 articles. He has served on the editorial boards of Hepatology, Journal of Hepatology, Hepatology Communications and Liver International and on numerous committee’s and faculties of the Australian Liver Association, Gastroenterology Society of Australia and American Association for the Study of Liver Disease.

Areas of Interest:
NAFLD and NASH

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Joint Symposium 4 (EASL-APASL)
Topic: Risk Stratification
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Gulnara Aghayeva

Head of the Department
Department of Liver Diseases
Baku Health Center
Azerbaijan

Bio:
Work Experience:
1983 – 1999 Republic Toxicological Center, Head of Resuscitation department
1999 - 2003 Azerbaijan State Medical University, Internal Disease Chair, Assistant Professor
1999 - 2008 “Khazar” University, Clinical Virology Chair, Assistant Professor
2008 – 2014 “Baku Medical center”, Head of the Liver Diseases Department
2014 – 2019 EGE Hospital, Head of the Liver Diseases Department
2019 - Present Baku Health Center, Liver Diseases Department, Head of Department
2019 - Present Medical Academy after Sechenov, Internal Diseases Chair, Lecturer
2016 - Present President of Azerbaijan Gastroenterologists and Hepatologists Association
2017 - Present Member Committee of Azerbaijan National Anti-Doping Agency (AMADA)
2018 Member of Editorial Board in Journal “Toxicology”, Azerbaijan
2019, 27-28 June President of APASL STC “Delta Hepatitis”
Awards:
1998 Grant for publishing in the book competition for the Step by Step Preschool program
2008 Recognition of the excellence of work presented at the 18th Conference of the APASL, Seoul, Korea
2013 Travel Award in APASL 2013, Singapore
2009, 2012, 2015 The winner of the nomination “The Best Doctor of the Year”
2015 Travel Award in APASL 2015, Istanbul, Turkey
2016 Travel Award in APASL 2017, Shanghai, China
Professional Conference:
2004 – 2016 APASL Annual participation (speaker)
2005 – 2016 EASL Annual participation
2008 – 2014 AASLD participation
2004 – 2013 Russian Gastroenterology and Hepatology Association, Annual participation, speaker
2008 - 2010 “Hepatology today”, speaker of Annual conference, Hepаtology Russia
2009 – 2011 Gastroenterology and Hepatology conference, speaker and Chairman in Kazakhstan
2004 – 2018 Educational sessions for medical professionals in the regions of Azerbaijan and Baku
2015 Good Clinical Practice (GCP). Clinical trial regulation. Workshop participation, Ukraine
2015-2018 Joined Turkish – Azerbaijan Hepatology Workshop, Chairman, Turkey
2018 STC APASL “Nonresponder”, speaker, co- chairman, Istanbul, Turkey
2019 February APASL Annual Meeting, co-chairman, speaker, Manila, Philippines
2019 April EASL, co-moderator in Closed Door meeting “ Viral Hepatitis Delta in Eurasia” , Expert Advisory Board
2019 November Egyptian Gastro-Hepato- Oncological Summit- speaker chairman
2019 December APASL STC “Eliminarion of Viral Hepatitis – speaker, coordinator, chairman
2020 February APASL Annual conferenсe- speaker, chairman
2020 June INEDSYS- Hepatitis B Masterclass Webinar Series
2020 September Course Director
2020 Egyptian GastroOncological and Hepatological Summit
2020 December International President
2021 January COVID-19 vaccination –Indian –Azerbaijani Webinar - Cochairman

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity, NAFLD and NASH

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Sang Hoon Ahn

Professor and Director
Yonsei University Severance Hospital
Seoul, Korea

Bio:
Sang Hoon Ahn is a Professor in the institute of Gastroenterology and the Department of Internal Medicine at Yonsei University College of Medicine in Seoul, Korea. He is also Director of the referral centre at Severance Hospital, Yonsei University Health System in Seoul.
Dr Ahn’s research interests include molecular biology and immunogenetics viral hepatitis and antiviral chemotherapy. He has completed and is complementing over 30 global and domestic clinical trials as a principal investigator in the field of viral hepatitis, cirrhosis and liver cancers. He has served as A/Editor or EB in manyl SCI(E) journals.

Session:
Gilead Lunch-time Symposium: Shaping tomorrow together: Optimising CHB management in the Asia-Pacific region
Topic: Minimising the risk of disease progression in patients with CHB
Date & Time: Thu, 4 Feb 2021 | 1200 - 1300

Prof Diana Alcantara-Payawal

Chairman
Department of Internal Medicine
Fatima Univeristy Medical Center
Philippines

Bio:
1. Secretary, Board of Regents Philippine College of Physician 2020
2. Immediate Past-President Asian Pacific Study of the Liver- 2018-2019
3. Past President, Hepatology Society of the Philippines 2012-2014 (March)
4. Past President, Philippine Society of Gastroenterology 2010-2011
5. Assistant Editor, Hepatology International 2019 to present
6. Treasurer, Board of Regents Philippine College of Physician 2019
7. APASL COVID task force 2020
8. Committee member, Scientific Committee Asian Pacific Digestive Week Federation (APDW) (2019 up to present)
9. Chair, Department of Internal Medicine Fatima University Medical Center 2017-present (Valenzuela and Antipolo)
10. Co-chair Section of Gastroenterology, Cardinal Santos Medical Center (2010-2020)

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatobiliary Neoplasia, Hepatotoxicity, NAFLD and NASH

Session:
S3: A Revisit of Tropical Liver Diseases
Topic: Liver Cysts that Require Medical Attention
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Okuda Oration
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1130 - 1200

Prof Raúl J Andrade

Full Professor of Medicine and Head Gastroenterology Service
Department of Medicine and Gastroenterology Service
University of Malaga & Virgen de la Victoria University Hospital
Spain

Bio:
Professor of Medicine and Director of the Department of Medicine at the University of Malaga. Founder and director of the Spanish Drug Induced Liver Injury (DILI) Registry. Principal investigator of the Prospective European DILI Registry awarded by the EASL. Chairman of the Clinical Practice Guidelines Council on Drug Induced Liver Injury 2016 appointed by the EASL. Chair of CIOMS working group on DILI 2017. Chair of COST ACTION CA17112. Member of steering committee of the Group of Special Interest in Hepatotoxicity (AASLD). Elected Fellow for the AASLD (2016) for significant contribution to the science and practice of hepatobiliary diseases.

Areas of Interest:
Hepatitis C, Hepatotoxicity, NAFLD and NASH

Session:
S23: Recent Advances in Drug-Induced Liver Injury
Topic: Epidemiology and Genetic Predisposition to Drug-Induced Liver Injury
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Paolo Angeli

Department of Medicine
Unit of Internal Medicine and Hepatology
University of Padova
Italy

Bio:
Prof. Paolo Angeli is Full Professor of Internal Medicine. He is the head of Unit of Internal Medicine and Hepatology (UIMH) of the University of Padova (Italy). He leads a research group working on the pathophysiology and treatment of acute, chronic and acute on chronic liver failure and on liver transplantation. He was the secretary of the International Club of Ascites from 2010 up to April 2018. From 2010 he is Associate Editor of the Journal of Hepatology. From the 1st of July 2019 hi is the Editor in Chief of the Journal of Hepatology. From January 2018 he is the Chair of the EASL-Clif Consortium. He is author of more than 318 papers on international journals with peer review, cited by JCR, with a global IF of 3275 and HI of 64. He has contributed to the guidelines and/or positional papers on the management of ascites, bacterial infections and acute renal injury (AKI) in patients with cirrhosis for the European Association for the Study of the Liver. He has contributed to the new diagnostic criteria for AKI in patients with cirrhosis as a result of a consensus process with almost all the international experts in this field.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Gut Liver Axis and Microbiome, Hepatotoxicity, Liver Transplantation and Liver Surgery, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
Post-graduate course - Session 3: ACLF - Management from guideline to clinical practice
Topic: Management of bacterial infection in cirrhosis
Date & Time: Thu, 4 Feb 2021 | 1050 – 1150

S21: Hot Topics in Cirrhosis and its Complications
Topic: An Update of Diagnosis and Management of Acute Kidney Injury in Cirrhosis
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Dr Monika Arora

Professor and Director
Department of Health Promotion
Public Health Foundation of India
India

Bio:
Dr Monika Arora is a public health scientist working in the area of health promotion and health advocacy with focus on NCD prevention and control. She is Executive Director of Delhi based NGO: HRIDAY (Health Related Information Dissemination Amongst Youth) in India. HRIDAY serves as the secretariat of Healthy India Alliance (India NCD Alliance). She is Board Member of NCD Alliance, Geneva for the period 2019-2021. She is also the Director of the Health Promotion Division and Professor at Public Health Foundation of India.

Areas of Interest:
Training and Education (Career Development)

Session:
Joint Symposium 3 (APASL-CEVHAP-WHO)
Topic: Where Cancer and NCD Advocacy Meet: strategies adopted by the NCD movements that could be replicated by the hepatitis fraternity to prioritize neglected themes and diseases
Date & Time: Sat, 6 Feb 2021 | 1310 - 1440

Assoc Prof Sumeet Asrani

Associate Professor of Medicine
Department of Hepatology
Baylor University Medical Center
United States

Bio:
Sumeet Asrani, MD, MSc is a transplant hepatologist at Baylor University Medical Center, part of Baylor Scott & White Health. He is also the medical director for the Center for Advanced Liver Disease and an associate professor for the Texas A&M College of Medicine. Dr. Asrani specializes in the management of patients with end-stage liver disease, liver transplantation candidates and recipients. His other clinical interests include liver cancer, viral hepatitis, autoimmune hepatitis, primary schlerosing cholangitis and alcoholic liver disease. His research interests focus on renal function in liver disease and organ allocation. Dr. Asrani has coauthored over 75 peer review articles and currently serves as an associate editor for the American Journal of Transplantation (AJT).

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Health Services Research, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
Post-graduate course - Session 2: Alcoholic liver disease - Management from guideline to clinical practice
Topic: Role of liver transplantation in alcoholic hepatitis
Date & Time: Thu, 4 Feb 2021 | 0915 - 1015

Prof Thomas Berg

Professor
Department of Hepatology and Gastroenterology
Univeristy Hospital in Leipzig
Germany

Bio:
Since December 2009, professor Thomas Berg has been the Head of the Section of Hepatology at the University Hospital in Leipzig, Germany, and since October 2018 acting Director of the Clinic of Gastroenterology at the University Hospital, Leipzig. His clinical and translational research is focused on chronic viral hepatitis, liver transplantation, hepatocellular carcinoma, genetics in liver disease, and liver failure, and he participated in numerous national and international clinical trials. He is Vice Secretary of the European Associations for the Study of the Liver (EASL), Board member of the EASL International Liver Foundation (EILF) and Co-Editor of the Journal of Hepatology since 2014. He is also member of the American (AASLD), European (EASL), and German (GASL) Associations for the Study of the Liver, The European Society for Organ Transplantation (ESOT), The European Liver and Intestine Transplant Association (ELITA), German Transplantation Society (DTG), Working Group Internal Oncology (AiO), Working Group Gastroenterological Oncology (AGO), German Cancer Society (DKG), German Society of Gastroenterology (DGVS), and the representative of the DGVS in the foundation council of the German liver foundation. He has published more than 350 articles in peer-reviewed journals and more than 100 reviews and textbook contributions. His h-index is 72 (Scopus)

Session:
S11: Roadmap towards a Cure in Patients with Chronic Hepatitis B
Topic: Natural course of Hepatitis B Virus infection and Definition of Cure
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Dr Chalermrat Bunchorntavakul

Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
Rajavithi Hospital, Ministry of Public Health
College of Medicine, Rangsit University
Thailand

Bio:
Chalermrat Bunchorntavakul, MD, is Assistant Professor of Medicine in the Division of Gastroenteology and Hepatology at Rajavithi Hospital, Ministry of Public Health, Bangkok, Thailand, in affiliation with College of Medicine, Rangsit University. Dr. Bunchorntavakul is currently active in clinical practice and is the acting Medical Director of Liver Transplant Program of the Excellent Center of Organ Transplantation, Ministry of Public Health. He also serves on the steering committee or subcommittee of several professional societies, such as Gastroenterological Association of Thailand

Session:
S21: Hot Topics in Cirrhosis and its Complications
Topic: Hepatic Encephalopathy: Current Challenges and Future Prospects
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

S23: Recent Advances in Drug-Induced Liver Injury
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Patrizia Burra

Full Professor, Head of Multivisceral Transplant Unit
Surgery, Oncology and Gastroenterology
University Hospital of Padova
Italy

Bio:
Patrizia Burra is Full Professor of Gastroenterology, Head of the Multivisceral Transplantation Unit and ViceRector on Research Training at Padua University. She is interested in clinical and translational studies in the setting of liver transplantation (HCV recurrence, HBV prophylaxis post-transplantation, acute alcoholic hepatitis, NASH/NAFLD, compliance and quality of life of transplant recipients). She has served as President of ELITA, Vice-President of ESOT, Chair of ILTS Education-Committee, Treasurer of ILTS and ILTS President. Currently she is Co-chair of The Lancet-EASL Commission on liver diseases in Europe, Deputy Editor of Journal of Hepatology and Associate Editor of Transplant International and Digestive and Liver Disease.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity, Liver Transplantation and Liver Surgery, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
SOTA 5
Topic: Principle of Organ Preservation and Machine Perfusion in Liver Transplantation
Date & Time: Sat, 6 Feb 2021 | 1130 - 1200

Dr Amna Subhan Butt

Associate Professor
Section of Gastroenterology, Department of Medicine
The Aga Khan University Hospital, Karachi
Pakistan

Bio:
Dr Amna Subhan Butt is Consultant Gastroenterologist and Program director, Gastroenterology Residency Program at The Aga Khan University Hospital. Dr. Butt has been recognized as a specialist in her field and over more than half a decade and currently serving as the General Secretory, Pakistan Society for the study of Liver Diseases, Chair Guideline Committee of Pakistan Society of Gastroenterology & GI Endoscopy (PSG) and member of guideline committee of World Gastroenterology Organization. She is also a co-investigator in APASL ACLF research consortium (AARC). She was previously the general secretory of PSG. She has published around 34 publications with 749 citations in peer-reviewed journals and received best abstract, best presentation award, international scholar awards several times in International Conferences.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Surgery, NAFLD and NASH, Other Viral Hepatitis, Training and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Sudhamshu K C

Coordinator, DM Heoatology
Department of Liver Unit
National Academy of Medical Sciences
Nepal

Bio:
Graduated from Dhaka University. Residency in First Department of Medicine of Graduate School of Medicine, Chiba university under Prof Okuda. Obtained PhD in 2004. Currently Professor of Hepatology in NAMS and Coordinator of DM Hepatology

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Dr Nataruks Chaijitraruch

Consultant
Department of Pediatric Gastroenterology and Hepatology
Chulalongkorn University
Thailand

Bio:
Pediatrics, Ramathibodi Hospital, Mahidol University, 2006
Pediatric Gastroenterology and Hepatology, Ramathibodi Hospital, Mahidol University, 2008
Doctor of Philosophy, King’s College London, UK 2014
Pediatric Hepatology Fellowship at King’s College Hospital, UK, 2015

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Human Cholestatic and Autoimmune Liver Diseases, Liver Transplantation and Liver Surgery, Metabolic and Genetic Disease, NAFLD and NASH, Pediatric Hepatology

Session:
S14: Advances in Common Pediatric Hepatology
Topic: Acute Liver Failure in Children
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Dr Siwaporn Chainuvati

Assistant Professor
Department of Internal medicine, Gastroenterology & Hepatology
Mahidol University, Siriraj hospital
Thailand

Bio:
Graduated from Mahidol university and continued GI/liver training in USA. Hepatology mentors were Dr. Roberto Groszmann and Dr. Guadalupe Garcia-Tsao. Now I have been practiced at Sirraj Hospital for 15 years focused on hepatitis and cirrhosis in limited resources

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Portal Hypertension and Other Complications of Cirrhosis

Session:
S8: The Myths and Realities of Portal Hypertension
Topic: Precision Medicine in Variceal Bleeding: Are We There Yet?
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S18: Strategies to Improve Long-term Post-Liver Transplantation
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Dr Roongruedee Chaiteeerakij

Consultant
Division of Gastroenterology and Hepatology
Department of Medicine
Chulalongkorn University
Thailand

Bio:
Dr. Chaiteerakij earned her medical degree and completed postgraduate training in Internal Medicine, and Gastroenterology and Hepatology at Chulalongkorn University, Bangkok, Thailand. She subsequently earned a Ph.D. in Clinical and Translational Science from the Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA. Dr. Chaiteerakij’s research interests focus on liver and bile duct cancer, including epidemiology; development of biomarkers for diagnosis and treatment of liver and bile duct cancers; and improvements in prevention, diagnosis, and treatment of hepatobiliary cancers.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity

Session:
S7: Clinical and Molecular Pathways of Hepaticocarcinogenesis
Topic: Novel Techniques for the Diagnosis of Cholangiocarcinoma
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S22: Team-based Management of Hepatocellular Carcinoma
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Asst Prof Naichaya Chamroonkul

Assistant Professor
Department of Internal Medicine
Prince of Songkla University
Thailand

Bio:
Naichaya Chamroonkul MD, graduated from faculty of medicine Siriraj hospital Mahidol university in 2003. After completed her training in gastroenterology and hepatology at Siriraj hospital she started her career as a lecturer at Prince of Songkla university Hatyai Thailand since 2009. In 2017-2019, she had been a visiting scholar in liver division Icahn school of medicine at Mount Sinai New York. She is currently assistant professor and chief of gastroenterology and hepatology unit, division of internal medicine, Prince of Songkla university. Her interest is focusing on cirrhosis and its complications, liver fibrosis and fatty liver disease.

Areas of Interest:
Genomics and Precision Medicine, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH

Session:
S6: Updates on Liver Fibrosis: From Pathophysiology to Potential Treatment
Topic: Antifibrotics in Liver Disease - Are We Getting Closer to Clinical Use?
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Prof Wah-Kheong Chan

Professor and Senior Consultant Gastroenterologist and Hepatologist
Department of Medicine
University of Malaya
Malaysia

Bio:
Dr Chan is Professor of Medicine at the University of Malaya and Senior Consultant Gastroenterologist and Hepatologist at the University of Malaya Medical Centre and the University of Malaya Specialist Centre. He is a Member of the Academy of Medicine of Malaysia and a Committee Member for the Malaysian Society of Gastroenterology and Hepatology. He is the Scientific Co-Chair for the Asia Pacific Digestive Week 2021. He is a member of the Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease, the Gut and Obesity in Asia (GO ASIA) Workgroup, and the Global NASH Council. He is Associate Editor for the Journal of Gastroenterology and Hepatology and is a reviewer for several international journals. He has published numerous full papers in peer-reviewed journals and presented in both local and international conferences. His main area of research interest is non-alcoholic fatty liver disease.

Areas of Interest:
NAFLD and NASH

Session:
Post-graduate course - Session 1: NAFL/ MAFLD
Topic: NAFLD - MAFLD : new definition and cardiovascular risk
Date & Time: Thu, 4 Feb 2021 | 0815 - 0915

S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Topic: Diet and Exercise: Which One Plays a More Important Role?
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Prof Henry LY Chan

Professor, Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Hong Kong

Bio:
Professor Henry Lik Yuen Chan is the Director of Center for Liver Health and Associate Dean (External Affairs) of Faculty of Medicine, The Chinese University of Hong Kong. Professor Chan is a world-renowned expert in viral hepatitis B, and is chairman of the Strategic Technical Advisory Committee on Viral Hepatitis for the Western Pacific Regional Office of World Health Organization. He has published over 450 papers in peer-reviewed journals, and is awarded Highly Cited Researcher by Clarivate Analytics in 2018 and 2019 for producing multiple top 1% cited papers under Web of Science.

Areas of Interest:
Hepatitis B and Hepatitis D

Session:
Post-graduate course - Session 4: HBV - Disease monitoring to cure
Topic: Long term durability of HBsAg lost; what should we do next?
Date & Time: Thu, 4 Feb 2021 | 1300 - 1400

Gilead Lunch-Time Symposium: Shaping tomorrow together: The countdown to HCV elimination
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

Gilead Lunch-Time Symposium: Shaping tomorrow together: The countdown to HCV elimination
Enhancing care for patients with HCV
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

Roche Lunch-Time Symposium: Innovations in HCC Diagnostics and Treatment : From Evidence to Practice
The Value of Diagnostics – The clinical usefulness of PIVKA-II in HCC Surveillance
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

S11: Roadmap towards a Cure in Patients with Chronic Hepatitis B
Topic: Can We Discontinue NUC Therapy?
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Dr Po-Lin Chan

Medical Officer (Hepatitis)
Division of Programmes for Disease Control
World Health Organisation Western Pacific Regional Office
Philippines

Bio:
Dr Po-Lin Chan is the Regional Technical Lead for viral hepatitis at the World Health Organization Regional Officer for the Western Pacific. She has worked in Africa, South Asia and East Asia in clinical services and conflict zones to advising government on public health initiatives. Passionately committed to health for all, she led WHO’s technical assistance to India for their establishment, scale-up and decentralisation of the HIV/STI national response. She supported China in HIV and viral hepatitis elimination, and now works in the Region to support the 37 countries in getting to viral hepatitis elimination as a public health threat

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Health Services Research, Hepatitis B and Hepatitis D, Hepatitis C, NAFLD and NASH, Other Viral Hepatitis, Pediatric Hepatology, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
Joint Symposium 2 (WHO WPRO_SEARO)
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1100 - 1200

Joint Symposium 2 (WHO WPRO_SEARO)
Topic: Beyond immunization for Hepatitis B prevention, the role of antivirals to get to zero transmission: WHO new 2020 guidelines on antiviral drug use among pregnant women for hepatitis B prevention of mother to child transmission
Date & Time: Sat, 6 Feb 2021 | 1100 - 1200

Joint Symposium 3 (APASL-CEVHAP-WHO)
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1440

Assoc Prof Stephen Lam Chan

Associate (Clinical) Professor
Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong

Bio:
Assoc Prof Stephen L. Chan is the Associate (Clinical) Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong. His main interest of research is clinical and translational studies on hepatobiliary-pancreatic and neuroendocrine cancers. Internationally, he is serving as the Associate Editor for the Journal of Hepatology and editorial board members of Liver International. Dr. Chan is also an international member of the NCI Hepatobiliary Task Force of the Gastrointestinal Steering Committee in United States. Dr. Chan has published over 130 peer-reviewed papers, with awards of young investigator award and gold medal dissertation by the Hong Kong College of Physician. Locally, Dr. Chan has established a charity Hand-in-hand cancer foundation to provide education and assistance to cancer patients.

Areas of Interest:
Hepatitis B and Hepatitis D, Inflammation and Immunobiology

Session:
Post-graduate course - Session 5: HCC - What's new
Topic: Role of chemotherapy in advanced HCC; Current trend
Date & Time: Thu, 4 Feb 2021 | 1400 - 1500

Dr Roger Chapman

Consultant Hepatologist
Department of Translational Hepatology
Oxford University
United Kingdom

Bio:
Dr Roger Chapman is a Consultant Emeritus in Hepatology at the Oxford University Hospital in Oxford, UK. He trained in liver disease with Professor Sheila Sherlock at the Royal Free Hospital in London. He has published 6 books, over 80 Book chapters and 260 original articles mainly in the field of autoimmune liver disease, viz Primary Sclerosing Cholangitis (PSC), Primary Biliary Cirrhosis (PBC) and latterly IgG4 related disease. He is a founding member (in 1992) of the International Autoimmune Hepatitis Group (IAHG) . More recently he has been involved in the foundation of the International PSC Study Group (2009) and the foundation of British Autoimmune Liver Disease Study Group (2010). He is one of the authors of the current European (EASL) guidelines for “Cholestatic liver diseases” and the first author of the North American (AASLD) guidelines on the “Management of Primary Sclerosing Cholangitis”. He was awarded a Fellowship of American Association for the Study of Liver Disease in 2014 and a lifetime achievement award from the British Association for the Study of Liver Disease in 2016.

Areas of Interest:
Human Cholestatic and Autoimmune Liver Diseases

Session:
S9: What's New in Autoimmune Liver Diseases?
Topic: New Thoughts on IgG4-related Hepatobiliary Disease
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Assoc Prof Phunchai Charatcharoenwitthaya

Associate Professor
Faculty of Medicine
Siriraj Hospital, Mahidol University
Thailand

Areas of Interest:
NAFLD and NASH

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Topic: Alcohol Drinking in Metabolic-associated Fatty Liver Diseases
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Oral Presentations
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Chao-Long Chen

Superintendent Emeritus / Professor of Surgery
Department of Surgery
Kaohsiung Chang Gung Memorial Hospital
Taiwan

Bio:
Professor Chao-Long Chen is a pioneer liver transplant surgeon who performed the first successful liver transplantation in Asia in 1984, and by 2019, has accomplished 1900 more. He obtained fellowship training in liver transplantation under Professor Thomas Starzl at the University of Pittsburgh, USA. He is a recipient of various honors and distinctions, both locally and internationally. He became Professor of Surgery in 1993 and was subsequently bestowed with honorary PhD and professorship by acclaimed international universities. In 1994, he performed the first LDLT in Taiwan and was bestowed with the National Award for Outstanding Contribution in Science and Technology in 1995. He did the first split liver transplantation in Asia in 1997 and started the adult LDLT in Taiwan by 1999. Further, he performed the first dual graft LDLT in Taiwan in 2002, pioneered routine microsurgical biliary reconstruction in the world in 2006, and performed Taiwan’s first segment 2 monosegment LDLT in 2013. He was bestowed the ILTS Distinguished Service Award in 2019. He was Superintendent of the Kaohsiung Chang Gung Memorial Hospital from 2003 and became Superintendent Emeritus since 2015. He has published more than 500 SCI-cited scientific articles, lectured in more than 300 international and overseas congresses, and has trained more than 360 fellows and observers from all across the world. He serves as associate editor of the American Journal of Transplantation and editorial board of Annals of Surgery among other high ranking scientific journals. He was elected as Academician of the Chinese Academy of Engineering in 2007 and as President of the International LDLT Group in 2020-21. He remains director of one of the leading global centers in LDLT.

Areas of Interest:
Liver Transplantation and Liver Surgery

Session:
HS2: Living Donor Liver Transplantation (LDLT) for HCC beyond Miland Criteria
Topic: There is no doubt for the benefits
Date & Time: Sat, 6 Feb 2021 | 1030 - 1100

Prof Chien-Jen Chen

Vice-president
Genomics Research Center
National Taiwan University College of Public Health
Taiwan

Bio:
Chien-Jen Chen is Vice-president of Academia Sinica, Taiwan, where he is also a Distinguished Professor in the Genomics Research Center. He is a professor at the Graduate Institute of Epidemiology, National Taiwan University College of Public Health, Taiwan and an adjunct professor in the Department of Biostatistics and Epidemiology at Tulane University School of Public Health and Tropical Medicine, New Orleans, USA. Professor Chen is an epidemiologist and public health practitioner, recognised for his in-depth research on the molecular and genomic epidemiology of virus-related cancers and chronic arsenic poisoning. Professor Chen’s REVEAL-HBV/HCV study is regarded as a classic in hepatology and epidemiology.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C

Session:
Gilead Lunch-time Symposium: Shaping tomorrow together: The countdown to HCV elimination
Topic: Best practices and policies in HCV elimination programmes
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

Prof Huey-Ling Chen

Professor
Department of Pediatrics, Department and Graduate Institute of Medical Education and Bioethics, College of Medicine
National Taiwan University
Taiwan

Bio:
Professor Chen graduated from the College of Medicine (MD), and Graduate Institute of Clinical Medicine (PhD) of National Taiwan University. Professor Chen’s clinical work is mainly in pediatric gastroenterology, hepatology, and nutrition. Her research interests center on pediatric liver diseases, prevention of hepatitis B virus (HBV) infection and mother-to-infant transmission of HBV, cholestatic liver diseases, genetic diagnosis of inherited liver diseases, and medical education. She and colleagues have published papers in Gastroenterology, Hepatology, Journal of Hepatology, Journal of Pediatrics, Journal of Pediatric Gastroenterology and Nutrition, etc. She is currently the President of Taiwan Society of Pediatric Gastroenterology, Hepatology, and Nutrition.

Areas of Interest:
Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis, Hepatitis B and Hepatitis D, Human Cholestatic and Autoimmune Liver Diseases, Liver Transplantation and Liver Surgery, Metabolic and Genetic Disease, NAFLD and NASH, Pediatric Hepatology, Training and Education (Career Development)

Session:
S14: Advances in Common Pediatric Hepatology
Topic: Metabolic-Associated Fatty Liver Disease (MAFLD) in Children
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Prof Jin-Jun Chen

Deputy Director
Hepatology Unit
Nanfang Hospital, Southern Medical University
China

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Genomics and Precision Medicine, Gut Liver Axis and Microbiome, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Assoc Prof Sakkarin Chirapongsathorn

Chief of Hepatobiliary Section
Department of Gastroenterology and Hepatology
Phramongkutklao College of Medicine, Royal Thai Army
Thailand

Bio:
Dr Sakkarin Chirapongsathorn is an Associate Professor and Chief of Hepatobiliary Section of Phramongkutklao College of Medicine, Royal Thai Army, Bangkok, Thailand. The broad goals of his research are to determine treatments to improve survival, quality of care, and quality of life of patients with chronic liver disease and non-alcoholic fatty liver disease. Dr Chirapongsathorn's published work is diverse but largely unified by the theme of identifying patients at risk for mortality in cirrhosis, NASH and other liver diseases.

Areas of Interest:
NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
S1: Enhancing Quality of Care in Hepatology
Topic: Quality Indicators and Improving the Quality of Care in Cirrhosis
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

S8: The Myths and Realities of Portal Hypertension
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Dr Su-Pin Choo

Senior Consultant
Medical Oncology
Curie Oncology
Singapore

Bio:
Dr Choo is a medical oncologist at Curie Oncology who subspecialises in gastrointestinal cancers including colorectal, hepatobiliary, pancreatic, stomach, oesophageal, anal and neuroendocrine cancers. She is a visiting consultant at the National Cancer Centre Singapore and is an adjunct Associate Professor at the Duke-NUS Graduate Medical School. She is the Immediate Past President of the Singapore Society of Oncology and founding member of the SSO- Cancer Immunotherapy Consortium. She is also a Council Member in the Chapter of Medical Oncology, Academy of Medicine Singapore and a Board Member of the Asian Oncology Society. She is a member of the ESMO Women For Oncology committee

Areas of Interest:
Genomics and Precision Medicine, Hepatobiliary Neoplasia, Inflammation and Immunobiology, Training and Education (Career Development)

Session:
Joint Symposum 1 (AASLD-APASL)
Topic: Combination Cancer Immunotherapy for HCC
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Dr Soonthorn Chonprasertsuk

Assistant Professor
Department of Medicine
Thammasat University
Thailand

Bio:
Doctor of Medicine, Chulalongkorn University, Thailand
Internal Medicine resident and GI fellow, Chulalongkorn University, Thailand
Research Fellow in Hepatology, University of North Carolina at Chapel Hill, USA
Director of Gastroenterology Unit, Thammasat University

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity

Session:
S3: A Revisit of Tropical Liver Diseases
Chairperson
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

S23: Recent Advances in Drug-Induced Liver Injury
Topic: Liver Injury Associated with Sporting Activities
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Assoc Prof Watcharasak Chotiyaputta

Associate Professor
Department of Medicine
Division of Gastroenterology
Siriraj Hospital, Mahidol University Thailand
Thailand

Bio:
Finished Gastroenterology training from Siriraj Hospital, Mahidol University, Thailand and Hepatology’s Research fellowship training from University of Michigan, USA

Areas of Interest:
Hepatitis B and Hepatitis D

Session:
S4: Current Knowledge of Occult Hepatitis B and Hepatitis B Co-Infection
Topic: An Update on Biology and Clinical Impact of Occult HBV Infection
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Assoc Prof Ashok Choudhury

Associate Professor
Department of Hepatology & Liver Transplant
Institute of Liver & Biliary Sciences, New Delhi
India

Bio:
Assoc Prof Ashok Choudhury currently working as Assoc. Prof of Hepatology and Liver Transplantation at Institute of Liver and Biliary Science (ILBS) New Delhi. He is a transplant hepatologist and a clinician researcher focused on liver injury/failure, ACLF, HCC, sepsis and liver transplant using both pre-clinical and translational studies. His academic activities appreciated globally with best abstract and fellow research award by AASLD at Boston in 2014, Young Investigator Award by ILTS in 2016; Seoul and by APASL 2017 at Shanghai and covered by the WebMD magazine in Europe. Currently academic editor for Journal of Clinical Translational Hepatology (JCTH) and peer reviwer for many reputed journals, had more than 50 publications, for his credit. Currently he is the principal cordinator for tha APASL ACLF rseasrch consortium (AARC) as well as for APASL COVILD-19 Liver Injury Spectrum (APCOLIS study).

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatobiliary Neoplasia, Liver Transplantation and Liver Surgery

Session:
Post-graduate course - Session 3: ACLF - Management from guideline to clinical practice
Topic: Pitfall of critical care in patients with ACLF
Date & Time: Thu, 4 Feb 2021 | 1050 - 1150

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S23: Recent Advances in Drug-Induced Liver Injury
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Raymond Chung

Director of Hepatology and Liver Center
Department of Medicine
Massachusetts General Hospital
United States

Bio:
Prof Raymond Chung is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar at MGH. Dr. Chung has made major contributions to fundamental, translational and clinical research in HCV and HBV. He has served as Co-Chair of the AASLD-IDSA HCV Guidance Panel and is a Principal Investigator in the NIH Hepatitis B Research Network. He is also Principal Investigator of the NIH U19 Cooperative Center in Human Immunology and PI of an NIH T32 Training Grant in Digestive Diseases at MGH. He is President-Elect of the AASLD and will serve as President in 2021. He has authored or coauthored over 300 publications.

Areas of Interest:
Cell and Molecular Biology, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH, Other Viral Hepatitis, Portal Hypertension and Other Complications of Cirrhosis

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Opening Ceremony
Opening Ceremony Speech
Date & Time: Fri, 5 Feb 2021 | 1030 - 1100

S16: Surveillance of Hepatocellular Carcinoma
Topic: Should we stop HCC surveillance after the eradication of viral hepatitis?
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Prof Massimo Colombo

Director, Liver Center
San Raffaele Hospital
Italy

Bio:
Professor Massimo Colombo is Director of the Liver Center at San Raffaele Hospital ,Milan,Italy..In the previous 15 years,he has been Chairman of the Department of Medicine and Organ Transplantation at IRCCS Maggiore Hospital in Milan, Italy. He has been a Professor of Medicine and Gastroenterology at the University of Milan for more than 25 years. Recipient of the 2010 EASL Recognition Award for outstanding medical and scientific contributions,AISF Distinguished Service Award, the Thannhauser Medal Award of the German Society of Gastroenterology and the Nelson Fausto Award of ILCA. Professor Colombo was Editor-in-Chief of the Journal of Hepatology from 2005–2009 Special Section Editor of Journal of Hepatology(2015-2019), and contributor of Selected Summary for Gastroenterology(2010-2021).He chaired the writing committees of EASL CPG of Benign Liver Tumors in 2014 and of Occupational Liver Diseases in 2017. In 2016 appointed Chairman of EASL International Liver Foundation (Geneva,Switzerland). Authored >500 original manuscripts in peer-reviewed journals, with an Hindex of 91(Google Scholar) and more than 27,000 citations.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia

Session:
S7: Clinical and Molecular Pathways of Hepaticocarcinogenesis
Topic: Distinctive Features of Hepatocellular Carcinoma in Metabolic-Associated Fatty Liver Diseases (MAFLD)
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Assoc Prof Yock-Young Dan

Senior Consultant
Department of Medicine
National Univesity of Singapore
Singapore

Bio:
Dr Dan Yock Young obtained his medical degree (MBBS. MMed) and PhD from the National University of Singapore 2003 and 2010 respectively. He is a clinician scientist with research interest in liver stem cells, Non-alcoholic fatty liver disease as well as cost effectiveness. He is currently Assistant Chief Executive and deputy Chairman Medical Board of National University Hospital in NUH,

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Cell and Molecular Biology, NAFLD and NASH

Session:
S17: Controversies in Hepatology
Topic: Risks of Hepatocellular Carcinoma after Treatment with Direct-acting Antiviral Agents for HCV Cirrhosis
Date & Time: Sat, 6 Feb 2021 | 0800 – 0940

Prof Harshad Devarbhavi

Head, Department of Gastroenterology and Hepatology
St. John’s Medical College Hospital, Bangalore
India

Bio:
Prof Harshad Devarbhavi is currently the professor and head of gastroenterology and hepatology at St. John’s Medical College Bangalore, India. He went to Mayo Clinic Rochester on the American College of Gastroenterology scholarship in 2001 and again as a fellow in Hepatology and Liver Transplantation in 2004. He is the authors of over 75 publications that include original articles, review papers, book chapters including the current edition of Zakim and Boyer text book of Hepatology. His research interests include drug-induced liver injury, pregnancy specific liver disease, Wilson disease and acute liver failure. He is on the editorial board of Hepatology International, Hepatology Communications and JCEH.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatotoxicity, Metabolic and Genetic Disease, Other Viral Hepatitis

Session:
Post-graduate course - Session 3: ACLF - Management from guideline to clinical practice
Topic: Drugs-induced ACLF; what we need to know
Date & Time: Thu, 4 Feb 2021 | 1050 - 1150

SOTA 2
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

S23: Recent Advances in Drug-Induced Liver Injury
Topic: Herbal Medicines Implicating in Liver Injury
Date & Time: Sat, 6 Feb 2021| 1520 - 1700

Prof A.Kadir Dokmeci

Consultant
Department of Liver Transplantation
Ankara University
Turkey

Bio:
He received his medical degree from the Ankara University School of Medicine (AUSM) in 1971 and qualified as a gastroenterologist in 1978.
He had studied at Chiba University School of Medicine in Japan as Prof. Okuda’s student from 1979 to 1981 for 2.5 years. He was appointed as a professor at AUSM in 1988 .
Prof. Dokmeci has been a visiting professor at the Chiba University from 1988 to 1989 and at the University of California, Irvine in 2003. He organized the 25th APASL Annual Conference in 2015 and the 5th APASL STC, Istanbul in 2009. He has contributed to editorials, reviews and book chapters. He is in editorial board in various journals such as Hepatology International, Digestive Endoscopy and Turkish Journal of Gastroenterology.
He published more than 100 papers in different journals.
He is currently Emeritus Professor and senior hepatologist in Liver Transplantation Center at Ankara University.
Also he is member of APASL Steering Committee and the collaborater in AARC. He received 2 international awards. - Inohana Award, Chiba University Japan (1998) - 2nd APASL Powell-Sarin Lifetime Achievement Award (2020)

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Human Cholestatic and Autoimmune Liver Diseases, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
State of the Art 2
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

APASL Distinguished Award presentation and lectures - The 2nd APASL Powell- Sarin Lifetime Achievement Award
Nonsurgical Treatment Options of HCC
Date & Time: Sat, 6 Feb 2021 | 1020 – 1130

Prof Ajay Duseja

Professor, Department of Hepatology
Postgraduate Institute of Medical Education and Research, Chandigarh
India

Bio:
Dr Ajay Duseja is presently working as Professor in the department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. For last more than 24 years, he is working as Faculty with focused research in the field of Hepatology. He is Fellow of National Academy of Medical Sciences (FAMS), Fellow of American Association for the Study of Liver Diseases (FAASLD), Fellow of American College of Gastroenterology (FACG) and Fellow of the Society of GI Endoscopy of India (FSGEI). He is the National Convener of the Indian National Association for the Study of Liver (INASL) Task Force on Nonalcoholic Fatty Liver Disease (NAFLD), member of the Chronic Liver Disease Foundation (CLDF) NASH Committee (USA), member of the Asia- Pacific Working Party on NAFLD and member of the Gut and Obesity in Asia (GOASIA) working group. He is also an active member of the INASL Task Force on Hepatitis C virus, Hepatocellular carcinoma, Acute-on-Chronic Liver Failure and Drug Induced Liver Injury. He is author of more than 250 papers in reputed international and national journals including 22 chapters. His main areas of interest include nonalcoholic fatty liver disease (NAFLD), acute-on-chronic liver failure (ACLF) and management of HCV in chronic kidney disease. He is the Associate Editor of the Journal of Clinical and Experimental Hepatology (JCEH), Associate Editor of JGH Open and is on the Editorial board of various international and national journals. He is the former Honorary Treasurer of the Indian National Association for the Study of Liver (INASL) and has been the office bearer and member of various other scientific societies.

Areas of Interest:
Hepatitis C, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
Post-graduate course - Session 1: NAFL/ MAFLD
Topic: Lean NAFLD; What's new
Date & Time: Thu, 4 Feb 2021 | 0815 - 0915

Latest Knowledge on Gut Microbiota in Liver Diseases
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Mohamed Elbasiony

Lecturer
Department of Internal medicine ( Hepatology and Gastroentrology Unit )
Mansoura University
Egypt

Bio:
Current positions:
Lecturer of internal medicine department
Director of endoscopy unit Egyptian liver Hospital
Educations:
M.B.B.Ch. in Medicine and Surgery Faculty of Medicine, Mansoura University, Nov. 2005
Master’s degree of Internal Medicine Faculty of Medicine, Mansoura University, May. 2010
MD degree of internal medicine Faculty of Medicine, Mansoura University, November ,2016

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Mohammed Eslam

Associate Professor of Hepatology
Storr Liver Centre
University of Sydney
Australia

Areas of Interest:
Genomics and Precision Medicine, Liver Fibrogenesis and Non-Parenchymal Cell Biology, Metabolic and Genetic Disease, NAFLD and NASH

Session:
SOTA 4
Topic: Genetics of Metabolic-Associated Fatty Liver Diseases (MAFLD): From Pathogenesis to Therapeutics
Date & Fri, 5 Feb 2021 | 0940 - 1010

Prof Donna Evon

Professor of Medicine
Division of Gastroenterology and Hepatology
The University of North Carolina at Chapel Hill
United States

Bio:
Donna Evon is a clinical health psychologist and behavioral scientist who has worked in the field of chronic liver disease for 15 years. She is a Professor of Medicine in the UNC Liver Program where she conducts research to understand the psycho-social-behavioral factors related to liver disease, patients’ needs and experiences, and applies this knowledge to the development and evaluation of psychosocial interventions to improve chronic liver disease health outcomes. Her research projects, funded by the NIH, PCORI and industry, utilize self-report surveys, qualitative methodologies and patient engagement groups. Clinically, she provides lifestyle and behavioral modification for patients with NAFLD.

Areas of Interest:
Health Services Research, Hepatitis C, NAFLD and NASH, Other Viral Hepatitis

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Prof Scott L Friedman

Fishberg Professor of Medicine
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
United States

Bio:
Prof Scott L Friedman is the Dean for Therapeutic Discovery and Chief of Liver Diseases, at the Icahn School of Medicine at Mount Sinai. He has performed pioneering research into mechanisms of fibrosis associated with chronic liver disease. His work has spawned an entire field that is now realizing its translational and therapeutic potential. Dr. Friedman has been awarded the EASL International Recognition Award and Distinguished Achievement Awards from the AASLD and the American Liver Foundation. He is widely respected as a key opinion leader working closely with the biotech and pharmaceutical industry in developing new therapies for liver disease.

Areas of Interest:
Hepatobiliary Neoplasia, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH

Session:
S6: Updates on Liver Fibrosis: From Pathophysiology to Potential Treatment
Topic: Mechanisms of Fibrosis Progression and Targets of Therapy
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Dr James Fung

Consultant
Department of Medicine
Queen Mary Hospital
Hong Kong

Bio:
Dr. James Fung is a Consultant at the Department of Medicine, and the Transplant Hepatologist at the Liver Transplant Centre, Queen Mary Hospital, Hong Kong. He graduated from the University of Auckland School of Medicine in 1997. In 2011 he attained his Doctor of Medicine studying non-invasive assessment of liver fibrosis. He has published widely and is a regular reviewer for major gastroenterology journals and a regular speaker. His main research interest includes viral hepatitis, liver fibrosis, advanced liver disease, hepatocellular carcinoma, and liver transplantation.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatitis C, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
S18: Strategies to Improve Long-term Post-Liver Transplantation
Topic: Preventing Recurrence of Viral Hepatitis after Liver Transplantation
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Prof Rino Gani

Head
Hepatobiliary Division
University of Indonesia
Indonesia

Bio:
Prof Rino A Gani finished MD program from Universitas Indonesia in 1987. After a short experience as the head of a community health center in the rural area, he returned to Universitas Indonesia to become an internist and consultant of gastroenterohepatology in the same university. As Chairman of Indonesia Association for Study of the Liver, he struggles to provide and to make access for the best medication for hepatitis available in Indonesia. He is also actively involved in the Ministry of Health as the head of the expert committee and arranges the national policy to control hepatitis.

Session:
S1: Enhancing Quality of Care in Hepatology
Chairperson
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

S10: What's new in Alcoholic Liver Disease?
Topic: Nutritional Support in Alcoholic Liver Disease
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

APASL Distinguished Award presentation and lectures
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

The 2nd APASL Rising Star Award
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1330

Prof Juan Carlos García-Pagán

Head of the Hepatic hemodynamic Unit
Hospital Clínic
Spain

Bio:
Dr. JC Garcia-Pagán is a Senior Consultant in Hepatology at the Liver Unit at Hospital Clínic in Barcelona. Dr. Garcia-Pagan earned his medical degree from the University of Barcelona Medical school and completed his gastroenterology/hepatology fellowship at the Liver Unit at Hospital Clínic in Barcelona. He has published more than 200 originals, chapters and reviews. Also he is professor in the University of Barcelona and has directed more than 20 Doctoral Thesis. Dr. Garcia-Pagán’s research has been mainly focused in the area of the pathophysiology, methods of evaluation and treatment of portal hypertension as well as in the natural history and treatment of vascular disorders of the liver.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis C, NAFLD and NASH

Session:
S8: The Myths and Realities of Portal Hypertension
Topic: Management of Portal Vein Thrombosis in Cirrhosis: When to Treat and How?
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

HS3: Refractory Esophageal Variceal Bleeding in Cirrhosis
Topic: TIPS
Date & Time: Sat, 6 Feb 2021 | 1430 - 1500

Prof Guadalupe Garcia-Tsao

Professor of Medicine
Department of Disgetive Diseases
Yale University/VA-Connecticut Healthcare System
United States

Bio:
Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, and Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System. Dr. Garcia-Tsao has an active practice in hepatology and clinical research duties as a principal investigator, with over 120 PubMed-verified original publications in peer-reviewed journals that have been cited over 30,000 times and with an H-index of 79. Dr. Garcia-Tsao is a leading expert on portal hypertension and related complications of cirrhosis.

Areas of Interest:
Portal Hypertension and Other Complications of Cirrhosis

Session:
S8: The Myths and Realities of Portal Hypertension
Topic: Portal Hypertensive Bleeding in Cirrhosis: From the Evolving Pathophysiology to the Natural Course and Outcomes
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Prof Jacob George

Head, Department of Gastroenterology and Hepatology
Storr Liver Centre
Westmead Hospital
Australia

Bio:
Jacob George is the Robert W. Storr Professor of Hepatic Medicine at the Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney and Head of the Department of Gastroenterology and Hepatology at Westmead Hospital and Director of Gastroenterology and Hepatology Services for the Western Sydney Local Health District. He undertakes basic and clinical research on NASH, hepatitis C, liver cancer and hepatic fibrosis. He is an Associate Editor for the Journal of Hepatology and has published over 410 papers, with over >31,000 citations and has an h index of 75.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, NAFLD and NASH

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Topic: Fatty Liver - from NAFLD to MAFLD
Date & Time: Fri, 5 Feb 2021 | 1520 – 1700

APASL Distinguished Award presentation and lectures - The 2nd APASL Okuda-Omata Distinguished Award
Topic: MAFLD: Where does the evidence point?
Date & Time: Sat, 6 Feb 2021 | 1020 – 1130

Joint Symposium 4 (EASL-APASL)
Topic: Evidence-based Dietary and Exercise for MAFLD
Date & Time: Sat, 6 Feb 2021 | 1520 – 1700

Prof Gregory Gores

Professor of Medicine, Executive Dean for Research
Department of Gastroenterology and Hepatology
Mayo Clinic
United States

Bio:
Gregory J. Gores, M.D. is a quintessential, senior academician; a “quadruple threat” with contributions to research, clinical practice, education, and leadership. His research contributions include sustained federal funding over three decades, over 700 publications, an H-index of 136, and over 57,000 citations (Scopus data base). Based on these accomplishments, he was appointed as a Distinguished Mayo Investigator. His clinical focus on hepatobiliary neoplasia has led to novel protocols regarding liver transplantation for cholangiocarcinoma. Educational activities include mentoring over 80 fellows, and directing a liver transplant fellowship program. These activities have been recognized by receipt of an American Gastroenterological Association Mentorship Award. Extramural leadership positions include past presidency of the American Association for the Study of Liver Disease (AASLD) and the International Liver Cancer Association, and a past Councilor of the American Gastroenterological Association (AGA). Intramural positions include serving as past Chair of the Gastroenterology and Hepatology Division at Mayo Clinic Rochester, and current Executive Dean for Research across the Mayo enterprise. His stature and accomplishments were recently recognized by prestigious awards from the Mayo Alumni Association, the AASLD, the German Society of Gastroenterology, and the Canadian Liver Foundation and Canadian Association for the Study of Liver.

Areas of Interest:
Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis, Hepatobiliary Neoplasia, Human Cholestatic and Autoimmune Liver Diseases, Inflammation and Immunobiology, Liver Transplantation and Liver Surgery, NAFLD and NASH

Session:
S7: Clinical and Molecular Pathways of Hepaticocarcinogenesis
Topic: Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Date & Time: Fri, 5 Feb 2021 |1310 - 1450

Prof Saeed Sadiq Hamid

Professor
Department of Medicine and Director Clinical Trials Unit
The Aga Khan University
Pakistan

Bio:
Saeed Sadiq Hamid is a professor in the Department of Medicine and Director of the Clinical Trials Unit at The Aga Khan University, Karachi, Pakistan. His main research interests are viral hepatitis and liver failure and his current work involves HCV micro-elimination projects in the province of Sindh, Pakistan. He was previously Vice-president of the Pakistan Society of Gastroenterology and President of the Pakistan Society for the Study of Liver Diseases. He is currently a member of the governing council of the World Gastroenterology Organization, Co-chair of the Coalition to Eradicate Viral Hepatitis in Asia-Pacific and a member of the oversight committee of EndHep2030

Areas of Interest:
Hepatitis C, Other Viral Hepatitis

Session:
Gilead Lunch-time Symposium: Shaping tomorrow together: The countdown to HCV elimination
Topic: How far have we come in HCV elimination
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Joint Symposium 3 (APASL-CEVHAP-WHO)
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1440

Prof Tao Han

Chair
Department of Hepatology and Gastroenterology & Infectious Disease
Tianjin Third Central Hospital affiliated to Nankai University and Tianjin Medical University
China

Bio:
Tao Han is Professor of Medicine in Tianjin Third Central Hospital affiliated to Nankai University and Tianjin Medical University. He is Chair of Severe Liver Disease and Artificial Liver Support group ,Standing Committee Membership, Chinese Hepatology Society. His major research focused on various liver disease such as viral hepatitis, liver cirrhosis,liver failure and liver cancer, etc

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplas, Hepatotoxicity, Human Cholestatic and Autoimmune Liver Diseases, Liver Fibrogenesis and Non-Parenchymal Cell Biolo, Metabolic and Genetic Disease, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof F. Blaine Hollinger

Professor of Medicine, Executive Dean for Research
Prof of Medicine (Hepatology), Molecular Virology & Epidemiology
Gastroenterology and Hepatology
Baylor College of Medicine
United States

Bio:
Dr. F. Blaine Hollinger is an experienced researcher and hepatologist who has engaged in several national multicenter clinical trials and basic scientific projects related to viral hepatitis, and has published over 275 peer-reviewed articles, books and chapters in this field. He is Professor of Medicine, Molecular Virology & Epidemiology and Director of the Eugene B. Casey Hepatitis Research Center. He is a Fellow of the AASLD, AGA and IDSA. Dr. Hollinger has been an advisor and consultant on program projects, grants, and contracts related to viral hepatitis and drug therapy for the NIH and the FDA. He served on the Blood Products Advisory Committee (BPAC) for the FDA becoming its Chairman in 1997 and again in 2010

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Other Viral Hepatitis

Session:
S4: Current Knowledge of Occult Hepatitis B and Hepatitis B Co-Infection
Topic: Occult Hepatitis B Infection and Hepatocellular Carcinoma
Date & Time: Fri, 5 Feb 2021 | 0800 – 0940

Prof Kai-Wen Huang

Professor
Department of Surgery
National Taiwan University
Taiwan

Bio:
Kai-Wen Huang, MD, MS, PhD, is the Professor of surgical oncology in Imperial College London and Director of Centre of Mini-invasive Interventional Oncology of the National Taiwan University Hospital and Graduate Institute of Clinical Medicine in Taipei, Taiwan
He received his MD degree, PhD degree, and his specialty training in Surgery at the Medical School of the National Taiwan University. In 2007, he was a research fellow In Tokyo and Nagoya, Japan. Dr. Huang has been actively involved in basic, clinical and translational research in interventional oncology, surgical oncology, nanomedicine and gene therapy. He has published more than 100 peer-reviewed articles in these areas. He received the “Ta-You Wu Memorial Award” from the National Science Council of Taiwan. Dr. Huang is an active member of the Society of Interventional Oncology (SIO) and Asian Pacific Association for the Study of the Liver (APASL). He has served on the editorial boards of several SCI journals. He is also the founder and board member of Asian Conference on Tumor Ablation (ACTA). In addition, Dr. Huang is the current president of Asia-Pacific Academia of Mini-invasive Intervention and Oncology (APAIO) and President of Taiwan Academy of Tumor Ablation

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Cell and Molecular Biology, Genomics and Precision Medicine, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Hepatobiliary Surgery, Inflammation and Immunobiology, Liver Fibrogenesis and Non-Parenchymal Cell Biology, Liver Transplantation and Liver Surgery, NAFLD and NASH, Training and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Yi-Hsiang Huang

Chief
Division of Gastroenterology & Hepatology
Taipei Veterans General Hospital
Taiwan

Bio:
Dr. Yi-Hsiang Huang is currently Chief of Division of Gastroenterology and Hepatology at Veterans General Hospital in Taipei. He is also the Director for the Department of Internal Medicine, a Professor for the Institute of Clinical Medicine at the National Yang-Ming University. Dr. Huang is the associate secretary general of the Taiwan Association for the Study of the Liver (TASL) and the Chinese Medical Association of Taiwan, and a board member of the Taiwan Liver Cancer Association (TLCA) and Taiwan Academy of Tumor Ablation. He has published over 170 articles in international peer-reviewed journals, including Hepatology and Journal of Hepatology

Areas of Interest:
Hepatobiliary Surgery, Other Viral Hepatitis

Session:
Eisai Lunch-Time Symposium: Focusing on Lenvatinib as a Novel Molecular Targeted Therapy in Intermediate Stage HCC
Topic: Optimal AE management for uHCC patients with Lenvatinib
Date & Time: Sat, 6 Feb 2021 | 1200 - 1300

Dr Pongphob Intaraprasong

Assistant Professor
Department of Gastroenterology and Hepatology
Ramathibodi Hospital, Mahidol University
Thailand

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Liver Transplantation and Liver Surgery

Session:
S17: Controversies in Hepatology
Topic: Age and Liver Transplantation
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Prof Syed Mohammad Wasim Jafri

Professor, Director WGO Karachi Training Center
Department of Medicine
Aga Khan University Karachi
Pakistan

Areas of Interest:
Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Hepatotoxicity, Human Cholestatic and Autoimmune Liver Diseases, Liver Transplantation and Liver Surgery, NAFLD and NASH, Other Viral Hepatitis, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
S3: A Revisit of Tropical Liver Diseases
Chairperson
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Young Investigator's Award
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Rajiv Jalan

Head, Liver Failure Group
Institute of Liver and Digestive Health
University College London
United Kingdom

Bio:
I am a clinician with a strong focus on translational research. I graduated in India, trained in Edinburgh and studied for my PhD in Maastricht. I moved to UCL as a Senior lecturer/Hon Consultant in 2000 and was awarded a personal chair in 2009. I spend about 50% of my time providing patient care as a Hepatologist at the secondary and tertiary level at the Royal Free Hospital where I also run a translational and basic science laboratory.

My work focused on liver failure. The most important observation we made was the discovery that systemic inflammation played a crucial role in the progression of liver injury and cirrhosis culminating in liver failure leading up to current hypotheses and the seminal observation that acute-on-chronic liver failure (ACLF) was a distinct clinical syndrome with defined clinical, prognostic and pathophysiological characteristics. ACLF is associated with high mortality rates, consumes huge healthcare resources and its treatment is a huge unmet need. In the past 15 years since I described this syndrome first, more than 800 papers have been published on this subject and many research groups and industry are focussed on this subject to better define, prognosticate, understand its pathogenesis and develop new treatments.

I have developed a vibrant clinical practice and laboratory with many novel therapies and established extensive collaborations with key investigators, Foundations and Industry around the world to study the pathophysiological basis of ACLF. I was the Founder member of the EASL CLIF Consortium (100 European hospitals), which now stands independently funded with the aim of developing new treatments for cirrhosis and liver failure.

My research has led to successful publications of about 396 original papers, editorials and reviews. My H-Index is 83 (Google Scholar; Total citations: >20K; 10-index: 246).

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Inflammation and Immunobiology, Portal Hypertension and Other Complications of Cirrhosis

Session:
SOTA 6
Topic: Roles of Artificial Liver Supporting Systems in Acute on Chronic Liver Failure: Rational and Clinical Implications
Date & Time: Sat, 6 Feb 2021 | 1130 - 1200

Prof Ji-Dong Jia

Director
Liver Research Center
Beijing Friendship Hospital, Capital Medical University
China

Bio:
Prof Jia is professor of medicine and director of the Liver Research Center, Beijing Friendship Hospital, Capital Medical University, China. He received his doctor’s degree from the Capita Medical University, China and finished his post-doc training at Free University of Berlin, Germany. His major clinical interest includes viral, autoimmune and genetic liver diseases, his major research area is liver fibrosis. He served as the President of Chinese Society of Hepatology(CSH,2006-2012), APASL (2009-2010) and ASL(2013-2016).

Areas of Interest:
Liver Fibrogenesis and Non-Parenchymal Cell Biology, Metabolic and Genetic Disease, Portal Hypertension and Other Complications of Cirrhosis, ining and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S9: What's New in Autoimmune Liver Diseases?
Topic: Epidemiology and Clinical Course of Primary Biliary Cholangitis in Asia
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S15: COVID-19: Lessons Learnt from Eastern and Western Worlds
Chairperson
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Dr Gonzague Jourdain

Senior Researcher
Health Research Division
French National Research Institute for Sustainable Development, France and Chiang Mai University
Thailand

Bio:
Gonzague Jourdain is a clinical epidemiologist working in Thailand. He was trained as an MD and earned a PhD in Epidemiology in France. He had led a research collaboration between his institution, the French National Research Institute for Sustainable Development (IRD), and Chiang Mai University in Thailand since 2013 and co-authored more 130 papers in international peer-reviewed journals, especially on perinatal transmission of HIV and HBV. His research currently focuses on simplifying methods to prevent mother-to-child transmission of hepatitis B virus, and the prevention of horizontal transmission of HIV, syphilis and viral hepatitis B and C.

Areas of Interest:
Hepatitis B and Hepatitis D

Session:
Joint Symposium 2 (WHO WPRO_SEARO)
Topic: Asking the right questions: operations research to implementing better: Questions to address through research to advance the implementation of prevention of mother-to-child transmission of hepatitis B
Date & Time: Sat, 6 Feb 2021 | 1100 - 1200

Prof Patrick Kamath

Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
United States

Bio:
Patrick S. Kamath is Professor of Medicine and Consultant in Gastroenterology and Hepatology at Mayo Clinic College of Medicine and Science. He is a Mayo Clinic Distinguished Educator, an AGA Distinguished Educator, and AASLD Distinguished Mentor. His major research area is identifying patients at risk for mortality in cirrhosis; he played a key role in developing the Model for End-stage Liver Disease (MELD). He has authored more than 350 publications including contributions to the New England Journal of Medicine, Gastroenterology, Hepatology, and Nature Genetics. He received the Lifetime Teaching Award for Excellence from the Department of Medicine at Mayo Clinic.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
S17: Controversies in Hepatology
Topic: Liver Transplantation in Acute on Chronic Liver Failure (ACLF): Science or Fiction?
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Prof Jia-Horng Kao

Vice Superintendent
Department of Gastroenterology and Hepatology
National Taiwan University Hospital
Taiwan

Bio:
Professor Jia-Horng Kao is the Chair Professor at the Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine. He is also the Vice Superintendent of the National Taiwan University Hospital. Professor Kao’s main research interests include the prevention, natural history, molecular virology, pathogenesis and treatment of chronic viral hepatitis and HCC. He has published more than 550 articles with the sum of times cited of 20,684 and h-index of 65 by Web of Science. He also contributed to 9 book chapters and one monograph. With his outstanding academic achievements, he has received several prestigious awards including the Okuda Award of Asian-Pacific Digestive Week (Bangkok, Thailand)/Journal of Gastroenterology and Hepatology (2012) and APASL Okuda-Omata Distinguished Achievement Award (2019).

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C

Session:
SOTA 1
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

Chainuvati Lecture
Topic: Prevention of Mother-to-Child Transmission: the Key of Hepatitis B Virus Elimination
Date & Time: Sat, 6 Feb 2021 | 0940 - 1010

Dr Md. Fazal Karim

Associate Professor and Head
Department of Hepatology
Sir Salimullah Medical College Mitford Hospital
Bangladesh

Bio:
I am a hepatologist working as Associate Professor & Head, Department of Hepatology, Sir Salimullah Medical College Mitford Hospital. It is a teaching hospital in old part of Dhaka city. I am a graduate of Dhaka Medical College. I did my MBBS in 1993. I have done post-graduation in Internal Medicine (FCPS in Medicine) from Bangladesh College of Physicians & Surgeons in 2003. Also did post-graduation in Hepatology (MD Hepatology) from Bangabandhu Sheikh Mujib Medical University, Dhaka in 2004. I have 13 years of experience in teaching. I specialize in liver related procedure- FNA, liver biopsy, endoscopy, colonoscopy, ERCP. I have large number of publications in national and international journals

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH, Other Viral Hepatitis, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof W-Ray Kim

Professor & Chief
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
United States

Bio:
Ray Kim, MD, is Professor and Chief in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine. Prior to assuming this post in November 2013, Dr. Kim was Professor of Medicine at Mayo Clinic College of Medicine. Dr. Kim earned his medical diploma at Seoul National University in Korea. He underwent training in gastroenterology and hepatology at Mayo Clinic in Rochester, MN. He also holds a Master in Science Degree in patient oriented research from Seoul National University and a Master in Business Administration from University of Pennsylvania. He has served on the Governing Board of the American Association for the Study of Liver Disease (AASLD), where he currently chairs the Global Outreach and Engagement Committee. Dr. Kim’s research interest has been in epidemiology and outcomes studies in chronic liver disease and liver cancer.

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

S1: Enhancing Quality of Care in Hepatology
Topic: Cost-effectiveness of Hepatitis C Screening
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

Prof Dong-Joon Kim

Professor and Director
Department of Internal Medicine
Institute for Liver and Digestive Diseases
Hallym University
South Korea

Bio:
Chairman, KASL (Korean Association for the Study of the Liver)

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Gut Liver Axis and Microbiome, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Dr Taya Kitiyakara

Head
Department of Gastroenterology and Hepatology
Ramathibodi Hospital
Thailand

Bio:
Dr Taya Kitiyakara is currently Head of Division of Gastroenterology/Hepatology at Faculty of Medicine, Ramathibodi hospital, Mahidol University.

Session:
S10: What's new in Alcoholic Liver Disease?
Topic: Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S16: Surveillance of Hepatocellular Carcinoma
Chairperson
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Prof Piyawat Komolmit

Head
Excellent Center in Liver Diseases
King Chulalongkorn Memorial Hospital
Thailand

Bio:
Dr Piyawat Komolmit is affiliated to Medicine, Chulalongkorn University, where Dr. Komolmit is currently working as Professor. Dr. Komolmit has authored and co-authored several national and international publications and also working as a reviewer for reputed professional journals. Dr. Komolmit is having an active association with different societies and academies around the world. Dr. Komolmit made his mark in the scientific community with the contributions and widely recognition from honourable subject experts around the world. Dr. Komolmit has received several awards for the contributions to the scientific community. Dr. Komolmit major research interest involves Gastroenterology.

Session:
S21: Hot Topics in Cirrhosis and its Complications
Topic: Management of the Critically-ill Cirrhotic Patients
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Masatoshi Kudo

Professor and Chairman
Department of Gastroenterology and Hepatology
Kindai University Faculty of Medicine
Japan

Bio:
Masatoshi Kudo studied Medicine at Kyoto University and graduated in 1978. Following this, he completed a clinical fellowship in Kobe City General Hospital followed by a research fellowship at the University of California Davis Medical Center in USA and Kyoto University Graduate School of Medicine, where he received his PhD degree in Medical Science in 1987. Professor Kudo is currently a Professor and Chairman at the Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine since 1999 and the Executive Board Member of Kindai University.

Professor Kudo has published 959 International scientific peer review papers in well regarded journals (Total IF=5430.285, H-Index 83) in addition to 945 domestic scientific papers. He has given 408 invited lectures in the area of his expertise on numerous occasions to international audiences. He serves as an Executive Council Board Member for Liver Cancer Study Group of Japan (LCSGJ), Chairman of Nationwide Survey Committee of LCSGJ, and a representative of LCSGJ Head Office. Professor Kudo is also a President of the Japan Society of Ultrasonics in Medicine (JSUM), President of Asia Pacific Primary Liver Cancer Association (APPLE), Past President of WFUMB, President of AFSUMB, an Executive Board Member of Japan Society of Hepatology (JSH), a Founding Board member of International Liver Cancer Association (ILCA). He is also serving as an Editor in Chief of LIVER CANCER (Karger) (IF=9.720).

His research interest is "Diagnosis and treatment of HCC". Professor Kudo is the first author of “Consensus based Practice Guideline of HCC Proposed by Japan Society of Hepatology” published in 2007, 2010 and 2014 revised version.

Areas of Interest:
Hepatobiliary Neoplasia

Session:
S22: Team-based Management of Hepatocellular Carcinoma
Topic: Goals and Targets for Personalized Therapies in Hepatocellular Carcinoma
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Dr Jennifer Lai

Associate Professor of Medicine
Division of Gastroenterology & Hepatology
University of California, San Francisco
United States

Areas of Interest:
Hepatobiliary Neoplasia

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Prof George Lau

Chairman
Department of Gastroenterology and Hepatology
Humanity & Health Medical Group
Hong Kong

Bio:
Prof. Lau is currently the Chairman of Humanity and Health Medical Group, Hong Kong and Chair Professor and Director of The 5th Medical Centre of Chinese PLA General Hospital - Hong Kong Humanity & Health Medical Group, Beijing, CHINA. He has a distinguished career in the conduct of translational and clinical trials in the field of CHB, CHC and HCC. He has pioneered work in adoptive clearance of HBV infection and the use of pre-emptive lamivudine to prevent HBV reactivation after chemotherapy. Prof. Lau’s has published more than 300 original publications with H-h-index of 84 (2020).

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Inflammation and Immunobiology, NAFLD and NASH

Session:
SOTA 3
Topic: Immunotherapy in Hepatology - Past, Present and Future
Date & Time: Fri, 5 Feb 2021 | 0940 – 1010

Presidential Lecture 1
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1130 - 1200

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

APASL HBV Reactivation 2021 Guideline
Topic: Historical Perspectives
Date & Time: Sat, 6 Feb 2021 | 0800 - 1000

APASL HBV Reactivation 2021 Guideline
Topic: Recommendations
Date & Time: Sat, 6 Feb 2021 | 0800 - 1000

Prof Mei-Hsuan Lee

Professor
Institute of Clinical Medicine
National Yang-Ming University
Taiwan

Bio:
Professor Mei-Hsuan Lee is Professor at the Institute of Clinical Medicine, National Yang-Ming University, Taiwan. She obtained her PhD in 2010 from the Graduate Institute of Epidemiology, National Taiwan University. She was a visiting scholar at the National Cancer Institute, USA; the University of Tokyo, Japan; and the Genomics Research Center, Academia Sinica, Taiwan. Professor Lee has received various honors and awards for her work, and is often invited to speak at local and international conferences. She currently serves on the editorial board of Scientific Reports, Journal of the Formosan Medical Association and Virology Journal.

Areas of Interest:
Genomics and Precision Medicine, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Metabolic and Genetic Disease, NAFLD and NASH

Session:
Gilead Lunch-time Symposium: Shaping Tomorrow Together: Learnings from a Real-world Survey of Liver Health in Asia
Topic: Asia Liver Index Survey: A barometer for public awareness on viral hepatitis and fatty liver disease
Date & Time: Sat, 6 Feb 2021 | 1200 - 1300

Dr Apinya Leerapun

Assistant Professor
Department of Internal Medicine, Faculty of Medicine
Chiang Mai University
Thailand

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH

Session:
S2: Novel Technologies in Hepatology
Chairperson
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

S17: Controversies in Hepatology
Topic: Benefit of Statin in Chronic Liver Diseases
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Dr Cosmas Rinaldi A Lesmana

Senior Lecturer and Consultant
Department of Internal Medicine, Hepatobiliary Division
Dr. Cipto Mangunkusumo National General Hospital
Indonesia

Bio:
Cosmas Rinaldi A. Lesmana is a Senior Lecturer and Consultant in the Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia in Jakarta. Dr Lesmana serves as one of the Research Coordinator Staff for the department. He is also work at Digestive Disease & GI Oncology Centre (DDOC), Medistra Hospital, Jakarta as well as at Liver-GI Centre, MRCCC Siloam Hospital, Jakarta as a senior consultant and interventional endoscopist. He carried out his medical and postgraduate training in Internal Medicine and also in Gastroenterology/Hepatology at Diponegoro University, Semarang and Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta. He underwent several additional short courses training in basic and advance endoscopy (ERCP) in Asian Institute of Gastroenterology (AIG), Hyderabad, India, and Hepatology (Fibroscan training) in Hopital Haut Leveaque, Bordeaux, France, and also basic molecular hepatitis virus at Victorian Infectious Disease Reference Laboratory (VIDRL), Melbourne, Australia. In 2011, he further continued his interest for portal hypertension training at Institute of Liver & Biliary Sciences (ILBS), New Delhi, India. In 2015, he underwent endoscopic ultrasound (EUS) training at Baldota Institute of Digestive Science (BIDS), Global Hospital, Mumbai, India. He has won several awards for his research, including being named 4th in the APASL Young Investigator Award in 2005, and 3rd in APASL 2010, the AASLD-APASL Award in 2008, Travel Grant Award from Society Gastrointestinal Intervention (SGI) Korea in 2010, as well as two times awards in AASLD (2012 and 2018). One of his research has been selected for presentation during Digestive Disease Week (DDW) meeting, 2017 in USA. Dr Lesmana is a member of several professional associations, including Past Executive Council Member of the Asian Pacific Association for the Study of the Liver (APASL), Fellow of American College of Physicians (FACP), Direct Fellow of American College of Gastroenterology (FACG) and Fellow of Indonesian Association of Internal Medicine (FINASIM). Currently, he is a member of Asian Endoscopic Ultrasound (EUS) Group (AEG). He has been involved as international EUS workshop instructor during AEG congress. He also has published many papers in peer-reviewed international journals and his interest includes hepatitis virus, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, pancreato-biliary diseases, and diagnostic as well as therapeutic endoscopy.

Areas of Interest:
Gut Liver Axis and Microbiome, Hepatobiliary Neoplasia, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
S13: Novel Endoscopic Interventions in Liver Diseases
Topic: Prevention and Management of Bleeding Risk Related to Invasive Procedures in Cirrhosis
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

HS3: Refractory Esophageal Variceal Bleeding in Cirrhosis
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1430 - 1500

Prof Lan-Juan Li

Director
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
Zhejiang University
China

Bio:
Prof. Li has been a Member of the Chinese Academy of Engineering since 2005. Her main research interests are diagnosis and treatment of infectious diseases, liver failure and artificial liver and infectious microecology. She pioneered the development of Li’s ALS, which has been deployed to over 300 hospitals in China and benefited patients in over 30 provinces. Prof. Li played a leading role in fighting against the outbreaks of COVID-19 in 2019, SARS in 2003 and avian flu H7N9 in 2013. Her works have been published in Nature, Lancet, New England Journal of Medicine, Nature Communication, BMJ,CID,Hepatology etc.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Gut Liver Axis and Microbiome, Other Viral Hepatitis, Portal Hypertension and Other Complications of Cirrhosis

Session:
S5: Latest Knowledge on Gut Microbiota in Liver Diseases
Topic: The Metabolic Role of The Microbiome: Implications for MAFLD
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Prof Suthat Liangpunsakul

Professor of Medicine, Biochemistry and Molecular Biology
Division of Gastroenterology and Hepatology, Department of Medicine
Indiana University School of Medicine
United States

Bio:
Born in Thailand, Dr. Liangpunsakul completed his medical training at Prince of Songkhla University, Thailand, in 1995, where he was awarded an MD degree, first class honors. He completed his Internal Medicine Residency at the University of Illinois in Chicago in 2000, and GI/Hepatology training at Indiana University in Indianapolis in 2003. He is currently a Professor of Medicine, Biochemistry and Molecular Biology and Showalter Scholar in the Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University. His research focuses on the molecular mechanism, risk factors, and treatment for alcohol-induced liver injury. He is currently the principal investigator of the research projects funded by National Institute of Health (NIH) and US Department of Veterans Affairs.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental

Session:
Post-graduate course - Session 2: Alcoholic liver disease - Management from guideline to clinical practice
Topic: Alcoholic Hepatitis-related Hospitalizations: disease burden and mortality rate
Date & Time: Thu, 4 Feb 2021 | 0915 - 1015

S10: What's new in Alcoholic Liver Disease?
Topic: Current Treatments for Alcohol Use Disorders in Chronic Liver Diseases
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Prof Seng-Gee Lim

Director
Department of Hepatology
National University Health System
Singapore

Bio:
Professor Seng Gee Lim graduated in 1980 from Monash Medical School completed his research MD at the Royal Free Hospital. He is a member of the editorial boards for Liver International, Journal of Viral Hepatitis, Hepatology International, Alimentary Pharmacology and Therapeutics, Lancet Gastroenterology & Hepatology, and Evidence Based Internal Medicine Solutions, He is also on the advisory board of Gilead Sciences, Novartis Pharmaceuticals, Bristol Myers Pharmaceuticals, Merck Sharpe and Dohme Pharmaceuticals, Springbank, Abbvie and Abbott Diagnostics. He is currently chairman of the Singapore Hepatology Conference and Science of HBV cure conference.

Session:
Post-graduate course - Session 4: HBV - Disease monitoring to cure
Topic: HBV Infection -Treatment strategies toward a cure
Date & Time: Thu, 4 Feb 2021 | 1300 - 1400

AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

GSK Product Theatre
Topic: Product Theatre
Date & Time: Thu, 4 Feb 2021 | 1430 - 1500

S20: Future Trends of Chronic Hepatitis C Treatment
Topic: Retreatment of HCV-Infected Patients with Direct-Acting Antiviral Failures
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Young-Suk Lim

Professor
Department of Gastroenterology
Asan Medical Center, University of Ulsan College of Medicine
South Korea

Bio:
Prof. Lim is currently the Vice Dean of University of Ulsan College of Medicine in Research Affairs since 2018, and the Secretary General, Korean Association for the Study of the Liver (KASL). Prof. Lim graduated from Seoul National University College of Medicine in 1992. He completed the Clinical Research Training Program at the Mayo Clinic in Rochester, Minnesota, USA in 2008. Prof. Lim was awarded the Emerging Leader Lecturer by the Asian Pacific Digestive Week 2015, Taipei, Taiwan. 2017. He has published many articles in prestigious international medical journals including JAMA Oncology, Gastroenterology, Gut, Hepatology, and Journal of Hepatology.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatobiliary Neoplasia

Session:
Post-graduate course - Session 5: HCC - What's new
Topic: Surveillance tool for hepatocellular carcinoma
Date & Time: Thu, 4 Feb 2021 | 1400 - 1500

Prof Chun-Yen Lin

Chief
Department of Internal Medicine
Chang Gung Memorial Hospital, Linko Medcial Center/Chang Gung Unicersity
Taiwan

Bio:
Professor Lin received his M.D. education at Taipei Medical University and specialty training in Chang Gung Memorial Hospital. Professor Lin was awarded PhD degree by the Oxford University and had been promoted as the professor and deputy head in school of medicine, Chang Gung university and now the head of department of internal medicine in Chang Gung Memorial Hospital, Linkou medical center. He also served as the secretary general of the Gastroenterology Society of Taiwan (GEST) and Taiwan Association of Study of Liver (TASL). Professor Lin’s clinical and research interests focus on the both immunological and clinical aspects of chronic hepatitis and tumour with more than one hundred peer-reviewed papers published.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Inflammation and Immunobiology, NAFLD and NASH

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Han-Chieh Lin

Professor of Medicine
Division of Hepatology and Gastroenterology
Taipei Veterans General Hospital
Taiwan

Bio:
Dr. Han-Chieh Lin is now the professor of Division of Hepatology & Gastroenterology at both Taipei Veterans General Hospital and National Yang-Ming University School of Medicine. Currently, he is also the president of Taiwan Association for the Study of the Liver (TASL) from 2020 to 2022. He had been served as the director of the division from 2006 to 2016. He also spent 1 year in Paris as a research fellow under the instruction of Professor Didier Lebrec from 1989 to 1990.

Dr. Lin has deeply involved in the research of pathophysiology of cirrhotic portal hypertension, liver fibrosis, and complications of cirrhosis. He has been invited to join the editorial board of “Journal of Hepatology (EASL)” from 1995 to 1999. He was the associate editor of “Liver International (IASL)” from January 2008 to April 2014, and also the associate editor of “Journal of Hepatology (EASL)” from January 2015 to December 2017. Currently, he is the academic editor of “PLoS One”, and the associate editor of “Hepatology International (APASL)”. He has published more than 300 peer-reviewed articles in SCI journals.

Areas of Interest:
NAFLD and NASH

Session:
S19: Highlights in Basic Sciences
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

S19: Highlights in Basic Sciences
Topic: Vascular Targets for the Treatment of Portal Hypertension
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Prof Chun-Jen Liu

Director
Hepatitis Research Center
National Taiwan University Hospital
Taiwan

Bio:
Chun-Jen Liu is a professor at the Department of Internal Medicine and Graduate Institute of Clinical Medicine at the National Taiwan University College of Medicine, and is currently Director of the Hepatitis Research Center at the National Taiwan University Hospital. Professor Liu received his MD from the National Taiwan University and was subsequently awarded his PhD by the Graduate Institute of Clinical Medicine at the National Taiwan University College of Medicine. Professor Liu’s professional interests focus on the role of host and viral factors in the pathogenesis and natural/treatment outcomes of chronic hepatitis B and C, carcinogenesis/treatment of hepatocellular carcinoma, and nonalcoholic fatty liver disease. He has published more than 280 peer-reviewed research articles. Professor Liu is also the principal investigator of several multicenter clinical trials involving patients with chronic viral hepatitis B and C, hepatocellular carcinoma and non-alcoholic fatty liver disease. His researches have been recognized by awards from the Liver Disease Prevention and Treatment Research Foundation and Professor JL Sung’s Research Foundation in Taiwan, and 2013 JGHF Emerging Leader Lectureship.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, NAFLD and NASH

Session:
S4: Current Knowledge of Occult Hepatitis B and Hepatitis B Co-Infection
Topic: Treatment of HBV and HCV Co-infection in the Era of Direct-Acting Antiviral Agents
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Prof Josep M Llovet

Professor of Research / Professor of Medicine
Division of Liver Diseases
ICAHN School of Medicine at Mount Sinai
United States

Bio:
Josep M. Llovet, MD, PhD is Professor of Medicine – Hepatic Oncology at University of Barcelona, Professor of Research-ICREA in the Liver Unit, IDIBAPS-Hospital Clínic of Barcelona and Director of the Liver Cancer Program and Full Professor of Medicine at the ICAHN School of Medicine at Mount Sinai, New York and Director. He obtained his degree in Medicine and Surgery from the University of Barcelona in 1986 and his PhD from the Autonomous University of Barcelona in 1995. Professor Llovet has been President, Secretary and Founder of the International Liver Cancer Association (ILCA) and Chairman of the European Clinical Practice Guidelines of management of liver cancer (EASL-EORTC). He is President of the AASLD-SIG of Hepatobiliary neoplasia. He has published more than 300 articles in peer-reviewed journals.

Areas of Interest:
Hepatobiliary Neoplasia

Session:
S7: Clinical and Molecular Pathways of Hepaticocarcinogenesis
Topic: Advances in Molecular Classification and Precision Oncology in Hepatocellular Carcinoma
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Prof Lungen Lu

Director
Department of Gastroenterology
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
China

Bio:
Director of Department of Gastroenterology, Shanghai General Hospital,
Ph.D. Supervisor
Vice Chairman of Chinese Society of Hepatology, Chinese Medical Association
Chairman of Professional Committee of Hepatology, Shanghai Medical Association
Published more than 210 papers
Editorial board member of Chinese Journal of Hepatology, Journal of Hepatology (Chinese Edition), etc
Reviewer for Liver International, Chinese Medical Journal, Chinese Journal of Digestion, and other journals

Areas of Interest:
Human Cholestatic and Autoimmune Liver Diseases, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
Grifols Lunch-time Symposium: Asian vs. European perspectives on the role of albumin in the management of patients with cirrhosis
Topic: How can patients with acute complications of cirrhosis benefit from albumin: Asian perspective
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

Prof Mamun Mahtab

Chairman
Department of Hepatology
Bangabandhu Sheikh Mujib Medical University
Bangladesh

Bio:
I graduated in 1995. Did MSc in Gastroenterology from University of London in 1998 and MD in Hepatology from Bangabandhu Sheikh Mujib Medical University in 2006. I am Fellow of the Royal College of Physicians of London, Royal College of Physicians of Ireland, Indian College of Physicians and American College of Gastroenterology. I am currently working as Chairman, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University. I am also a Visiting Professor at the Department of Gastroenterology & Metabology, Ehime University, Japan

Areas of Interest:
Hepatitis B and Hepatitis D

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Rakhi Maiwall

Additional Professor
Department of Hepatology
Institute of Liver and Biliary Sciences
India

Bio:
Dr Rakhi Maiwall is currently working as an Additional Professor of Hepatology at Institute of Liver and Biliary Sciences. She has special interest in renal dysfunction in patients with cirrhosis and liver failure and critical care hepatology. She heads the Liver Intensive Care at ILBS. She is the Vice-secretary of the International club of ascites has published original articles in indexed journals and has almost 85 publications and published 7 book chapters

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Gut Liver Axis and Microbiome, Inflammation and Immunobiology, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

The 2nd APASL Rising Star Award
Topic: TBA
Date & Time: Sat, 6 Feb 2021 | 1310 - 1330

Prof Michael P Manns

Director
Department of Gastroenterology
Hepatology and Endocrinology
Medical School of Hannover
Germany

Bio:
Professor Michael P. Manns, MD, is Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany. He received his postgraduate training at the Free University of Berlin in Germany and the University of Mainz, where he became Professor of Medicine in 1986. He has a long-term research interest in liver diseases, with a main focus on viral hepatitis, autoimmune liver diseases, hepatocellular carcinoma, liver transplantation, regenerative medicine, and cell therapy. He is Founder and Chairman of Hep-Net, a national network of competence on viral hepatitis, and the German Liver Foundation.

Session:
S9: What's New in Autoimmune Liver Diseases?
Topic: Understanding the Pathogenesis of Autoimmune Liver Diseases
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Dr Soe Thiha Maung

Medical Officer
Department of Medical Services
Ministry of Health and Sports, Myanmar
Myanmar

Bio:
Medical Officer, Department of Medical Sciences, Ministry of Health and Sports, Myanmar
Graduated from the University of Medicine 1, Yangon in 2015
Studied Internal Medicine with Special Interest in Hepatology at Yangon GI and Liver Centre
Obtained MRCP (UK) Diploma in 2019
Actively involved in Multi-centres Clinical Trials as co-investigator
Reviewer for the International Journals (Clinical Medicine, GastroHep, etc)
Co-investigator in AARC

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity, Human Cholestatic and Autoimmune Liver Diseases, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Rosmawati Mohamed

Consultant Hepatologist
Department of Medicine
University Malaya Medical Centre
Malaysia

Bio:
Professor Dr Rosmawati Mohamed is a Consultant Hepatologist at the University Malaya Medical Centre, Kuala Lumpur. She is the Co-chairperson and Founding Committee Member of the Coalition to Eradicate Viral Hepatitis in Asia Pacific and Executive Council Member of the Asian-Pacific Association for the Study of the Liver. Locally, she is the Master, Academy of Medicine of Malaysia and President of Hepatitis Free Malaysia. She has worked tirelessly as a hepatitis and cancer advocate and organised nationwide campaigns on World Hepatitis Day and World Cancer Day to increase public awareness on hepatitis and liver cancer.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, NAFLD and NASH

Session:
Joint Symposium 2 (WHO WPRO_SEARO)
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1100 - 1200

Gilead Lunch-Time Symposium: Shaping Tomorrow Together: Learnings from a Real-world Survey of Liver Health in Asia
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1200 - 1300

S7: Clinical and Molecular Pathways of Hepaticocarcinogenesis
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Joint Symposium 3 (APASL-CEVHAP-WHO)
Topic: Bridging the Gap between Hepatitis Strategies and Liver Cancer: Attempts to reduce the risk of HCC should aim at prevention and control of chronic viral hepatitis and at curbing the growing epidemic of obesity and NAFLD/NASH
Date & Time: Sat, 6 Feb 2021 | 1310 - 1400

Dr Manabu Morimoto

Vice President
Hepatobiliary and Pancreatic Oncology
Kanagawa Cancer Center, Yokohama
Japan

Bio:
Dr Manabu Morimoto is currently a Vice President and Staff of the Department of Hepatobiliary and Pancreatic oncology at Kanagawa Cancer Centre in Yokohama, Japan. Dr Morimoto completed his residency in Internal Medicine in 1990 and since then, have dedicated his career in the area of hepatobiliary and pancreatic oncology. He has actively involved in over 30 clinical trials as key investigator and over 40 trials as sub-investigator and has numerous publications involving the scientific and clinical investigation and treatment of hepatocellular carcinoma

Areas of Interest:
Hepatobiliary Neoplasia

Session:
Eisai Lunch-Time Symposium: Focusing on Lenvatinib as a Novel Molecular Targeted Therapy in Intermediate Stage HCC
Topic: Paradigm shift in the treatment strategy of BCLC-B/ Intermediate stage uHCC patients
Date & Time: Sat, 6 Feb 2021 | 1200 - 1300

Dr Mitra Nadim

Professor of Clinical Medicine
Department of Medicine
Keck School of Medicine, University of Southern California
USA

Bio:
I am a Professor of Clinical Medicine and am a nationally and internationally known nephrologist with expertise in the area of AKI in patients with end-stage liver disease and management of critically ill cirrhotic patients in the ICU. Over the past several years, I have organized 3 international consensus meetings that have resulted in significant contribution to the field of hepatology and liver transplantation. I am the author of more than 50 articles, reviews and book chapters and have participated in several National Guidelines in the area of AKI

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Liver Transplantation and Liver Surgery

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Nobuhiro Nakamoto

Assistant Professor

Division of Gastroenterology and Hepatology
Keio University School of Medicine
Japan

Bio:
Professor Nobuhiro Nakamoto is an Assistant Professor with the Division of Gastroenterology and Hepatology at the Department of Internal Medicine, Keio University School of Medicine.

Session:
S5: Latest Knowledge on Gut Microbiota in Liver Diseases
Topic: The Role of Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications
Date & Time: Fri, 5 Feb 2021 | 0800 – 0940

Prof Philip Newsome

Director / Secretary General of EASL
Centre for Liver and Gastrointestinal Research
University of Birmingham
United Kingdom

Bio:
Professor Newsome graduated from Medical School at University of Edinburgh in 1995, moved to Birmingham in 2007 and became Professor of Experimental Hepatology & Hon Consultant Hepatologist, running the metabolic services at Queen Elizabeth Hospital Birmingham. As Director of Centre for Liver and Gastrointestinal Research and Director of Research and Knowledge Transfer, at University of Birmingham, his laboratory group focusses on identifying novel targets in the pathogenesis of NAFLD and on the role of cell therapy in liver injury.

Areas of Interest:
Metabolic and Genetic Disease, NAFLD and NASH

Session:
Joint Symposium 4 (EASL-APASL)
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Joint Symposium 4 (EASL-APASL)
Topic: Disease Progression
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Dr Supot Nimanong

Medical Instructor
Department of Medicine
Siriraj Hospital, Mahidol University
Thailand

Bio:
CURRENT POSITION:
Instructor in Medicine, Division of Gastroenterology, Department of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. (2009-Present)
EDUCATION:
1994 - 2000 M.D. with 1st Class Honor, Faculty of Medicine, Siriraj Hospital, Mahidol University
2003 - 2006 Internal Medicine Resident, Faculty of Medicine, Siriraj Hospital, Mahidol University
2006 - 2007 Research Fellowship in Gastroenterology, Siriraj Hospital, Mahidol University
2007 - 2009 Fellowship in Gastroenterology, Siriraj Hospital, Mahidol University
2013 - 2015 Research Associate in Oncoimmunology, Hannover Medical School, Germany.

Areas of Interest:
Hepatobiliary Neoplasia

Session:
S7: Clinical and Molecular Pathways of Hepaticocarcinogenesis
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S16: Surveillance of Hepatocellular Carcinoma
Topic: Rationale for HCC surveillance in Patients with MAFLD
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Prof Qin Ning

Director
Department of Infectious Diseases
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
China

Bio:
Dr. Ning’s clinical care activities include hepatology, clinical immunology, and infectious disease, with focus on viral hepatitis.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatitis C, Inflammation and Immunobiology, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH

Session:
SOTA 1
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S15: COVID-19: Lessons Learnt from Eastern and Western Worlds
Topic: Immunological-Related Multifacet Presentations of COVID-19
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Assoc Prof Naoshi Nishida

Associate Professor
Hepatitis Research Center
Kindai University Faculty of Medicine
Japan

Bio:
2011-present: Associate Professor, Department of Gastroenterology and Hepatology, Kindai University, Faculty of Medicine, Osaka, Japan
2006 – 2011: Lecturer / Assistant Professor, Department of Gastroenterology and Hepatology, Kyoto University, Graduate School of Medicine, Kyoto, Japan
2004 – 2006: Research fellow, Division of Gastroenterology. Dept of Internal Medicine, Baylor University Medical Centre, Dallas, TX
1997 – 2004: Assistant Professor, Department of Medicine and Clinical Science, Kyoto University, Graduate School of Medicine, Kyoto, Japan
1996 – 1997: Instructor, Research Institute for Production Development, Kyoto, Japan Kyoto University (Ph.D), Osaka Medical School (M.D)
Research Area: Genomics, Liver Neoplasm, Medical Informatics
Research Interest: Hepatocellular Carcinoma, Treatment, Diagnosis, Genetics/Epigenetics, Molecular Carcinogenesis, Artificial Intelligence, Data Base Science

Areas of Interest:
Cell and Molecular Biology, Genomics and Precision Medicine, Hepatobiliary Neoplasia

Session:
S2: Novel Technologies in Hepatology
Topic: Current Status and Perspectives for Computer-aided Ultrasonic Diagnosis of Liver Lesions Using Deep Learning Technology
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

Asst Prof Eiichi Ogawa

Assistant Professor
General Internal Medicine
Kyushu University Hospital
Japan

Bio:
Eiichi Ogawa is an assistant professor in the Department of General Internal Medicine at Kyushu University Hospital, Japan. Professor Ogawa obtained his MD from Kobe University, Japan and subsequently completed residencies in internal medicine at the Kyushu University Hospital and fellowships in general internal medicine at the Mitsutake Internal Medicine and Cardiovascular Hospital, Nagasaki, Japan as well as the Kyushu University Hospital. He is a member of numerous national and international scientific societies including the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases (AASLD).

Areas of Interest:
Hepatitis C

Session:
Gilead Lunch-Time Symposium: Shaping tomorrow together: Optimising CHB management in the Asia-Pacific region
Topic: Enhancing care for patients with CHB
Date & Time: Thu, 4 Feb 2021 | 1200 - 1300

Prof Masao Omata

President, Honorary Professor
Department of Gastroenterology
Yamanashi Central and Kita Hospitals, University of Tokyo
Japan

Bio:
Masao Omata, MD, is a Co-Editor of Hepatology International (an official journal of APASL-Asian Pacific Association for the Study of the Liver) with Prof. Sarin. He graduated Chiba University in 1970, and joined the First Department of Internal Medicine of Chiba University chaired by Prof. Kunio Okuda. After three years training in Japan, he went to the United States (3 years at Yale and 3 years at USC-University of Southern California, Liver Unit) where he was trained by Prof. Gerald Klatskin at Yale and Robert L. Peters at USC. The publication in Gastroenterology in 1979 on the etiology of hepatocellular carcinoma (one of the first papers documented the virus etiology in USA where alcoholic liver disease was predominant) (Ref.101) was quoted in the textbook of Harrison for several editions. He was also a co-author of first documentation on “Fibrolamellar carcinoma” with Edmondson and Peters (Ref.10). In 1979, he returned to Dr. Okuda’s department, and started to introduce molecular biological techniques in clinical gastroenterology in 1982 and published approximately 90 papers including 2 N Engl J Med original articles (1985 and 1991) on molecular biological aspect of hepatitis viruses, especially on human and duck hepatitis B viruses until his move to University of Tokyo in 1992. He first reported the correlation of pre-core mutant and fulminant hepatitis (Ref.9), and extremely high eradication rate of acute hepatitis C by interferon (Ref.49), later confirmed by other groups. He first documented that the supercoiled or CCC (Covalantly Closed Circular) DNA of HBV was the key molecule for the resistance of anti-viral treatment in human samples (Yokosuka, Omata, Summers, Hepatology 1985). In 1992 (13 years after Chiba era), he was promoted to the chairman of Second Department of Internal Medicine at University of Tokyo. This was an unprecedented event in the history of Japanese medical society since the medical faculty at the University of Tokyo had never chosen the chairman of the major clinical departments from outside of University of Tokyo graduates until his appointment. Because of the re-organization of the departments in University of Tokyo, he became the chairman of Department of Gastroenterology in 1997, and has established a large and very strong department of Gastroenterology over 100 young gastroenterologists and hepatologists. In 2009, he was promoted to become the president of two hospitals; Yamanashi Central (691 beds) and Kita (200 beds) Hospitals to upgrade the medical care system in Yamanashi Prefecture, west of Tokyo, where, although scenic place with Mt. Fuji, hepatitis virus infection is endemic. The governor of Yamanashi has asked Prof. Omata to combat with the liver diseases of his homeland under his expertise, and also run the two hospitals as a president. Number of publications in English peer review journals in the last 28 years after he moved to University of Tokyo, are 1090 in all disciplines (both basic and clinical) of Gastroenterology and Hepatology. He was a president of the 40th Annual Meeting of Japan Society of Hepatology (10,000 members), a president of the APASL (Asian Pacific Association for the Study of the Liver)(2006-2007), a and a president of the 50th JSGE (Japanese Society of Gastroenterology)(28,000 members) 2008 meeting. Currently, he is an Editor-in-Chief of Hepatology International (the Official Journal of APASL), and is in charge of APASL-Tokyo-Secretariat.

Areas of Interest:
Hepatitis C

Session:
Opening Ceremony
Opening Ceremony Speech
Date & Time: Fri, 5 Feb 2021 | 1030 - 1100

APASL HBV Reactivation 2021 Guideline
Chairperson
Date & Time: Sat, 6 Feb 2021 | 0800 - 1000

APASL Distinguished Award presentation and lectures - 2nd APASL Okuda - Omata Distinguished Award
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1020 - 1040

Okuda Oration
Topic: Molecular Mechanisms of Multicentric Recurrence of HCC before and after DAA treatment
Date & Time: Sat, 6 Feb 2021 | 1130 - 1200

Prof Kim Olthoff

Associate Professor
Professor of Surgery & Chief of Transplant Surgery
University of Pennsylvania
United States

Bio:
Kim M. Olthoff, MD, is the Donald Guthrie Professor of Surgery at the University of Pennsylvania, and Chief of the Division of Transplant Surgery, leading the liver transplant programs at Penn and the Children’s Hospital of Philadelphia. Dr. Olthoff is Past-President for the American Society of Transplant Surgeons and chaired numerous committees for national and international transplant societies. She has a busy clinical practice in adult and pediatric liver transplantation, living donor surgery, and hepatobiliary surgery and an active research program in clinical and translational studies that focus on living donation and liver regeneration and early allograft dysfunction.

Areas of Interest:
Hepatobiliary Neoplasia, Hepatobiliary Surgery, Liver Transplantation and Liver Surgery

Session:
HS2: Living Donor Liver Transplantation (LDLT) for HCC beyond Miland Criteria
Topic: Its disadvantages are obvious
Date & Time: Sat, 6 Feb 2021 | 1030 - 1100

Prof Ngaraja R Padaki

Director and Cheif
Department of Hepatalogy
Asian Institute of Gastroenterology-hyderabad
India

Bio:
Present position:
Director and Chief of Hepatology AIG Hospitals, Gachibowli, Hyderabad, Telangana, India
President of Indian National Association for the study of Liver disease. (INASL)
Past positions:
Governing Council member ISG, INASL participant INASL task force Team for NAFLD, HBV, HCC
Contributed to INASL clinical practice guidelines on important liver related contemporary issues
Founding members of Coalition for Eradication of Viral Hepatitis in Asia Pacific (CEVHAP)
Authored chapters in API textbook, INASL monograms and original articles in basic research of HBV, HCV and NAFLD in peer reviewed journals
His fields of interest NAFLD, alcoholic liver disease, DILI
He has about 100 publications

Areas of Interest:
Hepatobiliary Neoplasia, Autoimmune Liver Diseases, NAFLD and NASH

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Assoc Prof Nonthalee Pausawasdi

Associate Professor
Department of Internal Medicine
Faculty of Medicine Siriraj Hospital
Thailand

Bio:
Nonthalee Pausawasdi graduated from the Prince of Songkla University. She received internal medicine residency training, GI fellowship, advanced endoscopy fellowship and postdoctoral research training from the University of Michigan Medical Center. She is an Associate Professor at the Faculty of Medicine Siriraj Hospital, Mahidol University, the Director of the World Gastroenterological Organization (WGO) endoscopy training program at the Siriraj endoscopy center in Bangkok, and the Vice President of the Thai Association of Gastrointestinal Endoscopy. Her clinical and research interest is in the area of therapeutic endoscopy, ERCP and EUS.

Areas of Interest:
Hepatobiliary Neoplasia, Portal Hypertension and Other Complications of Cirrhosis

Session:
S13: Novel Endoscopic Interventions in Liver Diseases
Topic: New Developments in Managing Variceal Bleeding
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Prof Calvin Pan

Professor of Medicine
Division of Gastroenterology and Hepatology
NYU Langone Health, NYU Grossman School of Medicine
United States

Bio:
Dr. Pan is a Professor at NYU Langone Health of NYU School of Medicine in New York, USA. His research interests include viral hepatitis and MAFLD. He served as a principal investigator for many multi-center trials on Hepatitis B or C. Widely published, Prof. Pan has presented his work as the leading author in the New England Journal of Medicine, Hepatology, and Journal of Hepatology. He is a chair-elect of the Hepatitis B Interest Group at the AASLD and the recipient of the James D. Bruce Memorial Award for Distinguished Contributions in Preventive Medicine from the American College of Physicians.

Areas of Interest:
Hepatitis B and Hepatitis D, NAFLD and NASH

Session:
Joint Symposium 2 (WHO WPRO_SEARO)
Topic: Addressing research gaps in HBV elimination of mother to child transmission - 2: The efficacy and safety of tenofovir alafenamide (TAF) for the prevention of HBV vertical transmission
Date & Time: Sat, 6 Feb 2021 | 1100 - 1200

Assoc Prof Anjana Pillai

Associate Professor of Medicine
Center for Liver Diseases
University of Chicago Medicine
United States

Bio:
Dr. Anjana Pillai is an Associate Professor of Medicine at the University of Chicago Medicine. She is a transplant hepatologist and specializes in the care of patients with complications from chronic liver disease. She is the medical director of the liver tumor program and the co-director of the liver tumor board. Her clinical and research interests are in hepatobiliary malignancies.

Areas of Interest:

Session:
Joint Symposium 1 (AASLD - APASL)
Topic: Immune Phenotype and Checkpoint inhibitors for the treatment of HCC
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Mr Eduardo Pisani

Chief Executive
All.Can International asbl
Belgium

Bio:
Eduardo has over three decades of international experience in senior roles for global healthcare companies and associations. He spent most of his professional life in Brussels and Geneva, where he gained an in-depth knowledge of the functioning of the European Union and of multilateral organisations, particularly in the area of health and pharmaceutical policy and legislation. He served on the board of international and European groups and on various advisory boards. He is currently leading All.Can International, a non-profit organisation in the field of cancer, and is active in a digital health start-up venture with a social impact mission focused on low-and middle-income countries in Africa and Asia. Eduardo has a degree in Law from the University of Catania, Italy.

Session:
Joint Symposium 3 (APASL-CEVHAP-WHO)
Topic: Building a Collaborative Environment: How All.Can came about as an international, multi-stakeholder coalition to tackle inefficiencies in cancer care; and how the organisation is now evolving its scope of work from prevention to survivorship with increasing emphasis is being placed on screening and timely diagnosis polices.
Date & Time: Sat, 6 Feb 2021 | 1310 - 1440

Assoc Prof Teerha Piratvisuth

Associate Professor
NKC Institute of Gastroenterology and Hepatology
Prince of Songkla University
Thailand

Bio:
Dr Teerha Piratvisuth is Associate Professor of Medicine at the Prince of Songkla University, Hat Yai, Thailand. He completed his medical degree with first class honor, at the Prince of Songkla University in 1985. During 1993–94 he studied as a Clinical Fellow in hepatology at King’s College School of Medicine and Dentistry in London, UK. In 1995 he moved to the US, where he spent a further year as a Clinical Fellow in hepatology and endoscopy at the University Texas, Houston Medical School. He also currently holds the positions of Vice Dean at Prince of Songkla University and Director of the NKC Institute of Gastroenterology and Hepatology. Dr Piratvisuth was a President of the Liver Society of Thailand during 2011-2012. He is a President of APASL 2011, a Vice President of APDW 2012, Scientific Committee Chairman of APLD 2016, Scientific Committee Chairman of Gastro 2018 and Honorary President APASL 2021. Dr Piratvisuth is a member of the steering committee of APASL Dr Piratvisuth has an extensive publication history on liver disease particularly hepatitis B&C and is on the editorial board of Hepatology International, Korean Journal of Gastroenterology and Chinese Journal of Infectious Disease and is a reviewer for the Journal of Gastroenterology and Hepatology, the Journal of Alimentary Pharmacology and Therapeutics, the Journal of Hepatology, Hepatology, Liver International, Hepatology International, the Journal of Viral Hepatitis, Antiviral Therapy and Journal of Antimicrobial chemotherapy.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity

Session:
Gilead Lunch-Time Symposium: Shaping tomorrow together: Optimising CHB management in the Asia-Pacific region
Chairperson
Date & Thu, 4 Feb 2021 | 1200 - 1300

Post-graduate course - Session 4: HBV - Disease monitoring to cure
Topic: Role of HBV core related antigen in clinical practice
Date & Time: Thu, 4 Feb 2021 | 1300 - 1400

SOTA 1
Topic: Unresolved Issues of Immune Tolerance in Chronic Hepatitis B
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

Assoc Prof Kittiyod Poovorawan

Associate Professor
Clinical tropical medicine, Faculty of Tropical Medicine
Mahidol University
Thailand

Bio:
Dr. Kittiyod Poovorawan is Associated Professor in the Department of Clinical Tropical Medicine, Mahidol University, Thailand. He is a medical doctor with expertise in internal medicine, gastroenterology, hepatology, and clinical research. He works as a gastroenterology consultant physician and deputy director at the Hospital for Tropical Diseases. His primary research area is liver diseases included viral hepatitis, liver abscess, and gastrointestinal involvement of tropical diseases. He is experienced in conducting clinical trials study focusing on viral hepatitis and tropical infectious diseases. He has published more than 50 international peer-reviewed articles in the area of infectious diseases, tropical medicine, and gastroenterology.

Areas of Interest:
Health Services Research, Hepatitis B and Hepatitis D, Hepatitis C, Other Viral Hepatitis

Session:
S3: A Revisit of Tropical Liver Diseases
Topic: Severe Liver Dysfunction from Dengue and Chikungunya Virus Infection
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

S6: Updates on Liver Fibrosis: From Pathophysiology to Potential Treatment
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Prof Xiao-Long Qi

Chief
Portal Hypertension Center
The First Hospital of Lanzhou University
China

Bio:
My research interest and clinical practice focuses on the patient-oriented clinical and translational research about the diagnosis and monitoring of cirrhosis and portal hypertension. I am Advisory board of EBioMedicine, and Editorial board of Hepatology International, author/co-author of over 112 peer-reviewed original and review articles in J Hepatol, Gut, Lancet Gastroenterol Hepatol, Trends Pharmac Sci, Ann Surg, Radiology, etc., and my research finding was highlighted by Lancet, and Nature.

Areas of Interest:
Portal Hypertension and Other Complications of Cirrhosis

Session:
S2: Novel Technologies in Hepatology
Topic: Liver Imaging in Precision Medicine
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Dr Ruveena Bhavani Rajaram

Consultant Gastroenterologist & Hepatologist
Department of Internal Medicine (Gastroenterology Unit)
University of Malaya Medical Centre
Malaysia

Bio:
Dr. Ruveena is a Consultant Gastroenterologist and Hepatologist & Internal Physician at University of Malaya Medical Centre (UMMC) and UM Specialist Centre (UMSC), Kuala Lumpur, Malaysia. She graduated from University of Malaya in 2006, obtained Membership of Royal College of Physicians and Surgeons of Glasgow in 2012 and is a board-certified Gastroenterologist and Hepatologist since 2018. Her area of expertise includes GI endoscopy (including therapeutic EUS and ERCP), viral hepatitis, pre and post liver transplantation care, advanced liver cirrhosis and its complications. She is part of the pioneer liver transplant team of UMMC and is involved in research and training of undergraduates, postgraduates and Gastroenterology and Hepatology fellows

Areas of Interest:
Hepatitis B and Hepatitis D, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Rajender Reddy

Ruimy Family President’s Distinguished Professor of Medicine Director of Hepatology
Medical Director of Liver Transplantation
Department of Medicine, Division of Gastroenterology/Hepatology
University of Pennsylvania
United States

Bio:
Rajender Reddy, MD is Professor of Medicine in the Division of Gastroenterology/Hepatology at the University of Pennsylvania in Philadelphia, Pennsylvania. He is the Director of Hepatology and the Director of the Viral Hepatitis Center. Dr. Reddy received his medical education from Osmania Medical College in Hyderabad, India. He then completed a residency in internal medicine at NewYork Medical College Hospitals, a fellowship in Gastroenterology at East Tennessee State University College of Medicine, and a fellowship in Hepatology at the University Of Miami School Of Medicine. Subsequently he joined the faculty at the University of Miami and in October 2001, Dr.Reddy moved to the University of Pennsylvania to the current position.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis C, Liver Transplantation and Liver Surgery

Session:
S15: COVID-19: Lessons Learnt from Eastern and Western Worlds
Topic: The Impacts of COVID-19 on the Practice of Hepatologists
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

HS1: Anticoagulants for Portal Vein Thrombosis in Cirrhosis: DOACs vs. LWMH and Warfarin
Topic: Direct-Acting Oral Anticoagulants (DOACs) are better
Date & Time: Sat, 6 Feb 2021 | 0940 - 1010

Prof Rungsun Rerknimitr

Chief of Gastroenterology
Department of Medicine
Chulalongkorn University
Thailand

Bio:
Rungsun Rerknimitr graduated from Chulalongkorn University, Thailand with honor. He obtained his American Board of Internal Medicine from Rush Medical College, Chicago in 1996. Later, he pursued his Gastroenterology fellowship from Louisiana State University in New Orleans. Before he returned to Thailand, he obtained an ERCP fellowship from Indiana University. He is currently a Professor of Medicine, Chief division of gastroenterology and a Director of Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Chulalongkorn University, Bangkok, Thailand. He is also a founding member and past president of the Thai Association of Gastrointestinal Endoscopy (TAGE) and also the past chief editor of the Thai Journal of Gastroenterology. He also leads many PhD candidates and post Doc fellows in the Center of Excellence in GI Oncology Endoscopy of Chulalongkorn University. His main research interests are in field of colorectal cancer including screening, adenoma detection and prediction, quality indexes in colonoscopy and palliative stenting. His other main endoscopic interest is therapeutic ERCP with a special interest in metallic stent clinical application. His extra-endoscopy medical interest is telemedicine.

Areas of Interest:
Hepatobiliary Neoplasia, Portal Hypertension and Other Complications of Cirrhosis

Session:
S13: Novel Endoscopic Interventions in Liver Diseases
Topic: An Approach to Indeterminate Biliary Stricture
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Dr Riad Salem

Chief, Interventional Radiology
Department of Radiology
Northwestern University
Chicago
United States

Bio:
Riad Salem, MD MBA is a Vice-Chair, Image-Guided Therapy and Chief, Interventional Radiology and Oncology in the Department of Radiology at Northwestern University (Chicago). His areas of interest include the use of image-guided techniques for the treatment of malignancies. These include chemoembolisation, bland embolisation, radioembolisation, radiofrequency and cryo/alcohol ablation. He is a graduate of McGill University in Montreal, Canada. He completed his radiology residency in Washington, DC. He has also completed a fellowship in interventional radiology (University of Pennsylvania), as well as a Master’s in Business Administration (Finance). He is a member of Alpha Omega Alpha medical honor society and a Fellow of the Society of Interventional Radiology. He has lectured internationally and published extensively on the subject of image-guided interventions and interventional oncology. Recently, he completed his term on the NCCN guidelines panel for hepatocellular carcinoma (2007-2010). His current research focus on hepatocellular carcinoma includes advances in minimally invasive therapies as well as imaging methodologies following locoregional treatment. He serves as co-PI of 2 international, randomised phase III trials involving locoregional therapy (radioembolisation) and sorafenib (STOP-HCC, YES-p).

Areas of Interest:
Health Services Research, Hepatobiliary Neoplasia, Portal Hypertension and Other Complications of Cirrhosis

Session:
Joint Symposium 1 (AASLD - APASL)
Topic: mRECIST for Immunotherapy of HCC: Performance and novel Refinements
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Prof Shiv K Sarin

Senior Professor
Department of Hepatology
Institute of Liver and Biliary Sciences
India

Bio:
Prof Shiv Kumar Sarin is the Senior Professor, Hepatology. He has set-up the Institute of Liver and Biliary Sciences (ILBS) in New Delhi, a dedicated Liver University and the largest liver set-up globally. Prof Sarin has more than 630 publications to his credit, edited 13 books on liver diseases and has helped develop 19 major guidelines. He has been awarded the prestigious Henry L. Bockus Medal -2017 by World Gastroenterology Organization. He is also a recipient of The World Academy of Medical Sciences (TWAS) International Prize, EASL International Recognition Award, besides being a founding Editor of Hepatology International. Prof. Sarin has shown leadership roles in being the President of the Asian Pacific Association of Liver (APASL), and Chairman Steering Committee of the APASL.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis C, NAFLD and NASH, Other Viral Hepatitis, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
Opening Ceremony
Date & Time: Fri, 5 Feb 2021 | 1030 - 1100

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Grifols Lunch-Time Symposium: Asian vs. European perspectives on the role of albumin in the management of patients with cirrhosis
Topic: Cirrhotic patient and the promise of preventative uses of albumin in Asia
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

APASL HBV Reactivation 2021 Guideline
Chairperson
Date & Time: Sat, 6 Feb 2021 | 0800 - 1000

APASL Distinguished Award presentation and lectures - The 2nd APASL Powell-Sarin Lifetime Achievement Award
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Prof Bernd Schnabl

Professor of Medicine
Department of Medicine
University of California San Diego
United States

Bio:
Dr. Schnabl is a trained gastroenterologist and physician-scientist. He is staff physician and attending at the VA San Diego Medical Center in La Jolla and the UCSD Medical Center. He recently became Director of the NIH-funded San Diego Digestive Diseases Research Center (SDDRC). His lab is particularly interested in the contribution of the gut microbiome to the onset and progression of liver disease. He is using system biology approaches to better understand the interaction between the intestinal microbiome and the liver during chronic liver disease. He is Associate Editor for Journal of Hepatology.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Gut Liver Axis and Microbiome

Session:
S5: Latest Knowledge on Gut Microbiota in Liver Diseases
Topic: Communication between Liver and Gut in Alcoholic Liver Diseases
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Assoc Prof Supatsri Sethasine

Gastroenterology and Hepatology Unit
Department of Medicine
Navamindradhiraj University
Thailand

Bio:
Head of Gastroenterology and Hepatology Unit
Faculty of medicine ,Navamindradhiraj university, Bangkok, Thailand

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatitis C, NAFLD and NASH, Other Viral Hepatitis

Session:
S16: Surveillance of Hepatocellular Carcinoma
Topic: Biomarkers and Risk Scores for HCC Surveillance: Present and Future Benefits
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Dr Olivier Segeral

Research Advisor
University of Health Sciences
ANRS
Cambodia

Bio:
Hospital practitioner in internal medicine department, Master in Public health in resource-limited setting, professional experience in infectious diseases and public health, specifically for the treatment and care of people living with HIV and viral hepatitis B and C. Assistant coordinator for research programs on HIV/AIDS and viral hepatitis for the French Agency for Research on AIDS and Viral Hepatitis (ANRS)

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C

Session:
Joint Symposium 2 (WHO WPRO_SEARO)
Topic: Addressing research gaps in HBV elimination of mother to child transmission -1: HBIg-free alternative strategy to prevent HBV mother-to-child transmission: the ANRS 12345 TA-PROHM study
Date & Time: Sat, 6 Feb 2021 | 1100 - 1200

Prof Abraham Shaked

Professor of Surgery
Department of Surgery
University of Pennsylvania
United States

Bio:
Abraham Shaked MD PhD is the Eldridge L. Eliason professor of Surgery, and the Executive Director of the Penn Transplant Institute at the University of Pennsylvania. He completed his residency at Mount Sinai in New York, and continued his clinical and scientific work at UCLA in Los Angeles. Dr. Shaked was recruited to direct the liver transplant program at the Hospital of the University of Pennsylvania and the Children Hospital of Philadelphia in 1995. The Penn Transplant Institute is a large center that provides the infrastructure for all thoracic, abdominal transplantation. Dr. Shaked is a past president of the American Society of Transplant Surgeons.

Areas of Interest:
Genomics and Precision Medicine, Inflammation and Immunobiology, Liver Transplantation and Liver Surgery, NAFLD and NASH, Pediatric Hepatology

Session:
S18: Strategies to Improve Long-term Post-Liver Transplantation
Topic: Personalized Immunosuppression in Liver Transplantation
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Prof Barjesh Chander Sharma

Professor
Department of Gastroenterology
Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
India

Bio:
Dr. Brajesh is a senior professor and has more than 20 years of clinical and teaching experience. Prior to joining ILBS, he served as Professor Gastroenterology at G.B.Pant hospital. He is the recipient of many prestigious awards such as Olympus J Mitra Award, ISG – SR Naik Memorial Award 2006, etc. He is the assistant editor of Hepatology International and serves as an editorial member of many gastroenterology journals such as the World Journal of Gastroenterology, J Gastroenterol Hepatol, and Journal of Clinical and Experimental Hepatology.

Areas of Interest:
Portal Hypertension and Other Complications of Cirrhosis

Session:
SOTA 6
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1130 - 1200

HS3: Refractory Esophageal Variceal Bleeding in Cirrhosis
Topic: Esophageal Stenting
Date & Time: Sat, 6 Feb 2021 | 1430 - 1500

Prof Manoj Kumar Sharma

Professor and Head
Department of Hepatology and Liver Transplantataion
Institute of Liver and Biliary Sciences, New Delhi
India

Bio:
Current position: Professor and Head Hepatology, Institute of Liver & Biliary Sciences, New Delhi, India.

AREAS OF INTEREST: Viral hepatitis; alcohol related liver diseases, Sleep in cirrhois, Portal hypertension.
PUBLICATIONS ORIGINAL ARTICLES : 125
PUBLICATIONS: REVIEWS: 50
H- INDEX=40

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Portal Hypertension and Other Complications of Cirrhosis

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

S15: COVID-19: Lessons Learnt from Eastern and Western Worlds
Topic: A Challenge in Management of Liver Injury in COVID-19
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

S21: Hot Topics in Cirrhosis and its Complications
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Dr Ying-Chun Shen

Attending physician, Assistant Professor
Department of Medical Oncology
National Taiwan University Cancer Center
Taiwan

Bio:
Dr. Shen is a medical oncologist, working at National Taiwan University Cancer Center, Taipei, Taiwan. She has been actively involved in clinical trials and translational research of hepatocellular carcinoma (HCC). Her current research interests are bridging the knowledge gap between HCC immunology and effective immunotherapeutic strategies to improve the outcome of HCC patients.

Areas of Interest:
Genomics and Precision Medicine, Gut Liver Axis and Microbiome, Hepatobiliary Neoplasia, Inflammation and Immunobiology

Session:
Joint Symposum 1 (AASLD-APASL)
Topic: Immunomodulatory Effects of Immunotherapy on Hepatocellular Carcinoma
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

S22: Team-based Management of Hepatocellular Carcinoma
Topic: Trends in the Treatment of Advanced HCC: Immune Checkpoint Inhibitors and Related Combination Therapies
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Gamal Shiha

Professor of Internal Medicine
Department of Gastroenterology & Hepatology
Egyptian Liver Research Institute And Hospital
Egypt

Bio:
Prof. Internal Medicine - Department Gastroenterology and liver unit; Faculty of Medicine, Mansoura University
Founder and Head of the the Association of Liver Patients’ Care (ALPC), Dakahlia, Egypt
Founder and CEO of Egyptian Liver Research Institute and Hospital (ELRIAH)
Asian Pacific for The Study of Liver (APASL) Member of Board (2006-2010)

Areas of Interest:
Hepatitis C, NAFLD and NASH, Other Viral Hepatitis

Session:
S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

APASL Distinguished Award presentation and lectures - The 2nd APASL Powell- Sarin Lifetime Achievement Award
Hepatocellular Carcinoma in the era of HCV elimination
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Prof Shuichiro Shiina

Professor
Department of Gastroenterology
Juntendo University
Japan

Bio:
Prof. Shuichiro Shiina graduated at the University of Tokyo in 1982 and received Ph.D. degree with a study “A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma (Gastroenterology 2005) in 2005. He moved to Juntendo University in 2012. Prof. Shiina is a pioneer of image-guided ablation therapies, such as percutaneous ethanol injection, microwave ablation (MWA) and radiofrequency ablation (RFA). He has performed ablation on over 14,000 patients with liver tumors (Am J Gastro 2012). Prof. Shiina published over 350 international scientific papers and over 450 domestic scientific papers. He was the president of APASL STC on HCC in Yokohama in 2018 and is the chairman of ACTA (Asian Conference on Tumor Ablation) in Tokyo in 2021.

Areas of Interest:
Hepatobiliary Neoplasia, Training and Education (Career Development)

Session:
Post-graduate course - Session 5: HCC - What's new
Topic: RFA and current approach for HCC
Date & Time: Thu, 4 Feb 2021 | 1400 - 1500

S22: Team-based Management of Hepatocellular Carcinoma
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Dr Douglas Simonetto

Assistant Professor of Medicine
Department of Gastroenterology and Hepatology
Mayo Clinic
United States

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Genomics and Precision Medicine, Portal Hypertension and Other Complications of Cirrhosis

Session:
S19: Highlights in Basic Sciences
Topic: Short telomeres: Cause and Consequence in Liver Diseases
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Dr Ashwani Singal

Associate Professor, Chief Clinical Research Program
Medicine, division of transplant hepatology
University of South Dakota Sanford SOM, Avera Transplant Institute
USA

Bio:
Dr. Singal directs hepatology elective for medical students at Sanford SOM. With research interests on ALD and NAFLD, his research is funded by ACG, NIH, and industry. With over 200 peer reviewed articles, he is on editorial board of liver transplantation, EIC for Translational Gastroenterology Hepatology, and AE for DLD, PLoS one, and JCTH. Dr. Singal reviews grants and abstracts for AGA and AASLD, and is on NIH study section. He is lead author on ALD guidelines, co-authored guidelines on vascular liver disorders, and is co-authoring guidelines on nutritional management in cirrhosis. Dr. Singal is awarded ACG Edgar Achkar Visiting Professorship, and chairs AASLD ALD SIG

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Gut Liver Axis and Microbiome, Health Services Research, Liver Transplantation and Liver Surgery, Metabolic and Genetic Disease, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Assoc Prof Abhasnee Sobhonslidsuk

Associate Professor
Department of Medicine
Ramathibodi Hospital
Thailand

Bio:
Office
Division of Gastroenterology and Hepatology Department of Medicine, Ramathibodi Hospital

Education
2002 Hepatology fellowship training program University of Miami School of Medicine
1998 Gastroenterology fellowship training program Ramathibodi Hospital, Mahidol University

Appointments
1. Chair of Scientific committee, The 30th Asia-Pacific Association of the Study of the Liver (APASL) 2021
2. Chair of Research committee, , The Gastroenterological Association of Thailand 2019 3. Secretary general, Liver Society of Thailand, 2017-8
4. Chair of Scientific committee, The Gastroenterological Association of Thailand 2011-4
5. Chair of Scientific committee, Liver Society of Thailand, 2011-2
6. Chair of Scientific committee, The 21st APASL 2011

Areas of Interest:
Hepatotoxicity

Session:
Joint Symposium 1 (AASLD - APASL)
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

S23: Recent Advances in Drug-Induced Liver Injury
Topic: Drug-Induced Liver Injury in the Setting of Chronic Liver Disease
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Jose D Sollano

Professor
Department of Gastroenterology
University of Santo Tomas
Philippines

Bio:
Jose D. Sollano, Jr., is Professor of Medicine at the University of Santo Tomas. His major interests include chronic hepatitis B, hepatocellular carcinoma, portal hypertension, therapeutic endoscopy of the biliopancreatic system, GERD and peptic ulcer disease, and of course, inflammatory bowel disease. He received the Most Outstanding Researcher Award of the Philippine College of Physicians in 2003 and a consistent Gold/Silver Awardee for Research of the University of Santo Tomas since 2001. In 2012, he is also a recipient of the Thomas Award for Research of the UST Medical Alumni Association.

Session:
SOTA 4
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

S13: Novel Endoscopic Interventions in Liver Diseases
Topic: Management of Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

APASL Distinguished Award presentation and lectures - The 2nd APASL Sollano-Lesmana Great Mentor Award
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Dr Sith Siramolpiwat

Assistant Professor
Department of Medicine
Thammasat University
Thailand

Bio:
After receiving Thai board of gastroenterology and hepatology, I obtained further training at Hepatic Hemodynamic Lab, Liver Unit, Hospital Clinic, Barcelona. I am now working as an assistant professor, Department of Medicine and Chulabhorn International College of Medicine, Thammasat University.

Areas of Interest:
Portal Hypertension and Other Complications of Cirrhosis

Session:
S8: The Myths and Realities of Portal Hypertension
Topic: Beta-blockers in Cirrhosis: Evidence-based Indications and Limitations
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Assoc Prof Simone Strasser

Senior Staff Specialist
AW Morrow Gastroenterology and Liver Centre
Royal Prince Alfred Hospital and University of Sydney
Australia

Bio:
A/Prof Simone Strasser is a Senior Staff Specialist in the AW Morrow Gastroenterology and Liver Centre and the Liver Transplant Unit at Royal Prince Alfred Hospital and the University of Sydney, Sydney Australia. She is President of the Gastroenterological Society of Australia (GESA), a member of the Executive Council of the Asian Pacific Association for the Study of the Liver (APASL) and an Associate Editor for Transplantation. She has interests in primary liver cancer, viral hepatitis, non-alcoholic fatty liver disease, advanced liver disease, and liver transplantation. She is Director of Hepatology Clinical Trials at RPAH leading clinical trials of new therapies for patients with liver disease and liver cancer.

Areas of Interest:
Hepatobiliary Neoplasia, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
S18: Strategies to Improve Long-term Post-Liver Transplantation
Topic: Nutritional and Metabolic Considerations in Liver Transplant Patients
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Dong-Jin Suh

Emeritus Professor
Department of Gastroenterology
Asan Medical Center
Korea

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH

Session:
Post-graduate course - Session 1: NAFL/ MAFLD
Chairperson
Date & Time: Thu, 4 Feb 2021 | 0815 - 0915

Post-graduate course - Session 2: Alcoholic liver disease - Management from guideline to clinical practice
Chairperson
Date & Time: Thu, 4 Feb 2021 | 0915 - 1015

Assoc Prof Wattana Sukeepaisarnjaroen

Associate Professor
Faculty of Medicine
KhonKaen University
Thailand

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Hepatotoxicity, Human Cholestatic and Autoimmune Liver Diseases, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH, Other Viral Hepatitis

Session:
S3: A Revisit of Tropical Liver Diseases
Topic: Opisthorchris Viverrini Associated Oriental Cholangitis
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

SOTA 5
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1130 - 1200

Prof Gyongyi Szabo

Professor of Medicine, Faculty Dean, Chief Academic Officer
Department of Medicine
Harvard Medical School/Beth Israel Deaconess Medical Center
United States

Bio:
Gyongyi Szabo, MD, PhD is Professor of Medicine at Harvard Medical School and Chief Academic Officer at Beth Israel Deaconess Medical Center in Boston. She is a physician scientist and a renowned expert in liver disease and inflammation. Her laboratory studies the cellular and molecular mechanisms of inflammation and innate immunity in liver injury to identify therapeutic targets in NASH and alcoholic liver disease. Her group discovered the critical role of inflammasome activation in liver inflammation and showed that IL-1 inhibition can improve alcoholic liver disease. She is a lead investigator on the AlcHeptNet NIH-supported multicenter clinical trial in alcoholic hepatitis. Dr. Szabo’s is former President of the AASLD, fellow of AGA and the American College of Physicians (ACP) as well as the inaugural Editor-in-Chief of Hepatology Communications.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Cell and Molecular Biology, Gut Liver Axis and Microbiome, Hepatitis C, Inflammation and Immunobiology, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH, Training and Education (Career Development)

Session:
Post-graduate course - Session 2: Alcoholic liver disease - Management from guideline to clinical practice
Topic: What’s new in management of alcoholic hepatitis from the current guideline
Date & Time: Thu, 4 Feb 2021 |0915 - 1015

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Chee-Kiat Tan

Clinical Professor / Senior Consultant
Department of Gastroenterology and Hepatology
Singapore General Hospital and Duke-NUS Medical School
Singapore

Bio:
Professor Chee-Kiat Tan is Senior Consultant, Department of Gastroenterology and Hepatology, Singapore General Hospital. He is also Clinical Professor in Duke-National University of Singapore (NUS) Medical School and Clinical Associate Professor in Yong Loo Lin School of Medicine, NUS. He graduated from NUS in 1984, obtained MRCP(UK) in 1989 and FRCP(Edinburgh) in 1998. He also has a Diploma in Medical Education from University of Dundee. He trained at Mayo Clinic, USA, from 1993–1994. Professor Tan’s interests lie in liver transplantation, liver cancer and viral hepatitis. He is currently Director of the National Organ Transplant Unit, Ministry of Health of Singapore.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Liver Transplantation and Liver Surgery, Other Viral Hepatitis, Training and Education (Career Development)

Session:
Gilead Lunch-time Symposium: Shaping Tomorrow Together: Learnings from a Real-world Survey of Liver Health in Asia
Topic: Singapore Liver Index: Time to demystify liver health and liver disease
Date & Time: Sat, 6 Feb 2021 | 1200 - 1300

Dr Soek-Siam Tan

Consultant Hepatologist
Department of Hepatology
Selayang Hospital
Malaysia

Bio:
Dr Soek-Siam Tan is a senior consultant in the Department of Hepatology, Selayang Hospital and the Immediate Past President of the Malaysian Society of Gastroenterology and Hepatology. She graduated from Trinity College, Dublin with honours in Medicine. She did her training in hepatology in Kuala Lumpur Hospital, and in the Institute of Liver Study at King’s College Hospital, United Kingdom. She is a member of the APASL-ACLF Research Consortium (AARC) since 2011. She had authored more than forty publications in peer review journals, a few clinical practice guidelines and book chapters. She is a member of the editorial board of the journal Hepatology International.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis C, Hepatotoxicity, Liver Transplantation and Liver Surgery, NAFLD and NASH

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Atsushi Tanaka

Professor
Department of Medicine
Teikyo University School of Medicine
Japan

Bio:
Prof Atsushi Tanaka was graduated with M.D. degree in 1988 from the University of Tokyo, Japan, and obtained his Ph.D. degree from the University of Tokyo in 1996, and became a Professor of Medicine at the Teikyo University School of Medicine in 2011. His area of expertise is autoimmune liver diseases, especially autoimmune hepatitis (AIH), PBC, primary sclerosing cholangitis (PSC), and IgG4-related sclerosing cholangitis. He has authored more than 180 peer-reviewed manuscripts devoted to these topics. He is a member of the Japan Society of Hepatology, the Japanese Society of Gastroenterology, the AASLD (FAASLD since 1996), the EASL, and APASL

Areas of Interest:
Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Human Cholestatic and Autoimmune Liver Diseases, Inflammation and Immunobiology

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S9: What's New in Autoimmune Liver Diseases?
Topic: Distinctive Features and Management of Autoimmune Hepatitis in Asia
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Prof Yasuhito Tanaka

Chief Professor
Department of Gastroenterology and Hepatology
Kumamoto University
Japan

Bio:
Professor Tanaka gained his MD in Internal Medicine from Nagoya City University, Nagoya, Japan in 1991 and has worked as a gastroenterologist (hepatologist) since then. In 2001 he completed his PhD in hepatology and also became a Visiting Fellow in viral hepatitis at the National Institutes of Health. He is currently Professor, Department of Gastroenterology and Hepatology, Kumamoto University; Director, Liver Disease Unit, Kumamoto University Hospital; and Director, Endoscopy Center, Kumamoto University Hospital

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Liver Fibrogenesis and Non-Parenchymal Cell Biology, Other Viral Hepatitis

Session:
GSK Product Theatre - New potential therapies for Chronic Hepatitis B (CHB): Will Hepatitis B core-related antigen (HBcrAg) identify durable and functional cure?
Date & Time: Thu, 4 Feb 2021 | 1430 - 1500

Assoc Prof Puneeta Tandon

Associate Professor
Department of Medicine
University of Alberta
Canada

Bio:
Dr. Tandon is an Associate Professor of Medicine, Co-Director of the Cirrhosis Care Clinic and Transplant Hepatologist. She obtained her training at the University of Alberta, the Hospital Clinic in Barcelona and Yale University. She is currently practicing out of the University of Alberta. Her clinical practice and research are focused on cirrhosis related complications, malnutrition, frailty, exercise therapy, palliative care, integrative health approaches such as meditation and knowledge translation. It is her career goal to provide wholistic, interdisciplinary, evidence based, patient-centered care through education, empowerment, engagement and team-work.

Areas of Interest:
Portal Hypertension and Other Complications of Cirrhosis

Session:
S21: Hot Topics in Cirrhosis and its Complications
Topic: Palliative Care in Advanced Liver Diseases
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Chung-Ngai Tang

Associate Professor
Department of Medicine
Pamela Youde Nethersole Eastern Hospital, Hospital Authority
Hong Kong

Bio:
Dr Tang is the Chief of Surgery and the Director of Minimal Access Surgery Training Centre (MASTC) at Pamela Youde Nethersole Eastern Hospital, Hong Kong (SAR), China. Dr Tang specializes in Hepatobiliary-Pancreatic Surgery and General Surgery. He is the first qualified Robotic General Surgeon in Hong Kong and the pioneer of MAS Hepatobiliary Surgery in Hong Kong. Dr Tang has accumulated more than 800 cases of Robotic-assisted hepatobiliary surgery / general surgery since 2009. He published extensively on MAS HBP surgery with more than 100 original publications in peer-reviewed journal / book chapter, and delivered about 200 invited lectures on laparoscopic and robot-assisted HPB surgery in local and international symposia He found the Hong Kong Society of Robotic Surgery in 2014 and he is also the Past President of Clinical Robotic Surgery Association (CRSA) and current President of Asia-Pacific Association of Robotic Surgeons (APARS).

Areas of Interest:
Hepatobiliary Surgery

Session:
S22: Team-based Management of Hepatocellular Carcinoma
Topic: Advanced Surgery in HCC: Laparoscopic and Robotic Liver Resection
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Pisit Tangkijvanich

Professor
Department of Biochemistry
Faculty of Medicine
Chulalongkorn University
Thailand

Bio:
Pisit Tangkijvanich is Professor of Biochemistry at Faculty of Medicine, Chulalongkorn University and Hepatologist at King Chulalongkorn Memorial Hospital. He is currently Head of Center of Excellence in Hepatitis and Liver Cancer at Chulalongkorn University. His main research areas are viral hepatitis, fibrogenesis, cirrhosis, liver cancer and gut microbiome. He is author of over 170 peer-review publications.

Areas of Interest:
Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Liver Fibrogenesis and Non-Parenchymal Cell Biology

Session:
S11: Roadmap towards a Cure in Patients with Chronic Hepatitis B
Topic: Emerging HBV Markers to Decide When to Discotinue NUC
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

S19: Highlights in Basic Sciences
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Young Investigator's Award
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Tawesak Tanwandee

Head
Division of Gastroenterology, Department of Medicine
Faculty of Medicine Siriraj Hospital, Mahidol University
Thailand

Bio:
Tawesak Tanwandee, MD, is hepatologist at division of gastroenterology and hepatology at Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand where he has been working for past 30 years. His current position is Associate Professor of Medicine and Head of Division of Gastroenterology (since 2008). He is president of APASL and was past president of Thai Association for the Study of the Liver (THASL), and president of the 4th ASEAN Perspective in Liver Diseases 2016. His research interest is about treatment of chronic hepatitis B and C, hepatocellular carcinoma and cost effective of treating hepatitis B and C. He received a MD with first class honor and gold medal and received Thai Board of Internal Medicine, Gastroenterology. He also spent 2 years performing research in virology at department of molecular virology, Baylor College of Medicine, Houston, TX. He is currently member of AGA, ACG, AASLD, EASL and APASL.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Portal Hypertension and Other Complications of Cirrhosis

Session:
Opening Post-Graduate course
Opening Post-Graduate Course
Date & Time: Thu, 4 Feb 2021 | 0800 - 0815

GSK Product Theatre - New potential therapies for Chronic Hepatitis B (CHB): Will Hepatitis B core-related antigen (HBcrAg) identify durable and functional cure?
Date & Time: Thu, 4 Feb 2021 | 1430 - 1500

Closing Post-Graduate Course
Closing Post-Graduate Course
Date & Time: Thu, 4 Feb 2021 | 1500 - 1510

S4: Current Knowledge of Occult Hepatitis B and Hepatitis B Co-Infection
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

APASL 2021 Opening ceremony
APASL 2021 Opening ceremony
Date & Time: Fri, 5 Feb 2021 | 1030 - 1100

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Presidential Lecture 1
Topic: Towards Chronic Viral Hepatitis Elimination by 2030
Date & Time: Fri, 5 Feb 2021 | 1130 - 1200

Grifols Lunch-Time Symposium: Asian vs. European perspectives on the role of albumin in the management of patients with cirrhosis
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

Gilead Lunch-time Symposium: Shaping Tomorrow Together: Learnings from a Real-world Survey of Liver Health in Asia
Topic: Thailand Liver Index: Progress and gaps in knowledge, awareness and attitudes towards HBV and HCV
Date & Time: Sat, 6 Feb 2021 | 1200 - 1300

Joint Symposium 3 (APASL-CEVHAP-WHO)
Topic: Welcome from APASL President
Date & Time: Sat, 6 Feb 2021 | 1310 - 1440

The 2nd APASL Rising Star Award
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1330

Joint Symposium 4 (EASL-APASL)
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

APASL 2021 Closing Ceremony
Date & Time: Sat, 6 Feb 2021

Dr Elliot Tapper

Assistant Professor
Division of Gastroenterology and Hepatology
University of Michigan
United States

Bio:
Elliot Tapper is Director of the Cirrhosis Program at the University of Michigan where he is Assistant Professor. His research focuses on health services and clinical trials that aim to improve the outcomes and well-being of people living with cirrhosis. He is funded by the NIH, PCORI, and Pharma. Please follow him on twitter @ebtapper

Areas of Interest:
Health Services Research, Portal Hypertension and Other Complications of Cirrhosis

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Dr Ryosuke Tateishi

Associate Professor
Department of Gastroenterology
The University of Tokyo Hospital
Japan

Bio:
Dr. Ryosuke Tateishi is an associate professor and a vice-chairman of the Department of Gastroenterology at the University of Tokyo Hospital. He has been served on a member of three guideline committees: Japanese Clinical Practice Guidelines for Liver Cancer, Asian Pacific Association for the Study of the Liver (APASL) hepatocellular carcinoma guidelines, and Asian Conference on Tumor Ablation (ACTA) guidelines. He published more than 170 international scientific papers in high-quality English Journals, including Gastroenterology, Hepatology, Gut, and Journal of Hepatology. He has also served as an associate editor in Hepatology Research.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH

Session:
S16: Surveillance of Hepatocellular Carcinoma
Chairperson
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

S22: Team-based Management of Hepatocellular Carcinoma
Topic: Precision Locoregional Therapies for HCC: Percutaneous Ablation and Radiotherapy
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Norah Terrault

Professor - Chief
Department of Medicine – Division of Gastrointestinal and Liver Diseases
Keck School of Medicine of USC
United States

Bio:
Dr. Norah Terrault is Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California. She received her MD from the University of Alberta and completed fellowships in Internal Medicine and Gastroenterology at the University of Toronto and a Masters in Public Health at the University of California at Berkeley. Dr. Terrault has focused her clinical and research activities on viral hepatitis and non-alcoholic fatty liver disease, especially in special populations including those with cirrhosis and those with transplants. In addition to multiple clinical trials related to preventing and treating chronic hepatitis viral hepatitis and fatty liver, Dr. Terrault has been PI on multiple NIH-funded studies, including the current NIH-supported HBV clinical research network (HBRN) and nonalcoholic steatohepatitis clinical research network (NASH CRN). She has authored 400 peer-reviewed manuscripts, editorials, invited reviews as well as US national guidelines for treatment of chronic hepatitis B and C. She is past associate editor for Hepatology and deputy editor for Liver Transplantation and co-edited Zakim and Boyer’s textbook in hepatology. She is the founder of ECHO-Plus, a multifaceted program to train and support primary care physicians in California to care for patients with hepatitis. She has a long history of mentoring fellows and junior faculty in clinical research and is passionate about creating research support and opportunities for the next generation of GI/Hepatology investigators. Dr. Terrault was recently elected as Councilor to the AASLD governing board and will serve as president in 2023.

Areas of Interest:
Hepatitis B and Hepatitis C

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Prof Alex Thompson

Director of Gastroenterology
Department of Gastroenterology
St Vincent’s Hospital and the University of Melbourne
Australia

Bio:
Professor Alex Thompson is Professor-Director of Gastroenterology at St. Vincent’s Hospital Melbourne (University of Melbourne) and Director of the State-wide Hepatitis Program in Victorian prisons. His research interests include models of care for hepatitis, with a focus on elimination and identifying host/viral determinants of the natural history and treatment outcomes of HBV and HCV infections. He was involved in the discovery of the association between IL28B and HCV treatment response. He has published widely in high impact journals including Nature, New England Journal of Medicine, Journal of Hepatology, Gastroenterology and Hepatology.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C

Session:
APASL HBV Reactivation 2021 Guideline
Topic: Pathogenesis and risk factors
Date & Time: Sat, 6 Feb 2021 | 0800 - 1000

S20: Future Trends of Chronic Hepatitis C Treatment
Topic: Long term Impact of Direct-Acting Antiviral Agents in HCV Cirrhosis
Date & Time: Sat, 6 Feb 2021 | 1310 – 1450

Prof Suporn Treepongkaruna

Professor
Department of Pediatrics, Ramathibodi Excellent Center in Organ Transplantation
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Thailand

Bio:
- Professor of Pediatrics, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
- Head, Division of Pediatric Gastroenterology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
- Chair, Ramathibodi Excellent Center for Organ Transplantation
- Assistant Dean for Academic Affairs, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
- President, Thai Society of Pediatric Gastroenterology and Hepatology
- President, Asian Pan-Pacific Society of Pediatric Gastroenterology, Hepatology and Nutrition (APPSPGHAN)
- Council Committee, the Federation of International Societies of Pediatric Gastroenterology, Hepatology and Nutrition (FISPGHAN)

Areas of Interest:
Liver Transplantation and Liver Surgery, Pediatric Hepatology

Session:
S14: Advances in Common Pediatric Hepatology
Topic: Liver Tranplantation: Transition from Pediatric to Adult Care
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Prof Sombat Treeprasertsuk

Professor
Department of Medicine
Chulalongkorn University
Thailand

Bio:
Medical Education: M.D. from Mahidol University, Ramathibodi Hospital, Faculty of Medicine, Thailand (1991). M.Sc. in Clinical Translational Science, CTS, from Mayo Clinic, Mayo Graduate School. Research Fellow in Clinical Liver Research, Division of Gastroenterology and Hepatology, Mayo Clinic (2010)., Ph.D. in Medicine from Chulalongkorn University (2012)

Current Administrative Positions: Professor of Internal Medicine (2015) at Chulalongkorn University, Bangkok, Thailand Currently, He is an Assistant to President, for Planning and budget, Chulalongkorn University, Bangkok, Thailand (2018)

Areas of Interest:
Hepatobiliary Neoplasia, Hepatotoxicity, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
Post-graduate course - Session 1: NAFL/ MAFLD
Chairperson
Date & Time: Thu, 4 Feb 2021 | 0815 - 0915

Post-graduate course - Session 2: Alcoholic liver disease - Management from guideline to clinical practice
Chairperson
Date & Time: Thu, 4 Feb 2021 | 0915 - 1015

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Topic: New Therapeutic Strategies for MAFLD - Beyond Weight Reduction
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

S21: Hot Topics in Cirrhosis and its Complications
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Dr Lisa VanWagner

Assistant Professor
Department of Medicine-GI & Hepatology and Preventive Medicine-Epidemiology
Northwestern University Feinberg School of Medicine
United States

Bio:
Dr. Lisa VanWagner is an Assistant Professor of Gastroenterology & Hepatology and Preventive Medicine at Northwestern University in Chicago, IL. Dr. VanWagner utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease risk prediction, prevention and treatment approaches in patients with chronic liver disease, particularly among patients with fatty liver disease and surrounding liver transplantation. Her scientific work has been recognized by leading professional organizations, with research awards from American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), American Society of Transplantation (AST) and American Heart Association (AHA). She has published over 75 peer-reviewed manuscripts.

Areas of Interest:
Health Services Research, Liver Transplantation and Liver Surgery, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Prof Fu-Sheng Wang

Director
Research Center for Biological Therapy
The Fifth Medical Center of Chinese PLA General Hospital
China

Bio:
Professor Fu-Sheng Wang, Member of Chinese Academy of Sciences, is the director of Treatment and Research Center for Infectious Diseases in Fifth Medical Center of Chinese PLA General Hospital, expert of the National Joint Prevention and Control Working Group, director of the National Infectious Disease Clinical Medical Research Center, and expert of the Military Biosecurity Group. He has been engaged in clinical diagnosis and treatment, and scientific research on infectious diseases for more than 30 years, and has participated in the fighting against several major epidemics, including SARS in 2003, the avian influenza in 2009, and COVID-19 in 2019.

Areas of Interest:
Hepatitis B and Hepatitis D, Inflammation and Immunobiology

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S19: Highlights in Basic Sciences
Topic: Evolution in Understanding of Hepatitis B Virus Virology and Immunology
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Prof Paul Watkins

Director
Institute for Drug Safety Sciences
University of North Carolina
United States

Bio:
Prof Paul Watkins is the Howard Q Ferguson Distinguished Professor of Medicine, Pharmacy and Public Health and director of the Institute for Drug Safety Sciences at the University of North Carolina, Chapel Hill. He serves as chair of the Steering, Executive and Genetics Committees for the U.S. Drug-Induced Liver Injury Network. Dr. Watkins is the recipient of numerous honors and awards including the Rawls-Palmer Award for Progress in Medicine from the American Society for Clinical Pharmacology and Therapeutics, the Agilent Thought Leader Award, and the Career Award from the Toxicology Section of the American Society of Pharmacology and Experimental Therapeutics.

Areas of Interest:
Hepatotoxicity

Session:
SOTA 2
Topic: Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

Prof Lai Wei

Director
Peking University Hepatology Institute
Peking University People’s Hospital
China

Bio:
Lai Wei is a Professor of Hepatology & Medicine, and is the Director of Peking University Hepatology Institute since 2004 and Chief of Department of Hepatology at Peking University People’s Hospital since 2001. His current research interests involve antiviral treatment of hepatitis B and C. Dr. Wei is the President of the Chinese Society of Hepatology. He served to develop the Chinese Guideline for Management of Hepatitis B, and Management, Diagnosis and Prevention of Hepatitis C virus Infection.

Session:
SOTA 3
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S20: Future Trends of Chronic Hepatitis C Treatment
Topic: WHO goal to eliminate HCV infection by 2030: opportunity and challenge
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Grace Lai-Hung Wong

Professor
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Hong Kong

Bio:
Grace Wong is a Professor in the Department of Medicine and Therapeutics and the Director of Medical Data Analytics Centre (MDAC) of the Chinese University of Hong Kong. Her main research interests include big data research in medicine, chronic viral hepatitis, liver fibrosis and liver cancer. She has published over 300 articles in peer-reviewed journals including Gastroenterology, Hepatology, and Gut. She has been awarded the Young Investigator Award of the Asian Pacific Association for the Study of the Liver in 2009, the Distinguished Research Paper Award for Young Investigators of the Hong Kong College of Physicians in 2010, 2013, 2014, and 2015, the Ten Outstanding Young Persons (TOYP) of Hong Kong in 2014, the Sir David Todd Lectureship of the Hong Kong College of Physicians in 2016, Distinguished Young Fellow of the Hong Kong Academy of Medicine, and the Emerging Leader Lectureship of the Journal of Gastroenterology and Hepatology Foundation (JGHF) at APDW 2017.

Areas of Interest:
Hepatitis B and Hepatitis D, NAFLD and NASH

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

S1: Enhancing Quality of Care in Hepatology
Topic: Transient Elastography for Screening of Liver Fibrosis: Cost-Effectiveness Analysis
Date & Time: Thu, 4 Feb 2021 | 1530 – 1645

APASL HBV Reactivation 2021 Guideline
Topic: Management and monitoring
Date & Time: Sat, 6 Feb 2021 | 0800 - 1000

Prof Vincent Wong

Professor
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Hong Kong

Bio:
Vincent Wong is a professor at the Division of Gastroenterology and Hepatology, The Chinese University of Hong Kong. His research focuses on viral hepatitis and non-alcoholic fatty liver disease (NAFLD), in particular the use of non-invasive tests for screening and diagnosis. He has authored over 400 articles in international medical journals, and his latest h index is 76. Together with the Asia-Pacific Working Party, he wrote the Asia-Pacific Guidelines on the Management of NAFLD in 2018. He is an associate editor of Clinical Gastroenterology and Hepatology and served as the president of the Hong Kong Association for the Study of Liver Diseases from 2015 to 2017. He is a fellow of the Royal College of Physicians of Edinburgh, Royal College of Physicians of London, Hong Kong College of Physicians and Hong Kong Academy of Medicine.

Areas of Interest:
NAFLD and NASH

Session:
Post-graduate course - Session 1: NAFL/ MAFLD
Topic: NAFLD and HCC risk
Date & Time: Thu, 4 Feb 2021 | 0815 - 0915

S6: Updates on Liver Fibrosis: From Pathophysiology to Potential Treatment
Topic: Diagnosis of Liver Fibrosis - Present and Future
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Oral Presentation
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Jia-Feng Wu

Professor
Department of Pediatrics
National Taiwan University Hospital
Taiwan

Bio:
Dr Wu’s research interests focus on the viral hepatitis, and cholestatic liver disease. Dr Wu’s researches cover the host factors and host-viral interactions on the natural course of chronic hepatitis infection from children to adults and the non-invasive assessment in both cholestatic liver disease and viral hepatitis in children. He has been actively engaged in many global clinical trials on the anti-viral therapy of chronic hepatitis B and hepatitis C virus infected children. He has served as a reviewer for more than 30 international scientific journals and internal medical congress, and published more than 100 peer-reviewed articles.

Areas of Interest:
Advanced Practice Providers (NP, PA, RN, PharmD, etc.), Health Services Research, Hepatitis B and Hepatitis D, Hepatitis C, Human Cholestatic and Autoimmune Liver Diseases, Pediatric Hepatology

Session:
S14: Advances in Common Pediatric Hepatology
Topic: Current Therapy of Chronic Hepatitis B and C in Children and Adolescents
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Assoc Prof Noriyo Yamashiki

Associate Professor
Department of Gastroenterology and Hepatology
Kansai Medical University
Taiwan

Bio:
My name is Noriyo Yamashiki and I am an Associate Professor at the Department of Gastroenterology and Hepatology, Kansai Medical University. I have graduated from Kansai Medical University in 1994. After GI training, I worked as research fellow in Hepatology/Liver Transplantation at University of Miami from 2000 through 2002. From 2005 through 2012, I worked as GI/Transplant Hepatologist at University of Tokyo. From 2015 through 2019, I worked as Transplant Hepatologist at Kyoto University.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatobiliary Neoplasia, Liver Transplantation and Liver Surgery

Session:
S10: What's new in Alcoholic Liver Disease?
Topic: Alcohol Relapse After Liver Transplantation: Risks and Minimization Strategies
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S10: What's new in Alcoholic Liver Disease?
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Prof Jin-Mo Yang

Professor
Department of Internal Medicine, Hepatology
Catholic University Medical College
St’Vincent Hospital
South Korea

Bio:
President elect of APASL
President of APASL 2022 SEOUL

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
Presidential Lecture 1
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1130 - 1200

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

HS1: Anticoagulants for Portal Vein Thrombosis in Cirrhosis: DOACs vs. LWMH and Warfarin
Topic: LWMH and Warfarin are preferred
Date & Time: Sat, 6 Feb 2021 | 0940 - 1010

Joint Symposium 3 (APASL-CEVHAP-WHO)
Closing Remarks by the President-elect APASL 2022
Date & Time: Sat, 6 Feb 2021 | 1310 - 1440

Prof Osamu Yokosukai

Director
Funabashi Central Hospital
Japan

Bio:
Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine. Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatobiliary Neoplasia

Session:
S20: Future Trends of Chronic Hepatitis C Treatment
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Hanry Yu

Professor of Physiology
National University of Singapore
Singapore

Bio:
Prof Yu takes interdisciplinary approach to liver research. He was trained as a cell biologist, venturing into biomaterials and regenerative medicine, AI, bioimaging, and mechanobiology. He studies pathophysiology of hepato-biliary diseases, dissects and quantifies the processes. Prof Yu is jointly appointed at the YLL School of Medicine, National University of Singapore; Mechanobiology Institute Singapore, and Institute of Bioengineering and Nanotechnology, A*STAR; and co-leads a research programme in the MIT research entity in Singapore. He published >200 papers and serves as a handling editor of Biomaterials.

Areas of Interest:
Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis, Hepatotoxicity, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH

Session:
S6: Updates on Liver Fibrosis: From Pathophysiology to Potential Treatment
Topic: Artificial Intelligence as a Novel Imaging of Liver Fibrosis
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Prof Ming-Lung Yu

Vice-President
Faculty of Medicine, College of Medicine
Kaohsiung Medical University
Taiwan

Bio:
Ming-Lung Yu is a chair professor at the College of Medicine and Senior Vice President of Kaohsiung Medical University, Taiwan. Professor Yu, a board-certified internist and gastroenterologist, currently teaches at the Kaohsiung Medical University and Kaohsiung Medical University Hospital where he holds the leading role in the Hepatitis Research Center and an advisory role at the Center for Cancer Research. He is also an adjunct professor at the College of Biological Science and Technology, National Chiao Tung University and the Institute of Biomedical Sciences, National Sun Yat-Sen University, both in Taiwan. Professor Yu’s research interests in the epidemiology and natural history of viral hepatitis have led him to publish more than 350 journal and review articles. He also holds various editorial roles including handling editor of PLoS ONE, the World Journal of Gastroenterology and Clinical and Molecular Hepatology, and a member of the editorial board of Hepatology, the Journal of Infectious Diseases and Kaohsiung Journal of Medical Science.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, NAFLD and NASH

Session:
S4: Current Knowledge of Occult Hepatitis B and Hepatitis B Co-Infection
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

APASL HBV Reactivation 2021 Guideline
Topic: Risk stratification
Date & Time: Sat, 6 Feb 2021 | 0800 – 1000

S20: Future Trends of Chronic Hepatitis C Treatment
Topic: Unmet Needs of Chronic Hepatitis C in the Era of Direct-Acting Antiviral agents
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Man-Fung Yuen

Chair Professor
Department of Medicine
The University of Hong Kong
Hong Kong

Bio:
Professor Yuen obtained his first bachelor degree of medicine in 1992. He further pursued his academic excellence through the achievement of obtaining 3 doctoral degrees including Doctor of Medicine with Sir Patrick Manson Gold Medal in 2001, Doctor of Philosophy in 2005 and Doctor of Science in 2017. Professor Yuen's research interests include prevention, natural history, molecular virology and treatment of chronic hepatitis B and C, and hepatocellular carcinoma. He is one of the top internationally renowned researchers in the field of hepatitis B disease. He has now published more than 430 papers in world renowned medical journals. At present, he is the pioneering clinical researcher leading numerous studies on novel antiviral and immunomodulatory agents for the treatment of chronic hepatitis B. He is also actively performing cutting edge research on novel markers for hepatitis B infection and occult hepatitis B infection. As a specialist of Gastroenterology and Hepatology, Professor Yuen have been providing clinical care and services for patients in Queen Mary Hospital, The University of Hong Kong for more than 20 years. He is also serving as medical advisor and consultant for different health related units of the Government of Hong Kong, many academic centres and commercial enterprises for different aspects related to the diseases of Gastroenterology and Hepatology.

Areas of Interest:
Hepatitis B and Hepatitis D

Session:
GSK Product Theatre - New potential therapies for Chronic Hepatitis B (CHB): Will Hepatitis B core-related antigen (HBcrAg) identify durable and functional cure?
Date & Time: Thu, 4 Feb 2021 | 1430 - 1500

S4: Current Knowledge of Occult Hepatitis B and Hepatitis B Co-Infection
Topic: Intrahepatic Hepatitis B Virus Replication in Occult HBV Infection: How to Assess and What is the Benefit?
Date & Time: Fri, 5 Feb 2021 |0800 - 0940

Prof Fabien Zoulim

Head, Department of Hepatology
Lyon University and INSERM
France

Bio:
Fabien Zoulim is Professor of Medicine at Lyon I University. He is the Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Viral Hepatitis Laboratory at INSERM Unit 1052. Dr Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. He served as a Governing Board member of EASL and has also received the William Prusoff award of ISAR. He is currently coordinating the ANRS “HBV cure” program in France and the “IP-cure-B” project within the EU H2020 workprogram. He co-founded the International Coalition to Eliminate HBV (ICE-HBV: http//:www.ice-hbv.org).

Areas of Interest:
Hepatitis B and Hepatitis D

Session:
S11: Roadmap towards a Cure in Patients with Chronic Hepatitis B
Topic: Can We Cure Hepatitis B Virus with Novel Direct Acting Antivirals?
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Prof Zaigham Abbas

Professor and Head
Department of HepatoGastroenterology
Dr. Ziauddin University Hospital Clifton Karachi
Pakistan

Bio:
Dr. Zaigham Abbas is heading of the Department of Hepatogastroenterology at the Ziauddin University Hospital, Karachi. He is the President of Pakistan Society for the Study of Liver Diseases (PSSLD), member and ex-Dean of the Faculty of Gastroenterology in the College of Physicians and Surgeons Pakistan, and Governor of the American College of Gastroenterology for Pakistan. He is a member of the Guidelines Committees and Hepatology Interest Group of the World Gastroenterology Organization. He is Associate Editor of Hepatology International. He is currently doing collaborative work with the Hepatitis Delta International Network and APASL ACLF Research Consortium. He has 240 publications to his credit.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Assoc Prof Leon Adams

Consultant Hepatologist
Medical School
University of Western Australia
Australia

Bio:
Leon Adams (MBBS, FRACP, PhD) is an Associate Professor (Medical School, University of Western Australia) and Consultant Hepatologist in the Liver Transplant Unit at Sir Charles Gairdner Hospital. His research interests focus on translational, clinical and epidemiological aspects of nonalcoholic fatty liver disease and non-invasive assessment of liver fibrosis, in which he has published over 150 articles. He has served on the editorial boards of Hepatology, Journal of Hepatology, Hepatology Communications and Liver International and on numerous committee’s and faculties of the Australian Liver Association, Gastroenterology Society of Australia and American Association for the Study of Liver Disease.

Areas of Interest:
NAFLD and NASH

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Joint Symposium 4 (EASL-APASL)
Topic: Risk Stratification
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Gulnara Aghayeva

Head of the Department
Department of Liver Diseases
Baku Health Center
Azerbaijan

Bio:
Work Experience:
1983 – 1999 Republic Toxicological Center, Head of Resuscitation department
1999 - 2003 Azerbaijan State Medical University, Internal Disease Chair, Assistant Professor
1999 - 2008 “Khazar” University, Clinical Virology Chair, Assistant Professor
2008 – 2014 “Baku Medical center”, Head of the Liver Diseases Department
2014 – 2019 EGE Hospital, Head of the Liver Diseases Department
2019 - Present Baku Health Center, Liver Diseases Department, Head of Department
2019 - Present Medical Academy after Sechenov, Internal Diseases Chair, Lecturer
2016 - Present President of Azerbaijan Gastroenterologists and Hepatologists Association
2017 - Present Member Committee of Azerbaijan National Anti-Doping Agency (AMADA)
2018 Member of Editorial Board in Journal “Toxicology”, Azerbaijan
2019, 27-28 June President of APASL STC “Delta Hepatitis”
Awards:
1998 Grant for publishing in the book competition for the Step by Step Preschool program
2008 Recognition of the excellence of work presented at the 18th Conference of the APASL, Seoul, Korea
2013 Travel Award in APASL 2013, Singapore
2009, 2012, 2015 The winner of the nomination “The Best Doctor of the Year”
2015 Travel Award in APASL 2015, Istanbul, Turkey
2016 Travel Award in APASL 2017, Shanghai, China
Professional Conference:
2004 – 2016 APASL Annual participation (speaker)
2005 – 2016 EASL Annual participation
2008 – 2014 AASLD participation
2004 – 2013 Russian Gastroenterology and Hepatology Association, Annual participation, speaker
2008 - 2010 “Hepatology today”, speaker of Annual conference, Hepаtology Russia
2009 – 2011 Gastroenterology and Hepatology conference, speaker and Chairman in Kazakhstan
2004 – 2018 Educational sessions for medical professionals in the regions of Azerbaijan and Baku
2015 Good Clinical Practice (GCP). Clinical trial regulation. Workshop participation, Ukraine
2015-2018 Joined Turkish – Azerbaijan Hepatology Workshop, Chairman, Turkey
2018 STC APASL “Nonresponder”, speaker, co- chairman, Istanbul, Turkey
2019 February APASL Annual Meeting, co-chairman, speaker, Manila, Philippines
2019 April EASL, co-moderator in Closed Door meeting “ Viral Hepatitis Delta in Eurasia” , Expert Advisory Board
2019 November Egyptian Gastro-Hepato- Oncological Summit- speaker chairman
2019 December APASL STC “Eliminarion of Viral Hepatitis – speaker, coordinator, chairman
2020 February APASL Annual conferenсe- speaker, chairman
2020 June INEDSYS- Hepatitis B Masterclass Webinar Series
2020 September Course Director
2020 Egyptian GastroOncological and Hepatological Summit
2020 December International President
2021 January COVID-19 vaccination –Indian –Azerbaijani Webinar - Cochairman

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity, NAFLD and NASH

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Sang Hoon Ahn

Professor and Director
Yonsei University Severance Hospital
Seoul, Korea

Bio:
Sang Hoon Ahn is a Professor in the institute of Gastroenterology and the Department of Internal Medicine at Yonsei University College of Medicine in Seoul, Korea. He is also Director of the referral centre at Severance Hospital, Yonsei University Health System in Seoul.
Dr Ahn’s research interests include molecular biology and immunogenetics viral hepatitis and antiviral chemotherapy. He has completed and is complementing over 30 global and domestic clinical trials as a principal investigator in the field of viral hepatitis, cirrhosis and liver cancers. He has served as A/Editor or EB in manyl SCI(E) journals.

Session:
Gilead Lunch-time Symposium: Shaping tomorrow together: Optimising CHB management in the Asia-Pacific region
Topic: Minimising the risk of disease progression in patients with CHB
Date & Time: Thu, 4 Feb 2021 | 1200 - 1300

Prof Diana Alcantara-Payawal

Chairman
Department of Internal Medicine
Fatima Univeristy Medical Center
Philippines

Bio:
1. Secretary, Board of Regents Philippine College of Physician 2020
2. Immediate Past-President Asian Pacific Study of the Liver- 2018-2019
3. Past President, Hepatology Society of the Philippines 2012-2014 (March)
4. Past President, Philippine Society of Gastroenterology 2010-2011
5. Assistant Editor, Hepatology International 2019 to present
6. Treasurer, Board of Regents Philippine College of Physician 2019
7. APASL COVID task force 2020
8. Committee member, Scientific Committee Asian Pacific Digestive Week Federation (APDW) (2019 up to present)
9. Chair, Department of Internal Medicine Fatima University Medical Center 2017-present (Valenzuela and Antipolo)
10. Co-chair Section of Gastroenterology, Cardinal Santos Medical Center (2010-2020)

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatobiliary Neoplasia, Hepatotoxicity, NAFLD and NASH

Session:
S3: A Revisit of Tropical Liver Diseases
Topic: Liver Cysts that Require Medical Attention
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Okuda Oration
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1130 - 1200

Prof Raúl J Andrade

Full Professor of Medicine and Head Gastroenterology Service
Department of Medicine and Gastroenterology Service
University of Malaga & Virgen de la Victoria University Hospital
Spain

Bio:
Professor of Medicine and Director of the Department of Medicine at the University of Malaga. Founder and director of the Spanish Drug Induced Liver Injury (DILI) Registry. Principal investigator of the Prospective European DILI Registry awarded by the EASL. Chairman of the Clinical Practice Guidelines Council on Drug Induced Liver Injury 2016 appointed by the EASL. Chair of CIOMS working group on DILI 2017. Chair of COST ACTION CA17112. Member of steering committee of the Group of Special Interest in Hepatotoxicity (AASLD). Elected Fellow for the AASLD (2016) for significant contribution to the science and practice of hepatobiliary diseases.

Areas of Interest:
Hepatitis C, Hepatotoxicity, NAFLD and NASH

Session:
S23: Recent Advances in Drug-Induced Liver Injury
Topic: Epidemiology and Genetic Predisposition to Drug-Induced Liver Injury
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Paolo Angeli

Department of Medicine
Unit of Internal Medicine and Hepatology
University of Padova
Italy

Bio:
Prof. Paolo Angeli is Full Professor of Internal Medicine. He is the head of Unit of Internal Medicine and Hepatology (UIMH) of the University of Padova (Italy). He leads a research group working on the pathophysiology and treatment of acute, chronic and acute on chronic liver failure and on liver transplantation. He was the secretary of the International Club of Ascites from 2010 up to April 2018. From 2010 he is Associate Editor of the Journal of Hepatology. From the 1st of July 2019 hi is the Editor in Chief of the Journal of Hepatology. From January 2018 he is the Chair of the EASL-Clif Consortium. He is author of more than 318 papers on international journals with peer review, cited by JCR, with a global IF of 3275 and HI of 64. He has contributed to the guidelines and/or positional papers on the management of ascites, bacterial infections and acute renal injury (AKI) in patients with cirrhosis for the European Association for the Study of the Liver. He has contributed to the new diagnostic criteria for AKI in patients with cirrhosis as a result of a consensus process with almost all the international experts in this field.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Gut Liver Axis and Microbiome, Hepatotoxicity, Liver Transplantation and Liver Surgery, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
Post-graduate course - Session 3: ACLF - Management from guideline to clinical practice
Topic: Management of bacterial infection in cirrhosis
Date & Time: Thu, 4 Feb 2021 | 1050 – 1150

S21: Hot Topics in Cirrhosis and its Complications
Topic: An Update of Diagnosis and Management of Acute Kidney Injury in Cirrhosis
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Dr Monika Arora

Professor and Director
Department of Health Promotion
Public Health Foundation of India
India

Bio:
Dr Monika Arora is a public health scientist working in the area of health promotion and health advocacy with focus on NCD prevention and control. She is Executive Director of Delhi based NGO: HRIDAY (Health Related Information Dissemination Amongst Youth) in India. HRIDAY serves as the secretariat of Healthy India Alliance (India NCD Alliance). She is Board Member of NCD Alliance, Geneva for the period 2019-2021. She is also the Director of the Health Promotion Division and Professor at Public Health Foundation of India.

Areas of Interest:
Training and Education (Career Development)

Session:
Joint Symposium 3 (APASL-CEVHAP-WHO)
Topic: Where Cancer and NCD Advocacy Meet: strategies adopted by the NCD movements that could be replicated by the hepatitis fraternity to prioritize neglected themes and diseases
Date & Time: Sat, 6 Feb 2021 | 1310 - 1440

Assoc Prof Sumeet Asrani

Associate Professor of Medicine
Department of Hepatology
Baylor University Medical Center
United States

Bio:
Sumeet Asrani, MD, MSc is a transplant hepatologist at Baylor University Medical Center, part of Baylor Scott & White Health. He is also the medical director for the Center for Advanced Liver Disease and an associate professor for the Texas A&M College of Medicine. Dr. Asrani specializes in the management of patients with end-stage liver disease, liver transplantation candidates and recipients. His other clinical interests include liver cancer, viral hepatitis, autoimmune hepatitis, primary schlerosing cholangitis and alcoholic liver disease. His research interests focus on renal function in liver disease and organ allocation. Dr. Asrani has coauthored over 75 peer review articles and currently serves as an associate editor for the American Journal of Transplantation (AJT).

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Health Services Research, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
Post-graduate course - Session 2: Alcoholic liver disease - Management from guideline to clinical practice
Topic: Role of liver transplantation in alcoholic hepatitis
Date & Time: Thu, 4 Feb 2021 | 0915 - 1015

Prof Thomas Berg

Professor
Department of Hepatology and Gastroenterology
Univeristy Hospital in Leipzig
Germany

Bio:
Since December 2009, professor Thomas Berg has been the Head of the Section of Hepatology at the University Hospital in Leipzig, Germany, and since October 2018 acting Director of the Clinic of Gastroenterology at the University Hospital, Leipzig. His clinical and translational research is focused on chronic viral hepatitis, liver transplantation, hepatocellular carcinoma, genetics in liver disease, and liver failure, and he participated in numerous national and international clinical trials. He is Vice Secretary of the European Associations for the Study of the Liver (EASL), Board member of the EASL International Liver Foundation (EILF) and Co-Editor of the Journal of Hepatology since 2014. He is also member of the American (AASLD), European (EASL), and German (GASL) Associations for the Study of the Liver, The European Society for Organ Transplantation (ESOT), The European Liver and Intestine Transplant Association (ELITA), German Transplantation Society (DTG), Working Group Internal Oncology (AiO), Working Group Gastroenterological Oncology (AGO), German Cancer Society (DKG), German Society of Gastroenterology (DGVS), and the representative of the DGVS in the foundation council of the German liver foundation. He has published more than 350 articles in peer-reviewed journals and more than 100 reviews and textbook contributions. His h-index is 72 (Scopus)

Session:
S11: Roadmap towards a Cure in Patients with Chronic Hepatitis B
Topic: Natural course of Hepatitis B Virus infection and Definition of Cure
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Dr Chalermrat Bunchorntavakul

Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
Rajavithi Hospital, Ministry of Public Health
College of Medicine, Rangsit University
Thailand

Bio:
Chalermrat Bunchorntavakul, MD, is Assistant Professor of Medicine in the Division of Gastroenteology and Hepatology at Rajavithi Hospital, Ministry of Public Health, Bangkok, Thailand, in affiliation with College of Medicine, Rangsit University. Dr. Bunchorntavakul is currently active in clinical practice and is the acting Medical Director of Liver Transplant Program of the Excellent Center of Organ Transplantation, Ministry of Public Health. He also serves on the steering committee or subcommittee of several professional societies, such as Gastroenterological Association of Thailand

Session:
S21: Hot Topics in Cirrhosis and its Complications
Topic: Hepatic Encephalopathy: Current Challenges and Future Prospects
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

S23: Recent Advances in Drug-Induced Liver Injury
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Patrizia Burra

Full Professor, Head of Multivisceral Transplant Unit
Surgery, Oncology and Gastroenterology
University Hospital of Padova
Italy

Bio:
Patrizia Burra is Full Professor of Gastroenterology, Head of the Multivisceral Transplantation Unit and ViceRector on Research Training at Padua University. She is interested in clinical and translational studies in the setting of liver transplantation (HCV recurrence, HBV prophylaxis post-transplantation, acute alcoholic hepatitis, NASH/NAFLD, compliance and quality of life of transplant recipients). She has served as President of ELITA, Vice-President of ESOT, Chair of ILTS Education-Committee, Treasurer of ILTS and ILTS President. Currently she is Co-chair of The Lancet-EASL Commission on liver diseases in Europe, Deputy Editor of Journal of Hepatology and Associate Editor of Transplant International and Digestive and Liver Disease.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity, Liver Transplantation and Liver Surgery, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
SOTA 5
Topic: Principle of Organ Preservation and Machine Perfusion in Liver Transplantation
Date & Time: Sat, 6 Feb 2021 | 1130 - 1200

Dr Amna Subhan Butt

Associate Professor
Section of Gastroenterology, Department of Medicine
The Aga Khan University Hospital, Karachi
Pakistan

Bio:
Dr Amna Subhan Butt is Consultant Gastroenterologist and Program director, Gastroenterology Residency Program at The Aga Khan University Hospital. Dr. Butt has been recognized as a specialist in her field and over more than half a decade and currently serving as the General Secretory, Pakistan Society for the study of Liver Diseases, Chair Guideline Committee of Pakistan Society of Gastroenterology & GI Endoscopy (PSG) and member of guideline committee of World Gastroenterology Organization. She is also a co-investigator in APASL ACLF research consortium (AARC). She was previously the general secretory of PSG. She has published around 34 publications with 749 citations in peer-reviewed journals and received best abstract, best presentation award, international scholar awards several times in International Conferences.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Surgery, NAFLD and NASH, Other Viral Hepatitis, Training and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Sudhamshu K C

Coordinator, DM Heoatology
Department of Liver Unit
National Academy of Medical Sciences
Nepal

Bio:
Graduated from Dhaka University. Residency in First Department of Medicine of Graduate School of Medicine, Chiba university under Prof Okuda. Obtained PhD in 2004. Currently Professor of Hepatology in NAMS and Coordinator of DM Hepatology

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Dr Nataruks Chaijitraruch

Consultant
Department of Pediatric Gastroenterology and Hepatology
Chulalongkorn University
Thailand

Bio:
Pediatrics, Ramathibodi Hospital, Mahidol University, 2006
Pediatric Gastroenterology and Hepatology, Ramathibodi Hospital, Mahidol University, 2008
Doctor of Philosophy, King’s College London, UK 2014
Pediatric Hepatology Fellowship at King’s College Hospital, UK, 2015

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Human Cholestatic and Autoimmune Liver Diseases, Liver Transplantation and Liver Surgery, Metabolic and Genetic Disease, NAFLD and NASH, Pediatric Hepatology

Session:
S14: Advances in Common Pediatric Hepatology
Topic: Acute Liver Failure in Children
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Dr Siwaporn Chainuvati

Assistant Professor
Department of Internal medicine, Gastroenterology & Hepatology
Mahidol University, Siriraj hospital
Thailand

Bio:
Graduated from Mahidol university and continued GI/liver training in USA. Hepatology mentors were Dr. Roberto Groszmann and Dr. Guadalupe Garcia-Tsao. Now I have been practiced at Sirraj Hospital for 15 years focused on hepatitis and cirrhosis in limited resources

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Portal Hypertension and Other Complications of Cirrhosis

Session:
S8: The Myths and Realities of Portal Hypertension
Topic: Precision Medicine in Variceal Bleeding: Are We There Yet?
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S18: Strategies to Improve Long-term Post-Liver Transplantation
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Dr Roongruedee Chaiteeerakij

Consultant
Division of Gastroenterology and Hepatology
Department of Medicine
Chulalongkorn University
Thailand

Bio:
Dr. Chaiteerakij earned her medical degree and completed postgraduate training in Internal Medicine, and Gastroenterology and Hepatology at Chulalongkorn University, Bangkok, Thailand. She subsequently earned a Ph.D. in Clinical and Translational Science from the Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA. Dr. Chaiteerakij’s research interests focus on liver and bile duct cancer, including epidemiology; development of biomarkers for diagnosis and treatment of liver and bile duct cancers; and improvements in prevention, diagnosis, and treatment of hepatobiliary cancers.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity

Session:
S7: Clinical and Molecular Pathways of Hepaticocarcinogenesis
Topic: Novel Techniques for the Diagnosis of Cholangiocarcinoma
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S22: Team-based Management of Hepatocellular Carcinoma
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Asst Prof Naichaya Chamroonkul

Assistant Professor
Department of Internal Medicine
Prince of Songkla University
Thailand

Bio:
Naichaya Chamroonkul MD, graduated from faculty of medicine Siriraj hospital Mahidol university in 2003. After completed her training in gastroenterology and hepatology at Siriraj hospital she started her career as a lecturer at Prince of Songkla university Hatyai Thailand since 2009. In 2017-2019, she had been a visiting scholar in liver division Icahn school of medicine at Mount Sinai New York. She is currently assistant professor and chief of gastroenterology and hepatology unit, division of internal medicine, Prince of Songkla university. Her interest is focusing on cirrhosis and its complications, liver fibrosis and fatty liver disease.

Areas of Interest:
Genomics and Precision Medicine, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH

Session:
S6: Updates on Liver Fibrosis: From Pathophysiology to Potential Treatment
Topic: Antifibrotics in Liver Disease - Are We Getting Closer to Clinical Use?
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Prof Wah-Kheong Chan

Professor and Senior Consultant Gastroenterologist and Hepatologist
Department of Medicine
University of Malaya
Malaysia

Bio:
Dr Chan is Professor of Medicine at the University of Malaya and Senior Consultant Gastroenterologist and Hepatologist at the University of Malaya Medical Centre and the University of Malaya Specialist Centre. He is a Member of the Academy of Medicine of Malaysia and a Committee Member for the Malaysian Society of Gastroenterology and Hepatology. He is the Scientific Co-Chair for the Asia Pacific Digestive Week 2021. He is a member of the Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease, the Gut and Obesity in Asia (GO ASIA) Workgroup, and the Global NASH Council. He is Associate Editor for the Journal of Gastroenterology and Hepatology and is a reviewer for several international journals. He has published numerous full papers in peer-reviewed journals and presented in both local and international conferences. His main area of research interest is non-alcoholic fatty liver disease.

Areas of Interest:
NAFLD and NASH

Session:
Post-graduate course - Session 1: NAFL/ MAFLD
Topic: NAFLD - MAFLD : new definition and cardiovascular risk
Date & Time: Thu, 4 Feb 2021 | 0815 - 0915

S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Topic: Diet and Exercise: Which One Plays a More Important Role?
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Prof Henry LY Chan

Professor, Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Hong Kong

Bio:
Professor Henry Lik Yuen Chan is the Director of Center for Liver Health and Associate Dean (External Affairs) of Faculty of Medicine, The Chinese University of Hong Kong. Professor Chan is a world-renowned expert in viral hepatitis B, and is chairman of the Strategic Technical Advisory Committee on Viral Hepatitis for the Western Pacific Regional Office of World Health Organization. He has published over 450 papers in peer-reviewed journals, and is awarded Highly Cited Researcher by Clarivate Analytics in 2018 and 2019 for producing multiple top 1% cited papers under Web of Science.

Areas of Interest:
Hepatitis B and Hepatitis D

Session:
Post-graduate course - Session 4: HBV - Disease monitoring to cure
Topic: Long term durability of HBsAg lost; what should we do next?
Date & Time: Thu, 4 Feb 2021 | 1300 - 1400

Gilead Lunch-Time Symposium: Shaping tomorrow together: The countdown to HCV elimination
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

Gilead Lunch-Time Symposium: Shaping tomorrow together: The countdown to HCV elimination
Enhancing care for patients with HCV
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

Roche Lunch-Time Symposium: Innovations in HCC Diagnostics and Treatment : From Evidence to Practice
The Value of Diagnostics – The clinical usefulness of PIVKA-II in HCC Surveillance
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

S11: Roadmap towards a Cure in Patients with Chronic Hepatitis B
Topic: Can We Discontinue NUC Therapy?
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Dr Po-Lin Chan

Medical Officer (Hepatitis)
Division of Programmes for Disease Control
World Health Organisation Western Pacific Regional Office
Philippines

Bio:
Dr Po-Lin Chan is the Regional Technical Lead for viral hepatitis at the World Health Organization Regional Officer for the Western Pacific. She has worked in Africa, South Asia and East Asia in clinical services and conflict zones to advising government on public health initiatives. Passionately committed to health for all, she led WHO’s technical assistance to India for their establishment, scale-up and decentralisation of the HIV/STI national response. She supported China in HIV and viral hepatitis elimination, and now works in the Region to support the 37 countries in getting to viral hepatitis elimination as a public health threat

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Health Services Research, Hepatitis B and Hepatitis D, Hepatitis C, NAFLD and NASH, Other Viral Hepatitis, Pediatric Hepatology, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
Joint Symposium 2 (WHO WPRO_SEARO)
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1100 - 1200

Joint Symposium 2 (WHO WPRO_SEARO)
Topic: Beyond immunization for Hepatitis B prevention, the role of antivirals to get to zero transmission: WHO new 2020 guidelines on antiviral drug use among pregnant women for hepatitis B prevention of mother to child transmission
Date & Time: Sat, 6 Feb 2021 | 1100 - 1200

Joint Symposium 3 (APASL-CEVHAP-WHO)
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1440

Assoc Prof Stephen Lam Chan

Associate (Clinical) Professor
Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong

Bio:
Assoc Prof Stephen L. Chan is the Associate (Clinical) Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong. His main interest of research is clinical and translational studies on hepatobiliary-pancreatic and neuroendocrine cancers. Internationally, he is serving as the Associate Editor for the Journal of Hepatology and editorial board members of Liver International. Dr. Chan is also an international member of the NCI Hepatobiliary Task Force of the Gastrointestinal Steering Committee in United States. Dr. Chan has published over 130 peer-reviewed papers, with awards of young investigator award and gold medal dissertation by the Hong Kong College of Physician. Locally, Dr. Chan has established a charity Hand-in-hand cancer foundation to provide education and assistance to cancer patients.

Areas of Interest:
Hepatitis B and Hepatitis D, Inflammation and Immunobiology

Session:
Post-graduate course - Session 5: HCC - What's new
Topic: Role of chemotherapy in advanced HCC; Current trend
Date & Time: Thu, 4 Feb 2021 | 1400 - 1500

Dr Roger Chapman

Consultant Hepatologist
Department of Translational Hepatology
Oxford University
United Kingdom

Bio:
Dr Roger Chapman is a Consultant Emeritus in Hepatology at the Oxford University Hospital in Oxford, UK. He trained in liver disease with Professor Sheila Sherlock at the Royal Free Hospital in London. He has published 6 books, over 80 Book chapters and 260 original articles mainly in the field of autoimmune liver disease, viz Primary Sclerosing Cholangitis (PSC), Primary Biliary Cirrhosis (PBC) and latterly IgG4 related disease. He is a founding member (in 1992) of the International Autoimmune Hepatitis Group (IAHG) . More recently he has been involved in the foundation of the International PSC Study Group (2009) and the foundation of British Autoimmune Liver Disease Study Group (2010). He is one of the authors of the current European (EASL) guidelines for “Cholestatic liver diseases” and the first author of the North American (AASLD) guidelines on the “Management of Primary Sclerosing Cholangitis”. He was awarded a Fellowship of American Association for the Study of Liver Disease in 2014 and a lifetime achievement award from the British Association for the Study of Liver Disease in 2016.

Areas of Interest:
Human Cholestatic and Autoimmune Liver Diseases

Session:
S9: What's New in Autoimmune Liver Diseases?
Topic: New Thoughts on IgG4-related Hepatobiliary Disease
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Assoc Prof Phunchai Charatcharoenwitthaya

Associate Professor
Faculty of Medicine
Siriraj Hospital, Mahidol University
Thailand

Areas of Interest:
NAFLD and NASH

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Topic: Alcohol Drinking in Metabolic-associated Fatty Liver Diseases
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Oral Presentations
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Chao-Long Chen

Superintendent Emeritus / Professor of Surgery
Department of Surgery
Kaohsiung Chang Gung Memorial Hospital
Taiwan

Bio:
Professor Chao-Long Chen is a pioneer liver transplant surgeon who performed the first successful liver transplantation in Asia in 1984, and by 2019, has accomplished 1900 more. He obtained fellowship training in liver transplantation under Professor Thomas Starzl at the University of Pittsburgh, USA. He is a recipient of various honors and distinctions, both locally and internationally. He became Professor of Surgery in 1993 and was subsequently bestowed with honorary PhD and professorship by acclaimed international universities. In 1994, he performed the first LDLT in Taiwan and was bestowed with the National Award for Outstanding Contribution in Science and Technology in 1995. He did the first split liver transplantation in Asia in 1997 and started the adult LDLT in Taiwan by 1999. Further, he performed the first dual graft LDLT in Taiwan in 2002, pioneered routine microsurgical biliary reconstruction in the world in 2006, and performed Taiwan’s first segment 2 monosegment LDLT in 2013. He was bestowed the ILTS Distinguished Service Award in 2019. He was Superintendent of the Kaohsiung Chang Gung Memorial Hospital from 2003 and became Superintendent Emeritus since 2015. He has published more than 500 SCI-cited scientific articles, lectured in more than 300 international and overseas congresses, and has trained more than 360 fellows and observers from all across the world. He serves as associate editor of the American Journal of Transplantation and editorial board of Annals of Surgery among other high ranking scientific journals. He was elected as Academician of the Chinese Academy of Engineering in 2007 and as President of the International LDLT Group in 2020-21. He remains director of one of the leading global centers in LDLT.

Areas of Interest:
Liver Transplantation and Liver Surgery

Session:
HS2: Living Donor Liver Transplantation (LDLT) for HCC beyond Miland Criteria
Topic: There is no doubt for the benefits
Date & Time: Sat, 6 Feb 2021 | 1030 - 1100

Prof Chien-Jen Chen

Vice-president
Genomics Research Center
National Taiwan University College of Public Health
Taiwan

Bio:
Chien-Jen Chen is Vice-president of Academia Sinica, Taiwan, where he is also a Distinguished Professor in the Genomics Research Center. He is a professor at the Graduate Institute of Epidemiology, National Taiwan University College of Public Health, Taiwan and an adjunct professor in the Department of Biostatistics and Epidemiology at Tulane University School of Public Health and Tropical Medicine, New Orleans, USA. Professor Chen is an epidemiologist and public health practitioner, recognised for his in-depth research on the molecular and genomic epidemiology of virus-related cancers and chronic arsenic poisoning. Professor Chen’s REVEAL-HBV/HCV study is regarded as a classic in hepatology and epidemiology.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C

Session:
Gilead Lunch-time Symposium: Shaping tomorrow together: The countdown to HCV elimination
Topic: Best practices and policies in HCV elimination programmes
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

Prof Huey-Ling Chen

Professor
Department of Pediatrics, Department and Graduate Institute of Medical Education and Bioethics, College of Medicine
National Taiwan University
Taiwan

Bio:
Professor Chen graduated from the College of Medicine (MD), and Graduate Institute of Clinical Medicine (PhD) of National Taiwan University. Professor Chen’s clinical work is mainly in pediatric gastroenterology, hepatology, and nutrition. Her research interests center on pediatric liver diseases, prevention of hepatitis B virus (HBV) infection and mother-to-infant transmission of HBV, cholestatic liver diseases, genetic diagnosis of inherited liver diseases, and medical education. She and colleagues have published papers in Gastroenterology, Hepatology, Journal of Hepatology, Journal of Pediatrics, Journal of Pediatric Gastroenterology and Nutrition, etc. She is currently the President of Taiwan Society of Pediatric Gastroenterology, Hepatology, and Nutrition.

Areas of Interest:
Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis, Hepatitis B and Hepatitis D, Human Cholestatic and Autoimmune Liver Diseases, Liver Transplantation and Liver Surgery, Metabolic and Genetic Disease, NAFLD and NASH, Pediatric Hepatology, Training and Education (Career Development)

Session:
S14: Advances in Common Pediatric Hepatology
Topic: Metabolic-Associated Fatty Liver Disease (MAFLD) in Children
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

Prof Jin-Jun Chen

Deputy Director
Hepatology Unit
Nanfang Hospital, Southern Medical University
China

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Genomics and Precision Medicine, Gut Liver Axis and Microbiome, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Assoc Prof Sakkarin Chirapongsathorn

Chief of Hepatobiliary Section
Department of Gastroenterology and Hepatology
Phramongkutklao College of Medicine, Royal Thai Army
Thailand

Bio:
Dr Sakkarin Chirapongsathorn is an Associate Professor and Chief of Hepatobiliary Section of Phramongkutklao College of Medicine, Royal Thai Army, Bangkok, Thailand. The broad goals of his research are to determine treatments to improve survival, quality of care, and quality of life of patients with chronic liver disease and non-alcoholic fatty liver disease. Dr Chirapongsathorn's published work is diverse but largely unified by the theme of identifying patients at risk for mortality in cirrhosis, NASH and other liver diseases.

Areas of Interest:
NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
S1: Enhancing Quality of Care in Hepatology
Topic: Quality Indicators and Improving the Quality of Care in Cirrhosis
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

S8: The Myths and Realities of Portal Hypertension
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Dr Su-Pin Choo

Senior Consultant
Medical Oncology
Curie Oncology
Singapore

Bio:
Dr Choo is a medical oncologist at Curie Oncology who subspecialises in gastrointestinal cancers including colorectal, hepatobiliary, pancreatic, stomach, oesophageal, anal and neuroendocrine cancers. She is a visiting consultant at the National Cancer Centre Singapore and is an adjunct Associate Professor at the Duke-NUS Graduate Medical School. She is the Immediate Past President of the Singapore Society of Oncology and founding member of the SSO- Cancer Immunotherapy Consortium. She is also a Council Member in the Chapter of Medical Oncology, Academy of Medicine Singapore and a Board Member of the Asian Oncology Society. She is a member of the ESMO Women For Oncology committee

Areas of Interest:
Genomics and Precision Medicine, Hepatobiliary Neoplasia, Inflammation and Immunobiology, Training and Education (Career Development)

Session:
Joint Symposum 1 (AASLD-APASL)
Topic: Combination Cancer Immunotherapy for HCC
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Dr Soonthorn Chonprasertsuk

Assistant Professor
Department of Medicine
Thammasat University
Thailand

Bio:
Doctor of Medicine, Chulalongkorn University, Thailand
Internal Medicine resident and GI fellow, Chulalongkorn University, Thailand
Research Fellow in Hepatology, University of North Carolina at Chapel Hill, USA
Director of Gastroenterology Unit, Thammasat University

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatotoxicity

Session:
S3: A Revisit of Tropical Liver Diseases
Chairperson
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

S23: Recent Advances in Drug-Induced Liver Injury
Topic: Liver Injury Associated with Sporting Activities
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Assoc Prof Watcharasak Chotiyaputta

Associate Professor
Department of Medicine
Division of Gastroenterology
Siriraj Hospital, Mahidol University Thailand
Thailand

Bio:
Finished Gastroenterology training from Siriraj Hospital, Mahidol University, Thailand and Hepatology’s Research fellowship training from University of Michigan, USA

Areas of Interest:
Hepatitis B and Hepatitis D

Session:
S4: Current Knowledge of Occult Hepatitis B and Hepatitis B Co-Infection
Topic: An Update on Biology and Clinical Impact of Occult HBV Infection
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Assoc Prof Ashok Choudhury

Associate Professor
Department of Hepatology & Liver Transplant
Institute of Liver & Biliary Sciences, New Delhi
India

Bio:
Assoc Prof Ashok Choudhury currently working as Assoc. Prof of Hepatology and Liver Transplantation at Institute of Liver and Biliary Science (ILBS) New Delhi. He is a transplant hepatologist and a clinician researcher focused on liver injury/failure, ACLF, HCC, sepsis and liver transplant using both pre-clinical and translational studies. His academic activities appreciated globally with best abstract and fellow research award by AASLD at Boston in 2014, Young Investigator Award by ILTS in 2016; Seoul and by APASL 2017 at Shanghai and covered by the WebMD magazine in Europe. Currently academic editor for Journal of Clinical Translational Hepatology (JCTH) and peer reviwer for many reputed journals, had more than 50 publications, for his credit. Currently he is the principal cordinator for tha APASL ACLF rseasrch consortium (AARC) as well as for APASL COVILD-19 Liver Injury Spectrum (APCOLIS study).

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatobiliary Neoplasia, Liver Transplantation and Liver Surgery

Session:
Post-graduate course - Session 3: ACLF - Management from guideline to clinical practice
Topic: Pitfall of critical care in patients with ACLF
Date & Time: Thu, 4 Feb 2021 | 1050 - 1150

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S23: Recent Advances in Drug-Induced Liver Injury
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Prof Raymond Chung

Director of Hepatology and Liver Center
Department of Medicine
Massachusetts General Hospital
United States

Bio:
Prof Raymond Chung is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar at MGH. Dr. Chung has made major contributions to fundamental, translational and clinical research in HCV and HBV. He has served as Co-Chair of the AASLD-IDSA HCV Guidance Panel and is a Principal Investigator in the NIH Hepatitis B Research Network. He is also Principal Investigator of the NIH U19 Cooperative Center in Human Immunology and PI of an NIH T32 Training Grant in Digestive Diseases at MGH. He is President-Elect of the AASLD and will serve as President in 2021. He has authored or coauthored over 300 publications.

Areas of Interest:
Cell and Molecular Biology, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH, Other Viral Hepatitis, Portal Hypertension and Other Complications of Cirrhosis

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Opening Ceremony
Opening Ceremony Speech
Date & Time: Fri, 5 Feb 2021 | 1030 - 1100

S16: Surveillance of Hepatocellular Carcinoma
Topic: Should we stop HCC surveillance after the eradication of viral hepatitis?
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Prof Massimo Colombo

Director, Liver Center
San Raffaele Hospital
Italy

Bio:
Professor Massimo Colombo is Director of the Liver Center at San Raffaele Hospital ,Milan,Italy..In the previous 15 years,he has been Chairman of the Department of Medicine and Organ Transplantation at IRCCS Maggiore Hospital in Milan, Italy. He has been a Professor of Medicine and Gastroenterology at the University of Milan for more than 25 years. Recipient of the 2010 EASL Recognition Award for outstanding medical and scientific contributions,AISF Distinguished Service Award, the Thannhauser Medal Award of the German Society of Gastroenterology and the Nelson Fausto Award of ILCA. Professor Colombo was Editor-in-Chief of the Journal of Hepatology from 2005–2009 Special Section Editor of Journal of Hepatology(2015-2019), and contributor of Selected Summary for Gastroenterology(2010-2021).He chaired the writing committees of EASL CPG of Benign Liver Tumors in 2014 and of Occupational Liver Diseases in 2017. In 2016 appointed Chairman of EASL International Liver Foundation (Geneva,Switzerland). Authored >500 original manuscripts in peer-reviewed journals, with an Hindex of 91(Google Scholar) and more than 27,000 citations.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia

Session:
S7: Clinical and Molecular Pathways of Hepaticocarcinogenesis
Topic: Distinctive Features of Hepatocellular Carcinoma in Metabolic-Associated Fatty Liver Diseases (MAFLD)
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Assoc Prof Yock-Young Dan

Senior Consultant
Department of Medicine
National Univesity of Singapore
Singapore

Bio:
Dr Dan Yock Young obtained his medical degree (MBBS. MMed) and PhD from the National University of Singapore 2003 and 2010 respectively. He is a clinician scientist with research interest in liver stem cells, Non-alcoholic fatty liver disease as well as cost effectiveness. He is currently Assistant Chief Executive and deputy Chairman Medical Board of National University Hospital in NUH,

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Cell and Molecular Biology, NAFLD and NASH

Session:
S17: Controversies in Hepatology
Topic: Risks of Hepatocellular Carcinoma after Treatment with Direct-acting Antiviral Agents for HCV Cirrhosis
Date & Time: Sat, 6 Feb 2021 | 0800 – 0940

Prof Harshad Devarbhavi

Head, Department of Gastroenterology and Hepatology
St. John’s Medical College Hospital, Bangalore
India

Bio:
Prof Harshad Devarbhavi is currently the professor and head of gastroenterology and hepatology at St. John’s Medical College Bangalore, India. He went to Mayo Clinic Rochester on the American College of Gastroenterology scholarship in 2001 and again as a fellow in Hepatology and Liver Transplantation in 2004. He is the authors of over 75 publications that include original articles, review papers, book chapters including the current edition of Zakim and Boyer text book of Hepatology. His research interests include drug-induced liver injury, pregnancy specific liver disease, Wilson disease and acute liver failure. He is on the editorial board of Hepatology International, Hepatology Communications and JCEH.

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatotoxicity, Metabolic and Genetic Disease, Other Viral Hepatitis

Session:
Post-graduate course - Session 3: ACLF - Management from guideline to clinical practice
Topic: Drugs-induced ACLF; what we need to know
Date & Time: Thu, 4 Feb 2021 | 1050 - 1150

SOTA 2
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

S23: Recent Advances in Drug-Induced Liver Injury
Topic: Herbal Medicines Implicating in Liver Injury
Date & Time: Sat, 6 Feb 2021| 1520 - 1700

Prof A.Kadir Dokmeci

Consultant
Department of Liver Transplantation
Ankara University
Turkey

Bio:
He received his medical degree from the Ankara University School of Medicine (AUSM) in 1971 and qualified as a gastroenterologist in 1978.
He had studied at Chiba University School of Medicine in Japan as Prof. Okuda’s student from 1979 to 1981 for 2.5 years. He was appointed as a professor at AUSM in 1988 .
Prof. Dokmeci has been a visiting professor at the Chiba University from 1988 to 1989 and at the University of California, Irvine in 2003. He organized the 25th APASL Annual Conference in 2015 and the 5th APASL STC, Istanbul in 2009. He has contributed to editorials, reviews and book chapters. He is in editorial board in various journals such as Hepatology International, Digestive Endoscopy and Turkish Journal of Gastroenterology.
He published more than 100 papers in different journals.
He is currently Emeritus Professor and senior hepatologist in Liver Transplantation Center at Ankara University.
Also he is member of APASL Steering Committee and the collaborater in AARC. He received 2 international awards. - Inohana Award, Chiba University Japan (1998) - 2nd APASL Powell-Sarin Lifetime Achievement Award (2020)

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Human Cholestatic and Autoimmune Liver Diseases, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
State of the Art 2
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

APASL Distinguished Award presentation and lectures - The 2nd APASL Powell- Sarin Lifetime Achievement Award
Nonsurgical Treatment Options of HCC
Date & Time: Sat, 6 Feb 2021 | 1020 – 1130

Prof Ajay Duseja

Professor, Department of Hepatology
Postgraduate Institute of Medical Education and Research, Chandigarh
India

Bio:
Dr Ajay Duseja is presently working as Professor in the department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. For last more than 24 years, he is working as Faculty with focused research in the field of Hepatology. He is Fellow of National Academy of Medical Sciences (FAMS), Fellow of American Association for the Study of Liver Diseases (FAASLD), Fellow of American College of Gastroenterology (FACG) and Fellow of the Society of GI Endoscopy of India (FSGEI). He is the National Convener of the Indian National Association for the Study of Liver (INASL) Task Force on Nonalcoholic Fatty Liver Disease (NAFLD), member of the Chronic Liver Disease Foundation (CLDF) NASH Committee (USA), member of the Asia- Pacific Working Party on NAFLD and member of the Gut and Obesity in Asia (GOASIA) working group. He is also an active member of the INASL Task Force on Hepatitis C virus, Hepatocellular carcinoma, Acute-on-Chronic Liver Failure and Drug Induced Liver Injury. He is author of more than 250 papers in reputed international and national journals including 22 chapters. His main areas of interest include nonalcoholic fatty liver disease (NAFLD), acute-on-chronic liver failure (ACLF) and management of HCV in chronic kidney disease. He is the Associate Editor of the Journal of Clinical and Experimental Hepatology (JCEH), Associate Editor of JGH Open and is on the Editorial board of various international and national journals. He is the former Honorary Treasurer of the Indian National Association for the Study of Liver (INASL) and has been the office bearer and member of various other scientific societies.

Areas of Interest:
Hepatitis C, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
Post-graduate course - Session 1: NAFL/ MAFLD
Topic: Lean NAFLD; What's new
Date & Time: Thu, 4 Feb 2021 | 0815 - 0915

Latest Knowledge on Gut Microbiota in Liver Diseases
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Mohamed Elbasiony

Lecturer
Department of Internal medicine ( Hepatology and Gastroentrology Unit )
Mansoura University
Egypt

Bio:
Current positions:
Lecturer of internal medicine department
Director of endoscopy unit Egyptian liver Hospital
Educations:
M.B.B.Ch. in Medicine and Surgery Faculty of Medicine, Mansoura University, Nov. 2005
Master’s degree of Internal Medicine Faculty of Medicine, Mansoura University, May. 2010
MD degree of internal medicine Faculty of Medicine, Mansoura University, November ,2016

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Mohammed Eslam

Associate Professor of Hepatology
Storr Liver Centre
University of Sydney
Australia

Areas of Interest:
Genomics and Precision Medicine, Liver Fibrogenesis and Non-Parenchymal Cell Biology, Metabolic and Genetic Disease, NAFLD and NASH

Session:
SOTA 4
Topic: Genetics of Metabolic-Associated Fatty Liver Diseases (MAFLD): From Pathogenesis to Therapeutics
Date & Fri, 5 Feb 2021 | 0940 - 1010

Prof Donna Evon

Professor of Medicine
Division of Gastroenterology and Hepatology
The University of North Carolina at Chapel Hill
United States

Bio:
Donna Evon is a clinical health psychologist and behavioral scientist who has worked in the field of chronic liver disease for 15 years. She is a Professor of Medicine in the UNC Liver Program where she conducts research to understand the psycho-social-behavioral factors related to liver disease, patients’ needs and experiences, and applies this knowledge to the development and evaluation of psychosocial interventions to improve chronic liver disease health outcomes. Her research projects, funded by the NIH, PCORI and industry, utilize self-report surveys, qualitative methodologies and patient engagement groups. Clinically, she provides lifestyle and behavioral modification for patients with NAFLD.

Areas of Interest:
Health Services Research, Hepatitis C, NAFLD and NASH, Other Viral Hepatitis

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Prof Scott L Friedman

Fishberg Professor of Medicine
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
United States

Bio:
Prof Scott L Friedman is the Dean for Therapeutic Discovery and Chief of Liver Diseases, at the Icahn School of Medicine at Mount Sinai. He has performed pioneering research into mechanisms of fibrosis associated with chronic liver disease. His work has spawned an entire field that is now realizing its translational and therapeutic potential. Dr. Friedman has been awarded the EASL International Recognition Award and Distinguished Achievement Awards from the AASLD and the American Liver Foundation. He is widely respected as a key opinion leader working closely with the biotech and pharmaceutical industry in developing new therapies for liver disease.

Areas of Interest:
Hepatobiliary Neoplasia, Liver Fibrogenesis and Non-Parenchymal Cell Biology, NAFLD and NASH

Session:
S6: Updates on Liver Fibrosis: From Pathophysiology to Potential Treatment
Topic: Mechanisms of Fibrosis Progression and Targets of Therapy
Date & Time: Fri, 5 Feb 2021 | 0800 - 0940

Dr James Fung

Consultant
Department of Medicine
Queen Mary Hospital
Hong Kong

Bio:
Dr. James Fung is a Consultant at the Department of Medicine, and the Transplant Hepatologist at the Liver Transplant Centre, Queen Mary Hospital, Hong Kong. He graduated from the University of Auckland School of Medicine in 1997. In 2011 he attained his Doctor of Medicine studying non-invasive assessment of liver fibrosis. He has published widely and is a regular reviewer for major gastroenterology journals and a regular speaker. His main research interest includes viral hepatitis, liver fibrosis, advanced liver disease, hepatocellular carcinoma, and liver transplantation.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis B and Hepatitis D, Hepatitis C, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
S18: Strategies to Improve Long-term Post-Liver Transplantation
Topic: Preventing Recurrence of Viral Hepatitis after Liver Transplantation
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

Prof Rino Gani

Head
Hepatobiliary Division
University of Indonesia
Indonesia

Bio:
Prof Rino A Gani finished MD program from Universitas Indonesia in 1987. After a short experience as the head of a community health center in the rural area, he returned to Universitas Indonesia to become an internist and consultant of gastroenterohepatology in the same university. As Chairman of Indonesia Association for Study of the Liver, he struggles to provide and to make access for the best medication for hepatitis available in Indonesia. He is also actively involved in the Ministry of Health as the head of the expert committee and arranges the national policy to control hepatitis.

Session:
S1: Enhancing Quality of Care in Hepatology
Chairperson
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

S10: What's new in Alcoholic Liver Disease?
Topic: Nutritional Support in Alcoholic Liver Disease
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

APASL Distinguished Award presentation and lectures
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1020 - 1130

The 2nd APASL Rising Star Award
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1330

Prof Juan Carlos García-Pagán

Head of the Hepatic hemodynamic Unit
Hospital Clínic
Spain

Bio:
Dr. JC Garcia-Pagán is a Senior Consultant in Hepatology at the Liver Unit at Hospital Clínic in Barcelona. Dr. Garcia-Pagan earned his medical degree from the University of Barcelona Medical school and completed his gastroenterology/hepatology fellowship at the Liver Unit at Hospital Clínic in Barcelona. He has published more than 200 originals, chapters and reviews. Also he is professor in the University of Barcelona and has directed more than 20 Doctoral Thesis. Dr. Garcia-Pagán’s research has been mainly focused in the area of the pathophysiology, methods of evaluation and treatment of portal hypertension as well as in the natural history and treatment of vascular disorders of the liver.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Hepatitis C, NAFLD and NASH

Session:
S8: The Myths and Realities of Portal Hypertension
Topic: Management of Portal Vein Thrombosis in Cirrhosis: When to Treat and How?
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

HS3: Refractory Esophageal Variceal Bleeding in Cirrhosis
Topic: TIPS
Date & Time: Sat, 6 Feb 2021 | 1430 - 1500

Prof Guadalupe Garcia-Tsao

Professor of Medicine
Department of Disgetive Diseases
Yale University/VA-Connecticut Healthcare System
United States

Bio:
Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, and Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System. Dr. Garcia-Tsao has an active practice in hepatology and clinical research duties as a principal investigator, with over 120 PubMed-verified original publications in peer-reviewed journals that have been cited over 30,000 times and with an H-index of 79. Dr. Garcia-Tsao is a leading expert on portal hypertension and related complications of cirrhosis.

Areas of Interest:
Portal Hypertension and Other Complications of Cirrhosis

Session:
S8: The Myths and Realities of Portal Hypertension
Topic: Portal Hypertensive Bleeding in Cirrhosis: From the Evolving Pathophysiology to the Natural Course and Outcomes
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

Prof Jacob George

Head, Department of Gastroenterology and Hepatology
Storr Liver Centre
Westmead Hospital
Australia

Bio:
Jacob George is the Robert W. Storr Professor of Hepatic Medicine at the Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney and Head of the Department of Gastroenterology and Hepatology at Westmead Hospital and Director of Gastroenterology and Hepatology Services for the Western Sydney Local Health District. He undertakes basic and clinical research on NASH, hepatitis C, liver cancer and hepatic fibrosis. He is an Associate Editor for the Journal of Hepatology and has published over 410 papers, with over >31,000 citations and has an h index of 75.

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, NAFLD and NASH

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S12: Multidisciplinary Care of Metabolic-Associated Fatty Liver Diseases (MAFLD) - A Journal Over 40 Years
Topic: Fatty Liver - from NAFLD to MAFLD
Date & Time: Fri, 5 Feb 2021 | 1520 – 1700

APASL Distinguished Award presentation and lectures - The 2nd APASL Okuda-Omata Distinguished Award
Topic: MAFLD: Where does the evidence point?
Date & Time: Sat, 6 Feb 2021 | 1020 – 1130

Joint Symposium 4 (EASL-APASL)
Topic: Evidence-based Dietary and Exercise for MAFLD
Date & Time: Sat, 6 Feb 2021 | 1520 – 1700

Prof Gregory Gores

Professor of Medicine, Executive Dean for Research
Department of Gastroenterology and Hepatology
Mayo Clinic
United States

Bio:
Gregory J. Gores, M.D. is a quintessential, senior academician; a “quadruple threat” with contributions to research, clinical practice, education, and leadership. His research contributions include sustained federal funding over three decades, over 700 publications, an H-index of 136, and over 57,000 citations (Scopus data base). Based on these accomplishments, he was appointed as a Distinguished Mayo Investigator. His clinical focus on hepatobiliary neoplasia has led to novel protocols regarding liver transplantation for cholangiocarcinoma. Educational activities include mentoring over 80 fellows, and directing a liver transplant fellowship program. These activities have been recognized by receipt of an American Gastroenterological Association Mentorship Award. Extramural leadership positions include past presidency of the American Association for the Study of Liver Disease (AASLD) and the International Liver Cancer Association, and a past Councilor of the American Gastroenterological Association (AGA). Intramural positions include serving as past Chair of the Gastroenterology and Hepatology Division at Mayo Clinic Rochester, and current Executive Dean for Research across the Mayo enterprise. His stature and accomplishments were recently recognized by prestigious awards from the Mayo Alumni Association, the AASLD, the German Society of Gastroenterology, and the Canadian Liver Foundation and Canadian Association for the Study of Liver.

Areas of Interest:
Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis, Hepatobiliary Neoplasia, Human Cholestatic and Autoimmune Liver Diseases, Inflammation and Immunobiology, Liver Transplantation and Liver Surgery, NAFLD and NASH

Session:
S7: Clinical and Molecular Pathways of Hepaticocarcinogenesis
Topic: Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Date & Time: Fri, 5 Feb 2021 |1310 - 1450

Prof Saeed Sadiq Hamid

Professor
Department of Medicine and Director Clinical Trials Unit
The Aga Khan University
Pakistan

Bio:
Saeed Sadiq Hamid is a professor in the Department of Medicine and Director of the Clinical Trials Unit at The Aga Khan University, Karachi, Pakistan. His main research interests are viral hepatitis and liver failure and his current work involves HCV micro-elimination projects in the province of Sindh, Pakistan. He was previously Vice-president of the Pakistan Society of Gastroenterology and President of the Pakistan Society for the Study of Liver Diseases. He is currently a member of the governing council of the World Gastroenterology Organization, Co-chair of the Coalition to Eradicate Viral Hepatitis in Asia-Pacific and a member of the oversight committee of EndHep2030

Areas of Interest:
Hepatitis C, Other Viral Hepatitis

Session:
Gilead Lunch-time Symposium: Shaping tomorrow together: The countdown to HCV elimination
Topic: How far have we come in HCV elimination
Date & Time: Fri, 5 Feb 2021 | 1200 - 1300

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Joint Symposium 3 (APASL-CEVHAP-WHO)
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1440

Prof Tao Han

Chair
Department of Hepatology and Gastroenterology & Infectious Disease
Tianjin Third Central Hospital affiliated to Nankai University and Tianjin Medical University
China

Bio:
Tao Han is Professor of Medicine in Tianjin Third Central Hospital affiliated to Nankai University and Tianjin Medical University. He is Chair of Severe Liver Disease and Artificial Liver Support group ,Standing Committee Membership, Chinese Hepatology Society. His major research focused on various liver disease such as viral hepatitis, liver cirrhosis,liver failure and liver cancer, etc

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Alcoholic Liver Diseases: Clinical and Experimental, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplas, Hepatotoxicity, Human Cholestatic and Autoimmune Liver Diseases, Liver Fibrogenesis and Non-Parenchymal Cell Biolo, Metabolic and Genetic Disease, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof F. Blaine Hollinger

Professor of Medicine, Executive Dean for Research
Prof of Medicine (Hepatology), Molecular Virology & Epidemiology
Gastroenterology and Hepatology
Baylor College of Medicine
United States

Bio:
Dr. F. Blaine Hollinger is an experienced researcher and hepatologist who has engaged in several national multicenter clinical trials and basic scientific projects related to viral hepatitis, and has published over 275 peer-reviewed articles, books and chapters in this field. He is Professor of Medicine, Molecular Virology & Epidemiology and Director of the Eugene B. Casey Hepatitis Research Center. He is a Fellow of the AASLD, AGA and IDSA. Dr. Hollinger has been an advisor and consultant on program projects, grants, and contracts related to viral hepatitis and drug therapy for the NIH and the FDA. He served on the Blood Products Advisory Committee (BPAC) for the FDA becoming its Chairman in 1997 and again in 2010

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Other Viral Hepatitis

Session:
S4: Current Knowledge of Occult Hepatitis B and Hepatitis B Co-Infection
Topic: Occult Hepatitis B Infection and Hepatocellular Carcinoma
Date & Time: Fri, 5 Feb 2021 | 0800 – 0940

Prof Kai-Wen Huang

Professor
Department of Surgery
National Taiwan University
Taiwan

Bio:
Kai-Wen Huang, MD, MS, PhD, is the Professor of surgical oncology in Imperial College London and Director of Centre of Mini-invasive Interventional Oncology of the National Taiwan University Hospital and Graduate Institute of Clinical Medicine in Taipei, Taiwan
He received his MD degree, PhD degree, and his specialty training in Surgery at the Medical School of the National Taiwan University. In 2007, he was a research fellow In Tokyo and Nagoya, Japan. Dr. Huang has been actively involved in basic, clinical and translational research in interventional oncology, surgical oncology, nanomedicine and gene therapy. He has published more than 100 peer-reviewed articles in these areas. He received the “Ta-You Wu Memorial Award” from the National Science Council of Taiwan. Dr. Huang is an active member of the Society of Interventional Oncology (SIO) and Asian Pacific Association for the Study of the Liver (APASL). He has served on the editorial boards of several SCI journals. He is also the founder and board member of Asian Conference on Tumor Ablation (ACTA). In addition, Dr. Huang is the current president of Asia-Pacific Academia of Mini-invasive Intervention and Oncology (APAIO) and President of Taiwan Academy of Tumor Ablation

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Cell and Molecular Biology, Genomics and Precision Medicine, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Hepatobiliary Surgery, Inflammation and Immunobiology, Liver Fibrogenesis and Non-Parenchymal Cell Biology, Liver Transplantation and Liver Surgery, NAFLD and NASH, Training and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof Yi-Hsiang Huang

Chief
Division of Gastroenterology & Hepatology
Taipei Veterans General Hospital
Taiwan

Bio:
Dr. Yi-Hsiang Huang is currently Chief of Division of Gastroenterology and Hepatology at Veterans General Hospital in Taipei. He is also the Director for the Department of Internal Medicine, a Professor for the Institute of Clinical Medicine at the National Yang-Ming University. Dr. Huang is the associate secretary general of the Taiwan Association for the Study of the Liver (TASL) and the Chinese Medical Association of Taiwan, and a board member of the Taiwan Liver Cancer Association (TLCA) and Taiwan Academy of Tumor Ablation. He has published over 170 articles in international peer-reviewed journals, including Hepatology and Journal of Hepatology

Areas of Interest:
Hepatobiliary Surgery, Other Viral Hepatitis

Session:
Eisai Lunch-Time Symposium: Focusing on Lenvatinib as a Novel Molecular Targeted Therapy in Intermediate Stage HCC
Topic: Optimal AE management for uHCC patients with Lenvatinib
Date & Time: Sat, 6 Feb 2021 | 1200 - 1300

Dr Pongphob Intaraprasong

Assistant Professor
Department of Gastroenterology and Hepatology
Ramathibodi Hospital, Mahidol University
Thailand

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Liver Transplantation and Liver Surgery

Session:
S17: Controversies in Hepatology
Topic: Age and Liver Transplantation
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Prof Syed Mohammad Wasim Jafri

Professor, Director WGO Karachi Training Center
Department of Medicine
Aga Khan University Karachi
Pakistan

Areas of Interest:
Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Hepatotoxicity, Human Cholestatic and Autoimmune Liver Diseases, Liver Transplantation and Liver Surgery, NAFLD and NASH, Other Viral Hepatitis, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
S3: A Revisit of Tropical Liver Diseases
Chairperson
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Young Investigator's Award
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Rajiv Jalan

Head, Liver Failure Group
Institute of Liver and Digestive Health
University College London
United Kingdom

Bio:
I am a clinician with a strong focus on translational research. I graduated in India, trained in Edinburgh and studied for my PhD in Maastricht. I moved to UCL as a Senior lecturer/Hon Consultant in 2000 and was awarded a personal chair in 2009. I spend about 50% of my time providing patient care as a Hepatologist at the secondary and tertiary level at the Royal Free Hospital where I also run a translational and basic science laboratory.

My work focused on liver failure. The most important observation we made was the discovery that systemic inflammation played a crucial role in the progression of liver injury and cirrhosis culminating in liver failure leading up to current hypotheses and the seminal observation that acute-on-chronic liver failure (ACLF) was a distinct clinical syndrome with defined clinical, prognostic and pathophysiological characteristics. ACLF is associated with high mortality rates, consumes huge healthcare resources and its treatment is a huge unmet need. In the past 15 years since I described this syndrome first, more than 800 papers have been published on this subject and many research groups and industry are focussed on this subject to better define, prognosticate, understand its pathogenesis and develop new treatments.

I have developed a vibrant clinical practice and laboratory with many novel therapies and established extensive collaborations with key investigators, Foundations and Industry around the world to study the pathophysiological basis of ACLF. I was the Founder member of the EASL CLIF Consortium (100 European hospitals), which now stands independently funded with the aim of developing new treatments for cirrhosis and liver failure.

My research has led to successful publications of about 396 original papers, editorials and reviews. My H-Index is 83 (Google Scholar; Total citations: >20K; 10-index: 246).

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Inflammation and Immunobiology, Portal Hypertension and Other Complications of Cirrhosis

Session:
SOTA 6
Topic: Roles of Artificial Liver Supporting Systems in Acute on Chronic Liver Failure: Rational and Clinical Implications
Date & Time: Sat, 6 Feb 2021 | 1130 - 1200

Prof Ji-Dong Jia

Director
Liver Research Center
Beijing Friendship Hospital, Capital Medical University
China

Bio:
Prof Jia is professor of medicine and director of the Liver Research Center, Beijing Friendship Hospital, Capital Medical University, China. He received his doctor’s degree from the Capita Medical University, China and finished his post-doc training at Free University of Berlin, Germany. His major clinical interest includes viral, autoimmune and genetic liver diseases, his major research area is liver fibrosis. He served as the President of Chinese Society of Hepatology(CSH,2006-2012), APASL (2009-2010) and ASL(2013-2016).

Areas of Interest:
Liver Fibrogenesis and Non-Parenchymal Cell Biology, Metabolic and Genetic Disease, Portal Hypertension and Other Complications of Cirrhosis, ining and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

S9: What's New in Autoimmune Liver Diseases?
Topic: Epidemiology and Clinical Course of Primary Biliary Cholangitis in Asia
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S15: COVID-19: Lessons Learnt from Eastern and Western Worlds
Chairperson
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Dr Gonzague Jourdain

Senior Researcher
Health Research Division
French National Research Institute for Sustainable Development, France and Chiang Mai University
Thailand

Bio:
Gonzague Jourdain is a clinical epidemiologist working in Thailand. He was trained as an MD and earned a PhD in Epidemiology in France. He had led a research collaboration between his institution, the French National Research Institute for Sustainable Development (IRD), and Chiang Mai University in Thailand since 2013 and co-authored more 130 papers in international peer-reviewed journals, especially on perinatal transmission of HIV and HBV. His research currently focuses on simplifying methods to prevent mother-to-child transmission of hepatitis B virus, and the prevention of horizontal transmission of HIV, syphilis and viral hepatitis B and C.

Areas of Interest:
Hepatitis B and Hepatitis D

Session:
Joint Symposium 2 (WHO WPRO_SEARO)
Topic: Asking the right questions: operations research to implementing better: Questions to address through research to advance the implementation of prevention of mother-to-child transmission of hepatitis B
Date & Time: Sat, 6 Feb 2021 | 1100 - 1200

Prof Patrick Kamath

Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
United States

Bio:
Patrick S. Kamath is Professor of Medicine and Consultant in Gastroenterology and Hepatology at Mayo Clinic College of Medicine and Science. He is a Mayo Clinic Distinguished Educator, an AGA Distinguished Educator, and AASLD Distinguished Mentor. His major research area is identifying patients at risk for mortality in cirrhosis; he played a key role in developing the Model for End-stage Liver Disease (MELD). He has authored more than 350 publications including contributions to the New England Journal of Medicine, Gastroenterology, Hepatology, and Nature Genetics. He received the Lifetime Teaching Award for Excellence from the Department of Medicine at Mayo Clinic.

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Liver Transplantation and Liver Surgery, Portal Hypertension and Other Complications of Cirrhosis

Session:
S17: Controversies in Hepatology
Topic: Liver Transplantation in Acute on Chronic Liver Failure (ACLF): Science or Fiction?
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Prof Jia-Horng Kao

Vice Superintendent
Department of Gastroenterology and Hepatology
National Taiwan University Hospital
Taiwan

Bio:
Professor Jia-Horng Kao is the Chair Professor at the Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine. He is also the Vice Superintendent of the National Taiwan University Hospital. Professor Kao’s main research interests include the prevention, natural history, molecular virology, pathogenesis and treatment of chronic viral hepatitis and HCC. He has published more than 550 articles with the sum of times cited of 20,684 and h-index of 65 by Web of Science. He also contributed to 9 book chapters and one monograph. With his outstanding academic achievements, he has received several prestigious awards including the Okuda Award of Asian-Pacific Digestive Week (Bangkok, Thailand)/Journal of Gastroenterology and Hepatology (2012) and APASL Okuda-Omata Distinguished Achievement Award (2019).

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C

Session:
SOTA 1
Chairperson
Date & Time: Fri, 5 Feb 2021 | 0940 - 1010

Chainuvati Lecture
Topic: Prevention of Mother-to-Child Transmission: the Key of Hepatitis B Virus Elimination
Date & Time: Sat, 6 Feb 2021 | 0940 - 1010

Dr Md. Fazal Karim

Associate Professor and Head
Department of Hepatology
Sir Salimullah Medical College Mitford Hospital
Bangladesh

Bio:
I am a hepatologist working as Associate Professor & Head, Department of Hepatology, Sir Salimullah Medical College Mitford Hospital. It is a teaching hospital in old part of Dhaka city. I am a graduate of Dhaka Medical College. I did my MBBS in 1993. I have done post-graduation in Internal Medicine (FCPS in Medicine) from Bangladesh College of Physicians & Surgeons in 2003. Also did post-graduation in Hepatology (MD Hepatology) from Bangabandhu Sheikh Mujib Medical University, Dhaka in 2004. I have 13 years of experience in teaching. I specialize in liver related procedure- FNA, liver biopsy, endoscopy, colonoscopy, ERCP. I have large number of publications in national and international journals

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH, Other Viral Hepatitis, Portal Hypertension and Other Complications of Cirrhosis, Training and Education (Career Development)

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Prof W-Ray Kim

Professor & Chief
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
United States

Bio:
Ray Kim, MD, is Professor and Chief in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine. Prior to assuming this post in November 2013, Dr. Kim was Professor of Medicine at Mayo Clinic College of Medicine. Dr. Kim earned his medical diploma at Seoul National University in Korea. He underwent training in gastroenterology and hepatology at Mayo Clinic in Rochester, MN. He also holds a Master in Science Degree in patient oriented research from Seoul National University and a Master in Business Administration from University of Pennsylvania. He has served on the Governing Board of the American Association for the Study of Liver Disease (AASLD), where he currently chairs the Global Outreach and Engagement Committee. Dr. Kim’s research interest has been in epidemiology and outcomes studies in chronic liver disease and liver cancer.

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

S1: Enhancing Quality of Care in Hepatology
Topic: Cost-effectiveness of Hepatitis C Screening
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

Prof Dong-Joon Kim

Professor and Director
Department of Internal Medicine
Institute for Liver and Digestive Diseases
Hallym University
South Korea

Bio:
Chairman, KASL (Korean Association for the Study of the Liver)

Areas of Interest:
Alcoholic Liver Diseases: Clinical and Experimental, Gut Liver Axis and Microbiome, Portal Hypertension and Other Complications of Cirrhosis

Session:
APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

Dr Taya Kitiyakara

Head
Department of Gastroenterology and Hepatology
Ramathibodi Hospital
Thailand

Bio:
Dr Taya Kitiyakara is currently Head of Division of Gastroenterology/Hepatology at Faculty of Medicine, Ramathibodi hospital, Mahidol University.

Session:
S10: What's new in Alcoholic Liver Disease?
Topic: Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease
Date & Time: Fri, 5 Feb 2021 | 1310 - 1450

S16: Surveillance of Hepatocellular Carcinoma
Chairperson
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Prof Piyawat Komolmit

Head
Excellent Center in Liver Diseases
King Chulalongkorn Memorial Hospital
Thailand

Bio:
Dr Piyawat Komolmit is affiliated to Medicine, Chulalongkorn University, where Dr. Komolmit is currently working as Professor. Dr. Komolmit has authored and co-authored several national and international publications and also working as a reviewer for reputed professional journals. Dr. Komolmit is having an active association with different societies and academies around the world. Dr. Komolmit made his mark in the scientific community with the contributions and widely recognition from honourable subject experts around the world. Dr. Komolmit has received several awards for the contributions to the scientific community. Dr. Komolmit major research interest involves Gastroenterology.

Session:
S21: Hot Topics in Cirrhosis and its Complications
Topic: Management of the Critically-ill Cirrhotic Patients
Date & Time: Sat, 6 Feb 2021 | 1310 - 1450

Prof Masatoshi Kudo

Professor and Chairman
Department of Gastroenterology and Hepatology
Kindai University Faculty of Medicine
Japan

Bio:
Masatoshi Kudo studied Medicine at Kyoto University and graduated in 1978. Following this, he completed a clinical fellowship in Kobe City General Hospital followed by a research fellowship at the University of California Davis Medical Center in USA and Kyoto University Graduate School of Medicine, where he received his PhD degree in Medical Science in 1987. Professor Kudo is currently a Professor and Chairman at the Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine since 1999 and the Executive Board Member of Kindai University.

Professor Kudo has published 959 International scientific peer review papers in well regarded journals (Total IF=5430.285, H-Index 83) in addition to 945 domestic scientific papers. He has given 408 invited lectures in the area of his expertise on numerous occasions to international audiences. He serves as an Executive Council Board Member for Liver Cancer Study Group of Japan (LCSGJ), Chairman of Nationwide Survey Committee of LCSGJ, and a representative of LCSGJ Head Office. Professor Kudo is also a President of the Japan Society of Ultrasonics in Medicine (JSUM), President of Asia Pacific Primary Liver Cancer Association (APPLE), Past President of WFUMB, President of AFSUMB, an Executive Board Member of Japan Society of Hepatology (JSH), a Founding Board member of International Liver Cancer Association (ILCA). He is also serving as an Editor in Chief of LIVER CANCER (Karger) (IF=9.720).

His research interest is "Diagnosis and treatment of HCC". Professor Kudo is the first author of “Consensus based Practice Guideline of HCC Proposed by Japan Society of Hepatology” published in 2007, 2010 and 2014 revised version.

Areas of Interest:
Hepatobiliary Neoplasia

Session:
S22: Team-based Management of Hepatocellular Carcinoma
Topic: Goals and Targets for Personalized Therapies in Hepatocellular Carcinoma
Date & Time: Sat, 6 Feb 2021 | 1520 - 1700

Dr Jennifer Lai

Associate Professor of Medicine
Division of Gastroenterology & Hepatology
University of California, San Francisco
United States

Areas of Interest:
Hepatobiliary Neoplasia

Session:
AASLD-APASL Research Methodology Virtual Workshop
Date & Time: Thu, 4 Feb 2021

Prof George Lau

Chairman
Department of Gastroenterology and Hepatology
Humanity & Health Medical Group
Hong Kong

Bio:
Prof. Lau is currently the Chairman of Humanity and Health Medical Group, Hong Kong and Chair Professor and Director of The 5th Medical Centre of Chinese PLA General Hospital - Hong Kong Humanity & Health Medical Group, Beijing, CHINA. He has a distinguished career in the conduct of translational and clinical trials in the field of CHB, CHC and HCC. He has pioneered work in adoptive clearance of HBV infection and the use of pre-emptive lamivudine to prevent HBV reactivation after chemotherapy. Prof. Lau’s has published more than 300 original publications with H-h-index of 84 (2020).

Areas of Interest:
Acute Liver Failure and Artificial Liver Support, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Inflammation and Immunobiology, NAFLD and NASH

Session:
SOTA 3
Topic: Immunotherapy in Hepatology - Past, Present and Future
Date & Time: Fri, 5 Feb 2021 | 0940 – 1010

Presidential Lecture 1
Chairperson
Date & Time: Fri, 5 Feb 2021 | 1130 - 1200

APASL-AARC Consensus Meeting- Practice Guidelines on Alcoholic Liver Disease and ACLF
Date & Time: Fri, 5 Feb 2021 | 1100 - 1650

APASL HBV Reactivation 2021 Guideline
Topic: Historical Perspectives
Date & Time: Sat, 6 Feb 2021 | 0800 - 1000

APASL HBV Reactivation 2021 Guideline
Topic: Recommendations
Date & Time: Sat, 6 Feb 2021 | 0800 - 1000

Prof Mei-Hsuan Lee

Professor
Institute of Clinical Medicine
National Yang-Ming University
Taiwan

Bio:
Professor Mei-Hsuan Lee is Professor at the Institute of Clinical Medicine, National Yang-Ming University, Taiwan. She obtained her PhD in 2010 from the Graduate Institute of Epidemiology, National Taiwan University. She was a visiting scholar at the National Cancer Institute, USA; the University of Tokyo, Japan; and the Genomics Research Center, Academia Sinica, Taiwan. Professor Lee has received various honors and awards for her work, and is often invited to speak at local and international conferences. She currently serves on the editorial board of Scientific Reports, Journal of the Formosan Medical Association and Virology Journal.

Areas of Interest:
Genomics and Precision Medicine, Gut Liver Axis and Microbiome, Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, Metabolic and Genetic Disease, NAFLD and NASH

Session:
Gilead Lunch-time Symposium: Shaping Tomorrow Together: Learnings from a Real-world Survey of Liver Health in Asia
Topic: Asia Liver Index Survey: A barometer for public awareness on viral hepatitis and fatty liver disease
Date & Time: Sat, 6 Feb 2021 | 1200 - 1300

Dr Apinya Leerapun

Assistant Professor
Department of Internal Medicine, Faculty of Medicine
Chiang Mai University
Thailand

Areas of Interest:
Hepatitis B and Hepatitis D, Hepatitis C, Hepatobiliary Neoplasia, NAFLD and NASH

Session:
S2: Novel Technologies in Hepatology
Chairperson
Date & Time: Thu, 4 Feb 2021 | 1530 - 1645

S17: Controversies in Hepatology
Topic: Benefit of Statin in Chronic Liver Diseases
Date & Time: Sat, 6 Feb 2021 | 0800 - 0940

Dr Cosmas Rinaldi A Lesmana

Senior Lecturer and Consultant
Department of Internal Medicine, Hepatobiliary Division
Dr. Cipto Mangunkusumo National General Hospital
Indonesia

Bio:
Cosmas Rinaldi A. Lesmana is a Senior Lecturer and Consultant in the Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia in Jakarta. Dr Lesmana serves as one of the Research Coordinator Staff for the department. He is also work at Digestive Disease & GI Oncology Centre (DDOC), Medistra Hospital, Jakarta as well as at Liver-GI Centre, MRCCC Siloam Hospital, Jakarta as a senior consultant and interventional endoscopist. He carried out his medical and postgraduate training in Internal Medicine and also in Gastroenterology/Hepatology at Diponegoro University, Semarang and Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta. He underwent several additional short courses training in basic and advance endoscopy (ERCP) in Asian Institute of Gastroenterology (AIG), Hyderabad, India, and Hepatology (Fibroscan training) in Hopital Haut Leveaque, Bordeaux, France, and also basic molecular hepatitis virus at Victorian Infectious Disease Reference Laboratory (VIDRL), Melbourne, Australia. In 2011, he further continued his interest for portal hypertension training at Institute of Liver & Biliary Sciences (ILBS), New Delhi, India. In 2015, he underwent endoscopic ultrasound (EUS) training at Baldota Institute of Digestive Science (BIDS), Global Hospital, Mumbai, India. He has won several awards for his research, including being named 4th in the APASL Young Investigator Award in 2005, and 3rd in APASL 2010, the AASLD-APASL Award in 2008, Travel Grant Award from Society Gastrointestinal Intervention (SGI) Korea in 2010, as well as two times awards in AASLD (2012 and 2018). One of his research has been selected for presentation during Digestive Disease Week (DDW) meeting, 2017 in USA. Dr Lesmana is a member of several professional associations, including Past Executive Council Member of the Asian Pacific Association for the Study of the Liver (APASL), Fellow of American College of Physicians (FACP), Direct Fellow of American College of Gastroenterology (FACG) and Fellow of Indonesian Association of Internal Medicine (FINASIM). Currently, he is a member of Asian Endoscopic Ultrasound (EUS) Group (AEG). He has been involved as international EUS workshop instructor during AEG congress. He also has published many papers in peer-reviewed international journals and his interest includes hepatitis virus, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, pancreato-biliary diseases, and diagnostic as well as therapeutic endoscopy.

Areas of Interest:
Gut Liver Axis and Microbiome, Hepatobiliary Neoplasia, NAFLD and NASH, Portal Hypertension and Other Complications of Cirrhosis

Session:
S13: Novel Endoscopic Interventions in Liver Diseases
Topic: Prevention and Management of Bleeding Risk Related to Invasive Procedures in Cirrhosis
Date & Time: Fri, 5 Feb 2021 | 1520 - 1700

HS3: Refractory Esophageal Variceal Bleeding in Cirrhosis
Chairperson
Date & Time: Sat, 6 Feb 2021 | 1430 - 1500